1	-LSB-Interaction	-lsb-interaction	NN	_	0	root	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	]	-rsb-	-RRB-	_	1	p	_	_
7	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interaction	interaction	NN	_	9	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	9	aux	_	_
9	been	be	VBN	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	subject	subject	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	much	much	JJ	_	14	attr	_	_
14	study	study	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	recent	recent	JJ	_	17	attr	_	_
17	years	year	NNS	_	11	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Contradictory	contradictory	JJ	_	2	attr	_	_
2	results	result	NNS	_	21	dep	_	_
3	regarding	regard	VBG	_	2	acl	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	platelet	platelet	NN	_	10	com	_	_
10	reactivity	reactivity	NN	_	5	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	on	on	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	outcome	outcome	NN	_	10	conj	_	_
15	in	in	IN	_	18	case	_	_
16	drug2	drug0	CD	_	18	num	_	_
17	-treated	-treated	JJ	_	18	attr	_	_
18	patients	patient	NNS	_	14	ppmod	_	_
19	have	have	VBP	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	0	root	_	_
22	in	in	IN	_	23	case	_	_
23	literature	literature	NN	_	21	ppmod	_	_
24	.	.	.	_	21	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	was	be	VBD	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	decrease	decrease	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	exposure	exposure	NN	_	10	obj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	AUC	auc	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	to	to	TO	_	20	aux	_	_
17	clopidogrel	clopidogrel	NN	_	20	attr	_	_
18	's	's	POS	_	20	case	_	_
19	active	active	JJ	_	20	attr	_	_
20	metabolite	metabolite	NN	_	12	ppmod	_	_
21	by	by	IN	_	22	case	_	_
22	50	0	CD	_	10	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	and	and	CC	_	10	cc	_	_
25	to	to	TO	_	27	aux	_	_
26	sharply	sharply	RB	_	27	adv	_	_
27	increase	increase	VB	_	10	conj	_	_
28	platelet	platelet	NN	_	29	com	_	_
29	reactivity	reactivity	NN	_	27	obj	_	_
30	,	,	,	_	27	p	_	_
31	as	as	IN	_	33	case	_	_
32	a	a	DT	_	33	det	_	_
33	result	result	NN	_	27	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	inhibition	inhibition	NN	_	33	ppmod	_	_
36	by	by	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	of	of	IN	_	39	case	_	_
39	CYP2C19	cyp0c0	NN	_	37	ppmod	_	_
40	,	,	,	_	39	p	_	_
41	a	a	DT	_	47	det	_	_
42	cytochrome	cytochrome	NN	_	43	com	_	_
43	P450	p0	NN	_	47	attr	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	CYP	cyp	NN	_	43	prn	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	enzyme	enzyme	NN	_	39	appo	_	_
48	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	much	much	RB	_	5	adv	_	_
5	weaker	weak	JJR	_	6	attr	_	_
6	effect	effect	NN	_	2	obj	_	_
7	on	on	IN	_	10	case	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	's	's	POS	_	10	case	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	on	on	IN	_	14	case	_	_
13	platelet	platelet	NN	_	14	com	_	_
14	reactivity	reactivity	NN	_	10	conj	_	_
15	during	during	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	use	use	NN	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	influence	influence	NN	_	16	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	when	when	WRB	_	8	adv	_	_
8	used	use	VBN	_	6	relcl	_	_
9	simultaneously	simultaneously	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	has	have	VBZ	_	16	aux	_	_
13	not	not	RB	_	16	neg	_	_
14	yet	yet	RB	_	16	adv	_	_
15	been	be	VBN	_	16	aux	_	_
16	investigated	investigate	VBN	_	0	root	_	_
17	in	in	IN	_	20	case	_	_
18	adequately	adequately	RB	_	19	adv	_	_
19	randomized	randomized	JJ	_	20	attr	_	_
20	studies	study	NNS	_	16	ppmod	_	_
21	.	.	.	_	16	p	_	_

1	Regulatory	regulatory	JJ	_	2	attr	_	_
2	agencies	agency	NNS	_	3	com	_	_
3	state	state	NN	_	0	root	_	_
4	that	that	IN	_	18	mark	_	_
5	the	the	DT	_	6	det	_	_
6	combination	combination	NN	_	18	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	12	det	_	_
11	CYP2C19	cyp0c0	NN	_	12	com	_	_
12	inhibitors	inhibitor	NNS	_	6	conj	_	_
13	drug2	drug0	NN	_	12	appo	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	avoided	avoid	VBN	_	3	comp	_	_
19	.	.	.	_	3	p	_	_

1	To	to	TO	_	2	aux	_	_
2	date	date	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	there	there	EX	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	conclusive	conclusive	JJ	_	8	attr	_	_
8	evidence	evidence	NN	_	5	obj	_	_
9	of	of	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	clinically-relevant	clinically-relevant	JJ	_	12	attr	_	_
12	interaction	interaction	NN	_	8	ppmod	_	_
13	between	between	IN	_	14	case	_	_
14	any	any	DT	_	12	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	.	.	.	_	5	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	3	p	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	3	adv	_	_
9	and	and	CC	_	8	cc	_	_
10	in	in	FW	_	11	adv	_	_
11	vivo	vivo	FW	_	8	conj	_	_
12	,	,	,	_	3	p	_	_
13	in	in	IN	_	17	case	_	_
14	human	human	JJ	_	17	attr	_	_
15	A375	a0	NN	_	17	com	_	_
16	melanoma	melanoma	NN	_	17	com	_	_
17	cells	cell	NNS	_	3	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	mechanisms	mechanism	NNS	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	interaction	interaction	NN	_	3	ppmod	_	_
6	between	between	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	alkyating	alkyating	JJ	_	10	attr	_	_
9	agent	agent	NN	_	10	com	_	_
10	drug1	drug0	NN	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	and	and	CC	_	10	cc	_	_
15	the	the	DT	_	16	det	_	_
16	pro-oxidant	pro-oxidant	JJ	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	in	in	IN	_	26	case	_	_
21	the	the	DT	_	26	det	_	_
22	human	human	JJ	_	26	attr	_	_
23	A375	a0	NN	_	26	com	_	_
24	melanoma	melanoma	NN	_	26	com	_	_
25	cell	cell	NN	_	26	com	_	_
26	line	line	NN	_	3	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	2	p	_	_
8	alone	alone	RB	_	2	adv	_	_
9	and	and	CC	_	8	cc	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	8	conj	_	_
12	,	,	,	_	2	p	_	_
13	was	be	VBD	_	14	aux	_	_
14	evaluated	evaluate	VBN	_	0	root	_	_
15	for	for	IN	_	17	case	_	_
16	growth	growth	NN	_	17	com	_	_
17	inhibition	inhibition	NN	_	14	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	MTT	mtt	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	17	p	_	_
22	radiolabeled	radiolabeled	VBN	_	24	attr	_	_
23	drug	drug	NN	_	24	com	_	_
24	uptake	uptake	NN	_	17	conj	_	_
25	,	,	,	_	24	p	_	_
26	cellular	cellular	JJ	_	28	attr	_	_
27	thiol	thiol	NN	_	28	com	_	_
28	content	content	NN	_	17	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	HPLC	hplc	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	28	p	_	_
33	and	and	CC	_	28	cc	_	_
34	DNA	dna	NN	_	36	com	_	_
35	strand	strand	NN	_	36	com	_	_
36	breaks	break	NNS	_	17	conj	_	_
37	(	-lrb-	-LRB-	_	39	p	_	_
38	Comet	comet	NN	_	39	com	_	_
39	assay	assay	NN	_	36	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	.	.	.	_	14	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	antitumor	antitumor	JJ	_	1	conj	_	_
4	effects	effect	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	evaluated	evaluate	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	mice	mouse	NNS	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Growth	growth	NN	_	2	com	_	_
2	inhibition	inhibition	NN	_	5	dep	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	2	adv	_	_
5	was	be	VBD	_	0	root	_	_
6	additive	additive	JJ	_	5	dep	_	_
7	with	with	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	two	#crd#	CD	_	10	num	_	_
10	drugs	drug	NNS	_	6	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	drug	drug	NN	_	7	com	_	_
7	uptake	uptake	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	number	number	NN	_	7	conj	_	_
12	of	of	IN	_	15	case	_	_
13	DNA	dna	NN	_	15	com	_	_
14	strand	strand	NN	_	15	com	_	_
15	breaks	break	NNS	_	11	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	>75	>0	CD	_	6	num	_	_
5	%	%	NN	_	6	meta	_	_
6	reduction	reduction	NN	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	cellular	cellular	JJ	_	9	attr	_	_
9	glutathione	glutathione	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	cysteine	cysteine	NN	_	9	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	6	ppmod	_	_
14	but	but	CC	_	13	cc	_	_
15	not	not	RB	_	14	com	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	.	.	.	_	2	p	_	_

1	Co-administration	co-administration	NN	_	8	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	two	#crd#	CD	_	5	num	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	mice	mouse	NNS	_	1	ppmod	_	_
8	caused	cause	VBD	_	0	root	_	_
9	an	an	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	area	area	NN	_	10	ppmod	_	_
14	under	under	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	curve	curve	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	both	both	DT	_	19	det	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	,	,	,	_	8	p	_	_
21	but	but	CC	_	8	cc	_	_
22	the	the	DT	_	23	det	_	_
23	combination	combination	NN	_	24	dep	_	_
24	was	be	VBD	_	8	conj	_	_
25	not	not	RB	_	24	neg	_	_
26	effective	effective	JJ	_	24	dep	_	_
27	in	in	IN	_	28	case	_	_
28	reducing	reduce	VBG	_	26	ppmod	_	_
29	human	human	JJ	_	32	attr	_	_
30	A375	a0	NN	_	32	com	_	_
31	melanoma	melanoma	NN	_	32	com	_	_
32	tumors	tumor	NNS	_	28	obj	_	_
33	in	in	FW	_	34	adv	_	_
34	vivo	vivo	FW	_	28	adv	_	_
35	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	show	show	VBP	_	0	root	_	_
5	additive	additive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	in	in	FW	_	12	adv	_	_
8	vitro	vitro	FW	_	12	adv	_	_
9	but	but	CC	_	12	cc	_	_
10	not	not	RB	_	9	com	_	_
11	in	in	FW	_	12	adv	_	_
12	vivo	vivo	FW	_	4	adv	_	_
13	in	in	IN	_	17	case	_	_
14	human	human	JJ	_	17	attr	_	_
15	A375	a0	NN	_	17	com	_	_
16	melanoma	melanoma	NN	_	17	com	_	_
17	cells	cell	NNS	_	4	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Enhancement	enhancement	NN	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	humoral	humoral	JJ	_	5	attr	_	_
4	immune	immune	JJ	_	5	attr	_	_
5	responses	response	NNS	_	1	ppmod	_	_
6	to	to	TO	_	5	ppmod	_	_
7	inactivated	inactivate	VBD	_	0	root	_	_
8	Newcastle	newcastle	JJ	_	9	attr	_	_
9	disease	disease	NN	_	7	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug1	drug0	NN	_	9	conj	_	_
12	by	by	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	administration	administration	NN	_	7	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	chickens	chicken	NNS	_	16	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Newcastle	newcastle	JJ	_	2	attr	_	_
2	disease	disease	NN	_	12	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	ND	nd	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	and	and	CC	_	2	cc	_	_
7	avian	avian	JJ	_	8	attr	_	_
8	influenza	influenza	NN	_	2	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	AI	ai	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	are	be	VBP	_	0	root	_	_
13	common	common	JJ	_	12	dep	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	poultry	poultry	NN	_	17	com	_	_
17	industry	industry	NN	_	13	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	objective	objective	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug2	drug0	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	on	on	IN	_	23	case	_	_
20	the	the	DT	_	23	det	_	_
21	humoral	humoral	JJ	_	23	attr	_	_
22	immune	immune	JJ	_	23	attr	_	_
23	responses	response	NNS	_	10	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	chickens	chicken	NNS	_	23	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	drug3	drug0	NN	_	23	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	drug4	drug0	NN	_	27	conj	_	_
31	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	experiment	experiment	NN	_	31	ppmod	_	_
3	1	0	CD	_	2	num	_	_
4	,	,	,	_	31	p	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	administration	administration	NN	_	31	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	at	at	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	dose	dose	NN	_	6	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	5	0	CD	_	14	num	_	_
14	mg/kg	mg/kg	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	BW	bw	NN	_	14	ppmod	_	_
17	for	for	IN	_	19	case	_	_
18	7	0	CD	_	19	num	_	_
19	d	d	NN	_	14	ppmod	_	_
20	on	on	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	immune	immune	JJ	_	23	attr	_	_
23	response	response	NN	_	14	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	chickens	chicken	NNS	_	23	ppmod	_	_
26	intramuscularly	intramuscularly	RB	_	27	adv	_	_
27	injected	inject	VBN	_	25	acl	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	was	be	VBD	_	31	aux	_	_
31	evaluated	evaluate	VBN	_	0	root	_	_
32	.	.	.	_	31	p	_	_

1	Results	result	NNS	_	2	dep	_	_
2	showed	show	VBD	_	0	root	_	_
3	that	that	IN	_	6	mark	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	increased	increase	VBD	_	2	comp	_	_
7	the	the	DT	_	9	det	_	_
8	antibody	antibody	NN	_	9	com	_	_
9	level	level	NN	_	6	obj	_	_
10	against	against	IN	_	11	case	_	_
11	ND	nd	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	serum	serum	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	chickens	chicken	NNS	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	experiment	experiment	NN	_	11	ppmod	_	_
3	2	0	CD	_	2	num	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	7	det	_	_
6	same	same	JJ	_	7	attr	_	_
7	regimen	regimen	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	chickens	chicken	NNS	_	11	ppmod	_	_
14	inoculated	inoculate	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	11	p	_	_
18	and	and	CC	_	11	cc	_	_
19	an	an	DT	_	23	det	_	_
20	enhanced	enhance	VBN	_	23	attr	_	_
21	serum	serum	NN	_	23	com	_	_
22	antibody	antibody	NN	_	23	com	_	_
23	response	response	NN	_	29	dep	_	_
24	to	to	TO	_	26	aux	_	_
25	AI	ai	NN	_	26	com	_	_
26	vaccination	vaccination	NN	_	23	ppmod	_	_
27	was	be	VBD	_	29	aux	_	_
28	also	also	RB	_	29	adv	_	_
29	observed	observe	VBN	_	11	conj	_	_
30	.	.	.	_	11	p	_	_

1	Considering	consider	VBG	_	19	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	safety	safety	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	19	p	_	_
7	because	because	IN	_	12	mark	_	_
8	no	no	DT	_	10	det	_	_
9	adverse	adverse	JJ	_	10	attr	_	_
10	effect	effect	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	found	find	VBN	_	19	advcl	_	_
13	throughout	throughout	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	experiments	experiment	NNS	_	12	ppmod	_	_
16	,	,	,	_	19	p	_	_
17	drug2	drug0	NN	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	be	be	VB	_	0	root	_	_
20	a	a	DT	_	23	det	_	_
21	promising	promising	JJ	_	23	attr	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	adjuvant	adjuvant	JJ	_	19	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	improve	improve	VB	_	23	acl	_	_
26	immunization	immunization	NN	_	25	obj	_	_
27	in	in	IN	_	28	case	_	_
28	poultry	poultry	NN	_	25	ppmod	_	_
29	.	.	.	_	19	p	_	_

1	Protective	protective	JJ	_	2	attr	_	_
2	effect	effect	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	against	against	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	acute	acute	JJ	_	10	attr	_	_
10	toxicity	toxicity	NN	_	2	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	diepoxybutane	diepoxybutane	NN	_	10	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	human	human	JJ	_	15	attr	_	_
15	lymphocytes	lymphocyte	NNS	_	12	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	biotransformation	biotransformation	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	oxidative	oxidative	JJ	_	5	attr	_	_
5	stress	stress	NN	_	2	conj	_	_
6	may	may	MD	_	7	modal	_	_
7	contribute	contribute	VB	_	0	root	_	_
8	to	to	TO	_	14	aux	_	_
9	1,2:3,4-diepoxybutane	0-diepoxybutane	NN	_	13	advnp	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	DEB	deb	NN	_	13	advnp	_	_
12	)	-rrb-	-RRB-	_	13	p	_	_
13	-induced	-induced	JJ	_	14	attr	_	_
14	toxicity	toxicity	NN	_	7	ppmod	_	_
15	to	to	TO	_	17	aux	_	_
16	human	human	JJ	_	17	attr	_	_
17	lymphocytes	lymphocyte	NNS	_	7	ppmod	_	_
18	of	of	IN	_	24	case	_	_
19	Fanconi	fanconi	NNP	_	20	com	_	_
20	Anemia	anemia	NN	_	24	attr	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	FA	fa	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	patients	patient	NNS	_	17	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	Thus	thus	RB	_	29	adv	_	_
2	,	,	,	_	29	p	_	_
3	the	the	DT	_	4	det	_	_
4	identification	identification	NN	_	29	dep	_	_
5	of	of	IN	_	7	case	_	_
6	putative	putative	JJ	_	7	attr	_	_
7	inhibitors	inhibitor	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	bioactivation	bioactivation	NN	_	7	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	as	as	RB	_	12	com	_	_
12	well	well	RB	_	4	cc	_	_
13	as	as	IN	_	12	com	_	_
14	the	the	DT	_	15	det	_	_
15	determination	determination	NN	_	4	conj	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	protective	protective	JJ	_	19	attr	_	_
19	role	role	NN	_	15	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	oxidant	oxidant	JJ	_	22	attr	_	_
22	defenses	defense	NNS	_	19	ppmod	_	_
23	,	,	,	_	15	p	_	_
24	on	on	IN	_	26	case	_	_
25	DEB-induced	deb-induced	JJ	_	26	attr	_	_
26	toxicity	toxicity	NN	_	15	ppmod	_	_
27	,	,	,	_	15	p	_	_
28	can	can	MD	_	29	modal	_	_
29	help	help	VB	_	0	root	_	_
30	to	to	TO	_	31	aux	_	_
31	understand	understand	VB	_	29	comp	_	_
32	what	what	WP	_	34	dep	_	_
33	is	be	VBZ	_	34	aux	_	_
34	failing	fail	VBG	_	31	comp	_	_
35	in	in	IN	_	37	case	_	_
36	FA	fa	NN	_	37	com	_	_
37	cells	cell	NNS	_	34	ppmod	_	_
38	.	.	.	_	29	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	work	work	NN	_	6	ppmod	_	_
5	we	we	PRP	_	6	dep	_	_
6	studied	study	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	contribution	contribution	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	several	several	JJ	_	12	attr	_	_
11	biochemical	biochemical	JJ	_	12	attr	_	_
12	pathways	pathway	NNS	_	8	ppmod	_	_
13	for	for	IN	_	16	case	_	_
14	DEB-induced	deb-induced	JJ	_	16	attr	_	_
15	acute	acute	JJ	_	16	attr	_	_
16	toxicity	toxicity	NN	_	8	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	human	human	JJ	_	20	attr	_	_
19	lymphocyte	lymphocyte	NN	_	20	com	_	_
20	suspensions	suspension	NNS	_	16	ppmod	_	_
21	,	,	,	_	6	p	_	_
22	by	by	IN	_	23	case	_	_
23	using	use	VBG	_	6	ppmod	_	_
24	inhibitors	inhibitor	NNS	_	23	obj	_	_
25	of	of	IN	_	27	case	_	_
26	epoxide	epoxide	NN	_	27	com	_	_
27	hydrolases	hydrolases	NNS	_	24	ppmod	_	_
28	,	,	,	_	24	p	_	_
29	inhibitors	inhibitor	NNS	_	24	conj	_	_
30	of	of	IN	_	32	case	_	_
31	protective	protective	JJ	_	32	attr	_	_
32	enzymes	enzyme	NNS	_	29	ppmod	_	_
33	as	as	IN	_	35	case	_	_
34	glutathione	glutathione	NN	_	35	com	_	_
35	S-transferase	s-transferase	NN	_	32	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	catalase	catalase	NN	_	35	conj	_	_
38	,	,	,	_	29	p	_	_
39	the	the	DT	_	40	det	_	_
40	depletion	depletion	NN	_	24	conj	_	_
41	of	of	IN	_	42	case	_	_
42	glutathione	glutathione	NN	_	40	ppmod	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	GSH	gsh	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	,	,	,	_	40	p	_	_
47	and	and	CC	_	40	cc	_	_
48	the	the	DT	_	49	det	_	_
49	inhibition	inhibition	NN	_	24	conj	_	_
50	of	of	IN	_	52	case	_	_
51	protein	protein	NN	_	52	com	_	_
52	synthesis	synthesis	NN	_	49	ppmod	_	_
53	;	;	:	_	6	p	_	_

1	and	and	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	variety	variety	NN	_	0	root	_	_
4	of	of	IN	_	7	case	_	_
5	putative	putative	JJ	_	7	attr	_	_
6	protective	protective	JJ	_	7	attr	_	_
7	compounds	compound	NNS	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	including	include	VBG	_	10	adv	_	_
10	antioxidants	antioxidant	NNS	_	7	ppmod	_	_
11	,	,	,	_	7	p	_	_
12	and	and	CC	_	3	cc	_	_
13	mitochondrial	mitochondrial	JJ	_	15	attr	_	_
14	protective	protective	JJ	_	15	attr	_	_
15	agents	agent	NNS	_	3	conj	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	present	present	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	reports	report	VBZ	_	15	advcl	_	_
5	two	#crd#	CD	_	7	num	_	_
6	novel	novel	JJ	_	7	attr	_	_
7	findings	finding	NNS	_	4	obj	_	_
8	:	:	:	_	15	p	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	i	i	LS	_	15	meta	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	it	it	PRP	_	15	dep	_	_
13	was	be	VBD	_	15	aux	_	_
14	clearly	clearly	RB	_	15	adv	_	_
15	evidenced	evidence	VBN	_	0	root	_	_
16	,	,	,	_	15	p	_	_
17	for	for	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	first	#ord#	JJ	_	20	attr	_	_
20	time	time	NN	_	15	ppmod	_	_
21	,	,	,	_	15	p	_	_
22	that	that	IN	_	33	mark	_	_
23	the	the	DT	_	25	det	_	_
24	acute	acute	JJ	_	25	attr	_	_
25	exposure	exposure	NN	_	33	dep	_	_
26	of	of	IN	_	30	case	_	_
27	freshly	freshly	RB	_	28	adv	_	_
28	isolated	isolate	VBN	_	30	attr	_	_
29	human	human	JJ	_	30	attr	_	_
30	lymphocytes	lymphocyte	NNS	_	25	ppmod	_	_
31	to	to	TO	_	32	aux	_	_
32	DEB	deb	NN	_	25	ppmod	_	_
33	results	result	VBZ	_	15	comp	_	_
34	in	in	IN	_	37	case	_	_
35	severe	severe	JJ	_	37	attr	_	_
36	GSH	gsh	NN	_	37	com	_	_
37	depletion	depletion	NN	_	33	ppmod	_	_
38	and	and	CC	_	37	cc	_	_
39	loss	loss	NN	_	37	conj	_	_
40	of	of	IN	_	41	case	_	_
41	ATP	atp	NN	_	39	ppmod	_	_
42	,	,	,	_	33	p	_	_
43	followed	followed	VBN	_	33	comp	_	_
44	by	by	IN	_	46	case	_	_
45	cell	cell	NN	_	46	com	_	_
46	death	death	NN	_	43	ppmod	_	_
47	;	;	:	_	15	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	ii	ii	LS	_	4	meta	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	elicits	elicit	VBZ	_	0	root	_	_
6	a	a	DT	_	9	det	_	_
7	significant	significant	JJ	_	9	attr	_	_
8	protective	protective	JJ	_	9	attr	_	_
9	effect	effect	NN	_	5	obj	_	_
10	on	on	IN	_	13	case	_	_
11	DEB	deb	NN	_	13	attr	_	_
12	induced	induced	JJ	_	13	attr	_	_
13	toxicity	toxicity	NN	_	9	ppmod	_	_
14	,	,	,	_	9	p	_	_
15	which	which	WDT	_	17	dep	_	_
16	was	be	VBD	_	17	aux	_	_
17	potentiated	potentiate	VBN	_	9	relcl	_	_
18	by	by	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	Collectively	collectively	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	these	these	DT	_	4	det	_	_
4	findings	finding	NNS	_	5	dep	_	_
5	contribute	contribute	VBP	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	increase	increase	VB	_	5	comp	_	_
8	our	our	PRP$	_	9	poss	_	_
9	knowledge	knowledge	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	DEB-induce	deb-induce	JJ	_	12	attr	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	and	and	CC	_	5	cc	_	_
14	will	will	MD	_	15	modal	_	_
15	be	be	VB	_	5	conj	_	_
16	very	very	RB	_	17	adv	_	_
17	useful	useful	JJ	_	15	dep	_	_
18	when	when	WRB	_	19	adv	_	_
19	applied	apply	VBN	_	17	comp	_	_
20	in	in	IN	_	21	case	_	_
21	studies	study	NNS	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	lymphocytes	lymphocyte	NNS	_	21	ppmod	_	_
24	from	from	IN	_	26	case	_	_
25	FA	fa	JJ	_	26	attr	_	_
26	patients	patient	NNS	_	23	ppmod	_	_
27	,	,	,	_	15	p	_	_
28	in	in	IN	_	31	mark	_	_
29	order	order	NN	_	31	dep	_	_
30	to	to	TO	_	31	aux	_	_
31	find	find	VB	_	15	comp	_	_
32	out	out	RP	_	31	prt	_	_
33	a	a	DT	_	35	det	_	_
34	protective	protective	JJ	_	35	attr	_	_
35	agent	agent	NN	_	31	obj	_	_
36	against	against	IN	_	41	case	_	_
37	spontaneous	spontaneous	JJ	_	41	attr	_	_
38	and	and	CC	_	37	cc	_	_
39	DEB-induced	deb-induced	JJ	_	37	conj	_	_
40	chromosome	chromosome	NN	_	41	com	_	_
41	instability	instability	NN	_	35	ppmod	_	_
42	.	.	.	_	5	p	_	_

1	Metabotropic	metabotropic	JJ	_	3	attr	_	_
2	glutamate	glutamate	NN	_	3	com	_	_
3	receptor	receptor	NN	_	5	attr	_	_
4	5	0	CD	_	3	num	_	_
5	antagonist	antagonist	NN	_	6	dep	_	_
6	protects	protect	VBZ	_	0	root	_	_
7	dopaminergic	dopaminergic	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	noradrenergic	noradrenergic	JJ	_	7	conj	_	_
10	neurons	neuron	NNS	_	6	obj	_	_
11	from	from	IN	_	12	case	_	_
12	degeneration	degeneration	NN	_	6	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	drug1	drug0	JJ	_	16	attr	_	_
15	-treated	-treated	JJ	_	16	attr	_	_
16	monkeys	monkey	NNS	_	12	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	Degeneration	degeneration	NN	_	15	dep	_	_
2	of	of	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	dopaminergic	dopaminergic	JJ	_	6	attr	_	_
5	nigrostriatal	nigrostriatal	JJ	_	6	attr	_	_
6	system	system	NN	_	1	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	of	of	IN	_	10	case	_	_
9	noradrenergic	noradrenergic	JJ	_	10	attr	_	_
10	neurons	neuron	NNS	_	6	conj	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	locus	locus	NN	_	14	com	_	_
14	coeruleus	coeruleus	NN	_	10	ppmod	_	_
15	are	be	VBP	_	0	root	_	_
16	important	important	JJ	_	18	attr	_	_
17	pathological	pathological	JJ	_	18	attr	_	_
18	features	feature	NNS	_	15	obj	_	_
19	of	of	IN	_	22	case	_	_
20	Parkinson	parkinson	NN	_	22	poss	_	_
21	's	's	POS	_	20	case	_	_
22	disease	disease	NN	_	18	ppmod	_	_
23	.	.	.	_	15	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	urgent	urgent	JJ	_	5	attr	_	_
5	need	need	NN	_	2	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	develop	develop	VB	_	5	acl	_	_
8	therapies	therapy	NNS	_	7	obj	_	_
9	that	that	IN	_	13	case	_	_
10	slow	slow	JJ	_	13	attr	_	_
11	down	down	JJ	_	13	attr	_	_
12	the	the	DT	_	13	det	_	_
13	progression	progression	NN	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	neurodegeneration	neurodegeneration	NN	_	13	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	Parkinson	parkinson	NN	_	19	poss	_	_
18	's	's	POS	_	17	case	_	_
19	disease	disease	NN	_	13	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	we	we	PRP	_	7	dep	_	_
7	tested	test	VBD	_	0	root	_	_
8	whether	whether	IN	_	20	mark	_	_
9	the	the	DT	_	16	det	_	_
10	highly	highly	RB	_	11	adv	_	_
11	specific	specific	JJ	_	16	attr	_	_
12	metabotropic	metabotropic	JJ	_	14	attr	_	_
13	glutamate	glutamate	NN	_	14	com	_	_
14	receptor	receptor	NN	_	16	attr	_	_
15	5	0	CD	_	14	num	_	_
16	antagonist	antagonist	NN	_	20	dep	_	_
17	,	,	,	_	16	p	_	_
18	drug1	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	reduces	reduce	VBZ	_	7	comp	_	_
21	dopaminergic	dopaminergic	JJ	_	25	attr	_	_
22	and	and	CC	_	21	cc	_	_
23	noradrenergic	noradrenergic	JJ	_	21	conj	_	_
24	neuronal	neuronal	JJ	_	25	attr	_	_
25	loss	loss	NN	_	20	obj	_	_
26	in	in	IN	_	27	case	_	_
27	monkeys	monkey	NNS	_	20	ppmod	_	_
28	rendered	render	VBN	_	27	acl	_	_
29	parkinsonian	parkinsonian	NN	_	28	obj	_	_
30	by	by	IN	_	32	case	_	_
31	chronic	chronic	JJ	_	32	attr	_	_
32	treatment	treatment	NN	_	28	ppmod	_	_
33	with	with	IN	_	35	case	_	_
34	low	low	JJ	_	35	attr	_	_
35	doses	dose	NNS	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	7	p	_	_

1	Weekly	weekly	JJ	_	4	attr	_	_
2	intramuscular	intramuscular	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	injections	injection	NNS	_	23	dep	_	_
5	(	-lrb-	-LRB-	_	9	p	_	_
6	0.2-0.5	0	CD	_	9	num	_	_
7	mg/kg	mg/kg	NN	_	9	com	_	_
8	body	body	NN	_	9	com	_	_
9	weight	weight	NN	_	4	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	23	p	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	23	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	daily	daily	JJ	_	16	attr	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	vehicle	vehicle	NN	_	18	conj	_	_
21	,	,	,	_	23	p	_	_
22	were	be	VBD	_	23	aux	_	_
23	performed	performed	VBN	_	0	root	_	_
24	until	until	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	development	development	NN	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	parkinsonian	parkinsonian	JJ	_	30	attr	_	_
29	motor	motor	NN	_	30	com	_	_
30	symptoms	symptom	NNS	_	26	ppmod	_	_
31	in	in	IN	_	32	case	_	_
32	either	either	DT	_	30	ppmod	_	_
33	of	of	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	two	#crd#	CD	_	37	num	_	_
36	experimental	experimental	JJ	_	37	attr	_	_
37	groups	group	NNS	_	32	ppmod	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	drug3	drug0	NN	_	37	prn	_	_
40	/	/	:	_	39	p	_	_
41	drug4	drug0	NN	_	39	conj	_	_
42	versus	versus	CC	_	41	cc	_	_
43	drug5	drug0	NN	_	44	com	_	_
44	/vehicle	/vehicle	NN	_	39	conj	_	_
45	)	-rrb-	-RRB-	_	39	p	_	_
46	.	.	.	_	23	p	_	_

1	After	after	IN	_	3	case	_	_
2	21	0	CD	_	3	num	_	_
3	weeks	week	NNS	_	12	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	treatment	treatment	NN	_	3	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	all	all	DT	_	11	det	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	/vehicle-treated	/vehicle-treated	JJ	_	11	attr	_	_
11	animals	animal	NNS	_	12	dep	_	_
12	displayed	display	VBD	_	27	advcl	_	_
13	parkinsonian	parkinsonian	JJ	_	14	attr	_	_
14	symptoms	symptom	NNS	_	12	obj	_	_
15	,	,	,	_	27	p	_	_
16	whereas	whereas	IN	_	27	case	_	_
17	none	none	NN	_	27	dep	_	_
18	of	of	IN	_	24	case	_	_
19	the	the	DT	_	24	det	_	_
20	drug3	drug0	NN	_	24	attr	_	_
21	/	/	:	_	24	p	_	_
22	drug4	drug0	NN	_	24	attr	_	_
23	-treated	-treated	JJ	_	24	attr	_	_
24	monkeys	monkey	NNS	_	17	ppmod	_	_
25	were	be	VBD	_	27	aux	_	_
26	significantly	significantly	RB	_	27	adv	_	_
27	affected	affect	VBN	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	These	these	DT	_	3	det	_	_
2	behavioural	behavioural	JJ	_	3	attr	_	_
3	observations	observation	NNS	_	4	dep	_	_
4	were	be	VBD	_	0	root	_	_
5	consistent	consistent	JJ	_	4	dep	_	_
6	with	with	IN	_	13	case	_	_
7	in	in	FW	_	8	adv	_	_
8	vivo	vivo	FW	_	11	attr	_	_
9	positron	positron	NN	_	11	com	_	_
10	emission	emission	NN	_	11	com	_	_
11	tomography	tomography	NN	_	13	com	_	_
12	dopamine	dopamine	NN	_	13	com	_	_
13	transporter	transporter	NN	_	5	ppmod	_	_
14	imaging	image	VBG	_	13	acl	_	_
15	data	datum	NNS	_	14	obj	_	_
16	,	,	,	_	13	p	_	_
17	and	and	CC	_	13	cc	_	_
18	with	with	IN	_	21	case	_	_
19	post-mortem	post-mortem	JJ	_	21	attr	_	_
20	stereological	stereological	JJ	_	21	attr	_	_
21	counts	count	NNS	_	13	conj	_	_
22	of	of	IN	_	25	case	_	_
23	midbrain	midbrain	JJ	_	25	attr	_	_
24	dopaminergic	dopaminergic	JJ	_	25	attr	_	_
25	neurons	neuron	NNS	_	21	ppmod	_	_
26	,	,	,	_	4	p	_	_
27	as	as	RB	_	28	com	_	_
28	well	well	RB	_	4	cc	_	_
29	as	as	IN	_	28	com	_	_
30	striatal	striatal	JJ	_	32	attr	_	_
31	intensity	intensity	NN	_	32	com	_	_
32	measurements	measurement	NNS	_	4	conj	_	_
33	of	of	IN	_	35	case	_	_
34	dopamine	dopamine	NN	_	35	com	_	_
35	transporter	transporter	NN	_	32	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	tyrosine	tyrosine	NN	_	38	com	_	_
38	hydroxylase	hydroxylase	NN	_	39	com	_	_
39	immunoreactivity	immunoreactivity	NN	_	35	conj	_	_
40	,	,	,	_	35	p	_	_
41	which	which	WDT	_	42	dep	_	_
42	were	be	VBD	_	35	relcl	_	_
43	all	all	RB	_	42	adv	_	_
44	significantly	significantly	RB	_	45	adv	_	_
45	higher	high	JJR	_	42	dep	_	_
46	in	in	IN	_	51	case	_	_
47	drug1	drug0	NN	_	51	attr	_	_
48	/	/	:	_	51	p	_	_
49	drug2	drug0	NN	_	51	attr	_	_
50	-treated	-treated	JJ	_	51	attr	_	_
51	animals	animal	NNS	_	45	ppmod	_	_
52	than	than	IN	_	56	case	_	_
53	in	in	IN	_	56	case	_	_
54	drug3	drug0	CD	_	56	num	_	_
55	/vehicle-treated	/vehicle-treated	JJ	_	56	attr	_	_
56	monkeys	monkey	NNS	_	45	ppmod	_	_
57	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	treatment	treatment	NN	_	5	dep	_	_
4	also	also	RB	_	5	adv	_	_
5	had	have	VBD	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	on	on	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	drug2	drug0	NN	_	12	advnp	_	_
12	-induced	-induced	JJ	_	13	attr	_	_
13	loss	loss	NN	_	5	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	norepinephrine	norepinephrine	NN	_	16	com	_	_
16	neurons	neuron	NNS	_	13	ppmod	_	_
17	in	in	IN	_	28	case	_	_
18	the	the	DT	_	20	det	_	_
19	locus	locus	NN	_	20	com	_	_
20	coeruleus	coeruleus	NN	_	28	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	adjoining	adjoining	JJ	_	23	attr	_	_
23	A5	a0	NN	_	20	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	A7	a0	NN	_	26	com	_	_
26	noradrenaline	noradrenaline	NN	_	23	conj	_	_
27	cell	cell	NN	_	28	com	_	_
28	groups	group	NNS	_	16	ppmod	_	_
29	.	.	.	_	5	p	_	_

1	In	in	IN	_	4	case	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	/vehicle-treated	/vehicle-treated	JJ	_	4	attr	_	_
4	animals	animal	NNS	_	16	ppmod	_	_
5	,	,	,	_	16	p	_	_
6	almost	almost	RB	_	7	adv	_	_
7	40	0	CD	_	9	num	_	_
8	%	%	NN	_	7	meta	_	_
9	loss	loss	NN	_	16	dep	_	_
10	of	of	IN	_	14	case	_	_
11	tyrosine	tyrosine	NN	_	12	advnp	_	_
12	hydroxylase-positive	hydroxylase-positive	JJ	_	14	attr	_	_
13	norepinephrine	norepinephrine	NN	_	14	com	_	_
14	neurons	neuron	NNS	_	9	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	found	find	VBN	_	0	root	_	_
17	in	in	IN	_	22	case	_	_
18	locus	locus	NN	_	22	com	_	_
19	coeruleus/A5/A7	coeruleus/a0/a0	NN	_	22	com	_	_
20	noradrenaline	noradrenaline	NN	_	22	com	_	_
21	cell	cell	NN	_	22	com	_	_
22	groups	group	NNS	_	16	ppmod	_	_
23	,	,	,	_	16	p	_	_
24	whereas	whereas	IN	_	30	mark	_	_
25	the	the	DT	_	26	det	_	_
26	extent	extent	NN	_	30	dep	_	_
27	of	of	IN	_	29	case	_	_
28	neuronal	neuronal	JJ	_	29	attr	_	_
29	loss	loss	NN	_	26	ppmod	_	_
30	was	be	VBD	_	16	comp	_	_
31	lower	low	JJR	_	33	attr	_	_
32	than	than	IN	_	31	com	_	_
33	15	0	CD	_	30	obj	_	_
34	%	%	NN	_	33	meta	_	_
35	of	of	IN	_	37	case	_	_
36	control	control	NN	_	37	com	_	_
37	values	value	NNS	_	33	ppmod	_	_
38	in	in	IN	_	43	case	_	_
39	drug2	drug0	NN	_	43	attr	_	_
40	/	/	:	_	43	p	_	_
41	drug3	drug0	NN	_	43	attr	_	_
42	-treated	-treated	JJ	_	43	attr	_	_
43	monkeys	monkey	NNS	_	30	ppmod	_	_
44	.	.	.	_	16	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	data	datum	NNS	_	3	dep	_	_
3	demonstrate	demonstrate	VBP	_	0	root	_	_
4	that	that	IN	_	18	mark	_	_
5	chronic	chronic	JJ	_	6	attr	_	_
6	treatment	treatment	NN	_	18	dep	_	_
7	with	with	IN	_	13	case	_	_
8	the	the	DT	_	11	det	_	_
9	metabotropic	metabotropic	JJ	_	11	attr	_	_
10	glutamate	glutamate	NN	_	11	com	_	_
11	receptor	receptor	NN	_	13	attr	_	_
12	5	0	CD	_	11	num	_	_
13	antagonist	antagonist	NN	_	6	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug1	drug0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	significantly	significantly	RB	_	18	adv	_	_
18	reduces	reduce	VBZ	_	3	comp	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	18	obj	_	_
21	towards	towards	IN	_	26	case	_	_
22	dopaminergic	dopaminergic	JJ	_	26	attr	_	_
23	and	and	CC	_	22	cc	_	_
24	noradrenergic	noradrenergic	JJ	_	22	conj	_	_
25	cell	cell	NN	_	26	com	_	_
26	groups	group	NNS	_	20	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	non-human	non-human	JJ	_	29	attr	_	_
29	primates	primate	NNS	_	20	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	dep	_	_
2	suggests	suggest	VBZ	_	0	root	_	_
3	that	that	IN	_	13	mark	_	_
4	the	the	DT	_	5	det	_	_
5	use	use	NN	_	13	dep	_	_
6	of	of	IN	_	11	case	_	_
7	metabotropic	metabotropic	JJ	_	11	attr	_	_
8	glutamate	glutamate	NN	_	11	attr	_	_
9	receptor	receptor	NN	_	11	attr	_	_
10	5	0	CD	_	11	num	_	_
11	antagonists	antagonist	NNS	_	5	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	be	be	VB	_	2	comp	_	_
14	a	a	DT	_	16	det	_	_
15	useful	useful	JJ	_	16	attr	_	_
16	strategy	strategy	NN	_	13	obj	_	_
17	to	to	TO	_	18	aux	_	_
18	reduce	reduce	VB	_	16	acl	_	_
19	degeneration	degeneration	NN	_	18	obj	_	_
20	of	of	IN	_	22	case	_	_
21	catecholaminergic	catecholaminergic	JJ	_	22	attr	_	_
22	neurons	neuron	NNS	_	19	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	Parkinson	parkinson	NN	_	26	poss	_	_
25	's	's	POS	_	24	case	_	_
26	disease	disease	NN	_	19	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	activity	activity	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	combined	combine	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	against	against	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	isolates	isolate	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	-resistant	-resistant	JJ	_	13	attr	_	_
15	Staphylococcus	staphylococcus	FW	_	16	adv	_	_
16	aureus	aureus	FW	_	14	adv	_	_
17	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	aimed	aim	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	evaluate	evaluate	VB	_	3	comp	_	_
6	the	the	DT	_	9	det	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	9	attr	_	_
9	activity	activity	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	combined	combine	VBN	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	against	against	IN	_	16	case	_	_
16	isolates	isolate	NNS	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	CD	_	16	ppmod	_	_
19	-resistant	-resistant	JJ	_	18	attr	_	_
20	Staphylococcus	staphylococcus	FW	_	21	attr	_	_
21	aureus	aureus	FW	_	18	attr	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	MRSA	mrsa	NN	_	18	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	total	total	NN	_	15	dep	_	_
3	of	of	IN	_	6	case	_	_
4	87	0	CD	_	6	num	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	isolates	isolate	NNS	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	MRSA	mrsa	NN	_	6	ppmod	_	_
9	collected	collect	VBN	_	6	acl	_	_
10	from	from	IN	_	13	case	_	_
11	three	#crd#	CD	_	13	num	_	_
12	Chinese	chinese	JJ	_	13	attr	_	_
13	hospitals	hospital	NNS	_	9	ppmod	_	_
14	were	be	VBD	_	15	aux	_	_
15	included	include	VBN	_	0	root	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	study	study	NN	_	15	ppmod	_	_
19	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	checkerboard	checkerboard	JJ	_	3	attr	_	_
3	method	method	NN	_	15	dep	_	_
4	with	with	IN	_	5	case	_	_
5	determination	determination	NN	_	3	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	fractional	fractional	JJ	_	10	attr	_	_
9	IC	ic	NN	_	10	com	_	_
10	index	index	NN	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	FICI	fici	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	was	be	VBD	_	15	aux	_	_
15	used	use	VBN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	determine	determine	VB	_	15	comp	_	_
18	whether	whether	IN	_	21	mark	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	combinations	combination	NNS	_	21	dep	_	_
21	act	act	VBP	_	17	comp	_	_
22	synergistically	synergistically	RB	_	21	adv	_	_
23	against	against	IN	_	25	case	_	_
24	these	these	DT	_	25	det	_	_
25	isolates	isolate	NNS	_	21	ppmod	_	_
26	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	susceptibility	susceptibility	NN	_	3	com	_	_
3	results	result	NNS	_	9	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	interpreted	interpret	VBN	_	0	root	_	_
10	according	accord	VBG	_	15	adv	_	_
11	to	to	TO	_	15	aux	_	_
12	the	the	DT	_	15	det	_	_
13	most	most	RBS	_	14	adv	_	_
14	relevant	relevant	JJ	_	15	attr	_	_
15	criteria	criterion	NNS	_	9	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	demonstrated	demonstrate	VBD	_	28	advcl	_	_
4	the	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	3	obj	_	_
7	:	:	:	_	28	p	_	_
8	76	0	CD	_	9	num	_	_
9	isolates	isolate	NNS	_	28	dep	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	87.4	0	CD	_	9	num	_	_
12	%	%	NN	_	11	meta	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_
14	showed	show	VBD	_	28	aux	_	_
15	synergistic	synergistic	JJ	_	16	attr	_	_
16	interactions	interaction	NNS	_	28	obj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	FICI	fici	NNP	_	16	prn	_	_
19	0.5	0	CD	_	18	num	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	and	and	CC	_	16	cc	_	_
22	11	0	CD	_	23	num	_	_
23	isolates	isolate	NNS	_	16	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	12.6	0	CD	_	23	num	_	_
26	%	%	NN	_	25	meta	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	showed	show	VBD	_	0	root	_	_
29	indifferent	indifferent	JJ	_	30	attr	_	_
30	interactions	interaction	NNS	_	28	obj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	0.5&amp	0&amp	NN	_	30	prn	_	_
33	;	;	:	_	32	p	_	_
34	lt	lt	NN	_	32	appo	_	_
35	;	;	:	_	32	p	_	_
36	FICI&amp	fici&amp	NN	_	32	appo	_	_
37	;	;	:	_	32	p	_	_
38	lt	lt	NN	_	32	appo	_	_
39	;	;	:	_	32	p	_	_
40	4	0	CD	_	32	appo	_	_
41	)	-rrb-	-RRB-	_	32	p	_	_
42	.	.	.	_	28	p	_	_

1	No	no	DT	_	3	det	_	_
2	antagonistic	antagonistic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	9	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	FICI	fici	NNP	_	3	prn	_	_
6	4	0	CD	_	5	num	_	_
7	)	-rrb-	-RRB-	_	5	p	_	_
8	were	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	combination	combination	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	can	can	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	synergistic	synergistic	JJ	_	8	dep	_	_
10	against	against	IN	_	11	case	_	_
11	MRSA	mrsa	NN	_	9	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	Further	far	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	required	require	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	determine	determine	VB	_	4	comp	_	_
7	the	the	DT	_	10	det	_	_
8	potential	potential	JJ	_	9	adv	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	role	role	NN	_	6	obj	_	_
11	of	of	IN	_	14	case	_	_
12	this	this	DT	_	14	det	_	_
13	combination	combination	NN	_	14	com	_	_
14	regimen	regimen	NN	_	10	ppmod	_	_
15	as	as	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	alternative	alternative	NN	_	10	ppmod	_	_
19	for	for	IN	_	21	case	_	_
20	certain	certain	JJ	_	21	attr	_	_
21	types	type	NNS	_	18	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	MRSA	mrsa	NN	_	24	com	_	_
24	infections	infection	NNS	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	enhances	enhance	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	4	advnp	_	_
4	-mediated	-mediated	JJ	_	7	attr	_	_
5	antibody-dependent	antibody-dependent	JJ	_	7	attr	_	_
6	cellular	cellular	JJ	_	7	attr	_	_
7	cytotoxicity	cytotoxicity	NN	_	2	obj	_	_
8	by	by	IN	_	9	case	_	_
9	up-regulation	up-regulation	NN	_	2	ppmod	_	_
10	of	of	IN	_	14	case	_	_
11	cell	cell	NN	_	14	com	_	_
12	surface	surface	NN	_	14	com	_	_
13	HER2	her0	NN	_	14	com	_	_
14	expression	expression	NN	_	9	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	it	it	PRP	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	previously	previously	RB	_	5	adv	_	_
5	reported	report	VBN	_	33	advcl	_	_
6	that	that	IN	_	11	mark	_	_
7	drug1	drug0	NN	_	11	dep	_	_
8	combined	combine	VBN	_	7	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	improved	improve	VBD	_	5	comp	_	_
12	the	the	DT	_	15	det	_	_
13	progression-free	progression-free	JJ	_	15	attr	_	_
14	survival	survival	NN	_	15	com	_	_
15	rate	rate	NN	_	11	obj	_	_
16	compared	compare	VBN	_	18	adv	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	11	ppmod	_	_
19	alone	alone	RB	_	18	adv	_	_
20	for	for	IN	_	21	case	_	_
21	patients	patient	NNS	_	11	ppmod	_	_
22	with	with	IN	_	28	case	_	_
23	drug4	drug0	NN	_	28	attr	_	_
24	-refractory	-refractory	JJ	_	28	attr	_	_
25	HER2-positive	her0-positive	JJ	_	28	attr	_	_
26	metastatic	metastatic	JJ	_	28	attr	_	_
27	breast	breast	NN	_	28	com	_	_
28	cancer	cancer	NN	_	21	ppmod	_	_
29	,	,	,	_	33	p	_	_
30	the	the	DT	_	31	det	_	_
31	mechanism	mechanism	NN	_	33	dep	_	_
32	is	be	VBZ	_	33	aux	_	_
33	purported	purport	VBN	_	0	root	_	_
34	to	to	TO	_	35	aux	_	_
35	be	be	VB	_	33	comp	_	_
36	an	an	DT	_	38	det	_	_
37	antiproliferative	antiproliferative	JJ	_	38	attr	_	_
38	effect	effect	NN	_	35	obj	_	_
39	relating	relate	VBG	_	38	acl	_	_
40	to	to	TO	_	42	aux	_	_
41	the	the	DT	_	42	det	_	_
42	synergism	synergism	NN	_	39	ppmod	_	_
43	of	of	IN	_	46	case	_	_
44	these	these	DT	_	46	det	_	_
45	two	#crd#	CD	_	46	num	_	_
46	agents	agent	NNS	_	42	ppmod	_	_
47	.	.	.	_	33	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	how	how	WRB	_	5	adv	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	interacts	interact	VBZ	_	2	comp	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	HER2-positive	her0-positive	JJ	_	11	attr	_	_
10	breast	breast	NN	_	11	com	_	_
11	cancer	cancer	NN	_	7	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	with	with	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	particular	particular	JJ	_	16	attr	_	_
16	focus	focus	NN	_	5	ppmod	_	_
17	on	on	IN	_	22	case	_	_
18	drug3	drug0	NN	_	22	attr	_	_
19	-mediated	-mediated	JJ	_	22	attr	_	_
20	antibody-dependent	antibody-dependent	JJ	_	22	attr	_	_
21	cellular	cellular	JJ	_	22	attr	_	_
22	cytotoxicity	cytotoxicity	NN	_	16	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	ADCC	adcc	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	.	.	.	_	2	p	_	_

1	In	in	IN	_	5	case	_	_
2	an	an	DT	_	5	det	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	assay	assay	NN	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	induced	induce	VBD	_	0	root	_	_
9	HER2	her0	NN	_	10	com	_	_
10	expression	expression	NN	_	8	obj	_	_
11	at	at	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	cell	cell	NN	_	14	com	_	_
14	surface	surface	NN	_	8	ppmod	_	_
15	of	of	IN	_	20	case	_	_
16	HER2-positive	her0-positive	JJ	_	20	attr	_	_
17	breast	breast	NN	_	20	com	_	_
18	cancer	cancer	NN	_	20	com	_	_
19	cell	cell	NN	_	20	com	_	_
20	lines	line	NNS	_	14	ppmod	_	_
21	,	,	,	_	8	p	_	_
22	leading	lead	VBG	_	8	comp	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	enhancement	enhancement	NN	_	22	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	drug2	drug0	NN	_	29	attr	_	_
28	-mediated	-mediated	JJ	_	29	attr	_	_
29	ADCC	adcc	NN	_	25	ppmod	_	_
30	.	.	.	_	8	p	_	_

1	Furthermore	furthermore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	present	present	VBP	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	case	case	NN	_	7	com	_	_
7	report	report	NN	_	4	obj	_	_
8	in	in	IN	_	9	case	_	_
9	which	which	WDT	_	16	ppmod	_	_
10	a	a	DT	_	13	det	_	_
11	second	#ord#	JJ	_	13	attr	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	treatment	treatment	NN	_	16	dep	_	_
14	following	follow	VBG	_	15	adv	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	resulted	result	VBD	_	7	relcl	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	marked	marked	JJ	_	20	attr	_	_
20	shrinkage	shrinkage	NN	_	16	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	multiple	multiple	JJ	_	24	attr	_	_
23	metastatic	metastatic	JJ	_	24	attr	_	_
24	tumors	tumor	NNS	_	20	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	HER2-positive	her0-positive	JJ	_	28	attr	_	_
27	breast	breast	NN	_	28	com	_	_
28	cancer	cancer	NN	_	24	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	have	have	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	potential	potential	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	convert	convert	VBP	_	5	acl	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	-refractory	-refractory	NN	_	7	obj	_	_
10	to	to	TO	_	13	aux	_	_
11	drug3	drug0	NN	_	13	attr	_	_
12	-sensitive	-sensitive	JJ	_	13	attr	_	_
13	tumors	tumor	NNS	_	7	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	HER2-positive	her0-positive	JJ	_	17	attr	_	_
16	breast	breast	NN	_	17	com	_	_
17	cancer	cancer	NN	_	13	ppmod	_	_
18	by	by	IN	_	19	case	_	_
19	up-regulation	up-regulation	NN	_	3	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	cell	cell	NN	_	24	com	_	_
23	surface	surface	NN	_	24	com	_	_
24	expression	expression	NN	_	19	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	HER2	her0	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	Improved	improved	JJ	_	4	attr	_	_
2	parathyroid	parathyroid	JJ	_	3	attr	_	_
3	hormone	hormone	NN	_	4	com	_	_
4	control	control	NN	_	8	dep	_	_
5	by	by	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	reduction	reduction	NN	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	requirement	requirement	NN	_	10	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	with	with	IN	_	19	case	_	_
17	end-stage	end-stage	JJ	_	19	attr	_	_
18	renal	renal	JJ	_	19	attr	_	_
19	disease	disease	NN	_	15	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Uncontrolled	uncontrolled	JJ	_	2	attr	_	_
2	hy-per-parathyroidism	hy-per-parathyroidism	NN	_	3	dep	_	_
3	causes	cause	VBZ	_	0	root	_	_
4	bone	bone	NN	_	5	com	_	_
5	marrow	marrow	NN	_	6	com	_	_
6	fibrosis	fibrosis	NN	_	3	obj	_	_
7	,	,	,	_	3	p	_	_
8	leading	lead	VBG	_	3	comp	_	_
9	to	to	TO	_	14	aux	_	_
10	drug1	drug0	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	resistance	resistance	NN	_	8	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Medical	medical	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	5	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	effective	effective	JJ	_	5	dep	_	_
7	in	in	IN	_	8	case	_	_
8	reducing	reduce	VBG	_	6	ppmod	_	_
9	plasma	plasma	NN	_	11	attr	_	_
10	parathyroid	parathyroid	JJ	_	11	attr	_	_
11	hormone	hormone	NN	_	15	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	PTH	pth	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	levels	level	NNS	_	8	obj	_	_
16	,	,	,	_	5	p	_	_
17	but	but	CC	_	5	cc	_	_
18	its	its	PRP$	_	19	poss	_	_
19	effect	effect	NN	_	23	dep	_	_
20	on	on	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	dosing	dosing	NN	_	19	ppmod	_	_
23	is	be	VBZ	_	5	conj	_	_
24	unknown	unknown	JJ	_	23	dep	_	_
25	.	.	.	_	5	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	AND	and	CC	_	1	cc	_	_
3	AIMS	aim	NNS	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	We	we	PRP	_	6	dep	_	_
6	conducted	conduct	VBN	_	1	acl	_	_
7	a	a	DT	_	10	det	_	_
8	retrospective	retrospective	JJ	_	10	attr	_	_
9	cohort	cohort	NN	_	10	com	_	_
10	study	study	NN	_	6	obj	_	_
11	of	of	IN	_	19	case	_	_
12	40	0	CD	_	19	num	_	_
13	end-stage	end-stage	JJ	_	15	attr	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	disease	disease	NN	_	19	attr	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	ESRD	esrd	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	patients	patient	NNS	_	10	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	age	age	NN	_	19	prn	_	_
22	:	:	:	_	21	p	_	_
23	55	0	CD	_	27	num	_	_
24	14	0	CD	_	27	num	_	_
25	;	;	:	_	27	p	_	_
26	mean	mean	NN	_	27	com	_	_
27	SD	sd	NN	_	21	appo	_	_
28	;	;	:	_	21	p	_	_
29	21	0	CD	_	21	appo	_	_
30	:	:	:	_	21	p	_	_
31	male	male	NN	_	21	appo	_	_
32	)	-rrb-	-RRB-	_	21	p	_	_
33	who	who	WP	_	34	dep	_	_
34	had	have	VBD	_	19	relcl	_	_
35	at	at	IN	_	37	case	_	_
36	least	least	JJS	_	37	attr	_	_
37	12	0	CD	_	38	num	_	_
38	months	month	NNS	_	34	obj	_	_
39	of	of	IN	_	41	case	_	_
40	drug1	drug0	NN	_	41	com	_	_
41	therapy	therapy	NN	_	38	ppmod	_	_
42	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	distribution	distribution	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	renal	renal	JJ	_	6	attr	_	_
5	replacement	replacement	NN	_	6	com	_	_
6	therapies	therapy	NNS	_	2	ppmod	_	_
7	were	be	VBD	_	0	root	_	_
8	:	:	:	_	7	p	_	_
9	14	0	CD	_	11	num	_	_
10	peritoneal	peritoneal	JJ	_	11	attr	_	_
11	dialysis	dialysis	NNS	_	7	obj	_	_
12	,	,	,	_	11	p	_	_
13	18	0	CD	_	15	num	_	_
14	conventional	conventional	JJ	_	15	attr	_	_
15	hemodialysis	hemodialysis	NN	_	11	appo	_	_
16	and	and	CC	_	15	cc	_	_
17	8	0	CD	_	19	num	_	_
18	nocturnal	nocturnal	JJ	_	19	attr	_	_
19	hemodialysis	hemodialysis	NN	_	15	conj	_	_
20	.	.	.	_	7	p	_	_

1	Standard	standard	JJ	_	5	attr	_	_
2	dialysis	dialysis	NN	_	5	attr	_	_
3	related	related	JJ	_	5	attr	_	_
4	biochemical	biochemical	JJ	_	5	attr	_	_
5	indices	index	NNS	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	medications	medication	NNS	_	5	conj	_	_
8	used	use	VBN	_	5	acl	_	_
9	were	be	VBD	_	10	aux	_	_
10	recorded	record	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	primary	primary	JJ	_	3	attr	_	_
3	objective	objective	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	study	study	NN	_	3	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	ascertain	ascertain	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	difference	difference	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	responsiveness	responsiveness	NN	_	11	ppmod	_	_
15	before	before	IN	_	11	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	after	after	IN	_	19	case	_	_
18	12	0	CD	_	19	num	_	_
19	months	month	NNS	_	15	conj	_	_
20	of	of	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	19	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	Our	our	PRP$	_	3	poss	_	_
2	secondary	secondary	JJ	_	3	attr	_	_
3	objective	objective	NN	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	determine	determine	VB	_	4	comp	_	_
7	if	if	IN	_	9	mark	_	_
8	there	there	EX	_	9	dep	_	_
9	was	be	VBD	_	6	comp	_	_
10	a	a	DT	_	11	det	_	_
11	relationship	relationship	NN	_	9	obj	_	_
12	between	between	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	changes	change	NNS	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	PTH	pth	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	requirement	requirement	NN	_	16	conj	_	_
20	.	.	.	_	4	p	_	_

1	Overall	overall	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	PTH	pth	NN	_	4	com	_	_
4	levels	level	NNS	_	5	dep	_	_
5	decreased	decrease	VBD	_	0	root	_	_
6	from	from	IN	_	29	case	_	_
7	197.5	0	CD	_	29	num	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	151.8	0	CD	_	11	num	_	_
10	;	;	:	_	11	p	_	_
11	249.2	0	CD	_	7	num	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	to	to	TO	_	7	attr	_	_
14	66.1	0	CD	_	7	appo	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	41.2	0	CD	_	18	num	_	_
17	;	;	:	_	18	p	_	_
18	136.5	0	CD	_	7	num	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	median	median	NN	_	7	prn	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	25th	#ord#	NN	_	21	prn	_	_
24	;	;	:	_	23	p	_	_
25	75th	#ord#	NN	_	26	com	_	_
26	percentile	percentile	NN	_	23	appo	_	_
27	)	-rrb-	-RRB-	_	23	p	_	_
28	)	-rrb-	-RRB-	_	21	p	_	_
29	pmol/l	pmol/l	NN	_	5	ppmod	_	_
30	;	;	:	_	5	p	_	_

1	p	p	NN	_	2	com	_	_
2	&amp	&amp	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_
4	lt	lt	NN	_	2	appo	_	_
5	;	;	:	_	2	p	_	_

1	0.001	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	from	from	IN	_	13	case	_	_
5	30.0	0	CD	_	13	num	_	_
6	6	0	CD	_	13	num	_	_
7	to	to	TO	_	6	cc	_	_
8	63	0	CD	_	6	conj	_	_
9	25	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	13	attr	_	_
11	,	,	,	_	13	p	_	_
12	p	p	NN	_	13	com	_	_
13	&lt	&lt	NN	_	3	ppmod	_	_
14	;	;	:	_	3	p	_	_

1	0.05	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Hemoglobin	hemoglobin	NN	_	2	dep	_	_
2	remained	remain	VBD	_	0	root	_	_
3	unchanged	unchanged	JJ	_	2	dep	_	_
4	(	-lrb-	-LRB-	_	10	p	_	_
5	116	0	CD	_	10	num	_	_
6	13	0	CD	_	10	num	_	_
7	to	to	TO	_	6	cc	_	_
8	116	0	CD	_	6	conj	_	_
9	13	0	CD	_	10	num	_	_
10	g/l	g/l	NN	_	3	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	2	p	_	_
13	while	while	IN	_	16	mark	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	requirement	requirement	NN	_	16	dep	_	_
16	decreased	decrease	VBD	_	2	comp	_	_
17	from	from	IN	_	22	case	_	_
18	40	0	CD	_	22	num	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	20	0	CD	_	22	num	_	_
21	;	;	:	_	22	p	_	_
22	60	0	CD	_	16	ppmod	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	to	to	TO	_	31	aux	_	_
25	24	0	CD	_	31	num	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	19	0	CD	_	29	num	_	_
28	;	;	:	_	29	p	_	_
29	59	0	CD	_	25	num	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	g/week	g/week	NN	_	16	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	p	p	NN	_	31	appo	_	_
34	=	=	JJ	_	33	attr	_	_
35	0.02	0	CD	_	34	num	_	_
36	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	remainder	remainder	NN	_	21	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	dialysis-related	dialysis-related	JJ	_	6	attr	_	_
6	biochemistry	biochemistry	NN	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	electrolytes	electrolyte	NNS	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	calcium	calcium	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	phosphate	phosphate	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	iron	iron	NN	_	15	com	_	_
15	status	status	NN	_	8	appo	_	_
16	)	-rrb-	-RRB-	_	8	p	_	_
17	and	and	CC	_	6	cc	_	_
18	vitamin	vitamin	NN	_	20	com	_	_
19	D	d	NN	_	20	com	_	_
20	use	use	NN	_	6	conj	_	_
21	remained	remain	VBD	_	0	root	_	_
22	unchanged	unchanged	JJ	_	21	dep	_	_
23	.	.	.	_	21	p	_	_

1	A	a	DT	_	2	det	_	_
2	reduction	reduction	NN	_	12	dep	_	_
3	in	in	IN	_	5	case	_	_
4	PTH	pth	NN	_	5	com	_	_
5	level	level	NN	_	2	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	greater	great	JJR	_	9	attr	_	_
8	than	than	IN	_	7	com	_	_
9	30	0	CD	_	5	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	was	be	VBD	_	12	aux	_	_
12	experienced	experience	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	82.5	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	33/40	0	NN	_	14	num	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	of	of	IN	_	21	case	_	_
20	our	our	PRP$	_	21	poss	_	_
21	cohort	cohort	NN	_	14	ppmod	_	_
22	.	.	.	_	12	p	_	_

1	Among	among	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	responders	responder	NNS	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	the	the	DT	_	14	dep	_	_
6	fall	fall	VBP	_	5	acl	_	_
7	in	in	IN	_	8	case	_	_
8	PTH	pth	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	reduction	reduction	NN	_	12	com	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	requirement	requirement	NN	_	8	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	related	related	JJ	_	0	root	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	R	r	NN	_	14	prn	_	_
17	=	=	JJ	_	16	attr	_	_
18	-0.48	0	CD	_	17	num	_	_
19	,	,	,	_	16	p	_	_
20	p	p	NN	_	21	dep	_	_
21	=	=	JJ	_	16	advcl	_	_
22	0.004	0	CD	_	21	obj	_	_
23	)	-rrb-	-RRB-	_	16	p	_	_
24	.	.	.	_	14	p	_	_

1	Reduction	reduction	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	PTH	pth	NN	_	1	ppmod	_	_
4	by	by	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	decrease	decrease	NN	_	7	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	requirement	requirement	NN	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	interface	interface	NN	_	10	dep	_	_
3	between	between	IN	_	4	case	_	_
4	bone	bone	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	bone	bone	NN	_	7	com	_	_
7	marrow	marrow	NN	_	4	conj	_	_
8	in	in	IN	_	9	case	_	_
9	uremia	uremia	NN	_	2	ppmod	_	_
10	represents	represent	VBZ	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	critical	critical	JJ	_	13	attr	_	_
13	step	step	NN	_	10	obj	_	_
14	in	in	IN	_	18	case	_	_
15	red	red	JJ	_	18	attr	_	_
16	blood	blood	NN	_	18	com	_	_
17	cell	cell	NN	_	18	com	_	_
18	production	production	NN	_	13	ppmod	_	_
19	which	which	WDT	_	20	dep	_	_
20	merits	merit	NNS	_	13	relcl	_	_
21	further	far	JJ	_	22	attr	_	_
22	investigation	investigation	NN	_	20	obj	_	_
23	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	5	0	CD	_	9	num	_	_
9	milligrams	milligram	NNS	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	at	at	IN	_	15	case	_	_
15	doses	dose	NNS	_	6	ppmod	_	_
16	less	less	JJR	_	15	attr	_	_
17	than	than	IN	_	19	case	_	_
18	800	0	CD	_	19	num	_	_
19	milligrams	milligram	NNS	_	16	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	nonpregnant	nonpregnant	JJ	_	22	attr	_	_
22	women	woman	NNS	_	19	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	only	only	RB	_	5	adv	_	_
5	known	known	JJ	_	6	attr	_	_
6	component	component	NN	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	diet	diet	NN	_	6	ppmod	_	_
10	that	that	WDT	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	affect	affect	VB	_	6	relcl	_	_
13	absorption	absorption	NN	_	12	obj	_	_
14	of	of	IN	_	16	case	_	_
15	both	both	CC	_	16	cc	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	2	p	_	_

1	However	however	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	4	det	_	_
4	evidence	evidence	NN	_	13	dep	_	_
5	for	for	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	effect	effect	NN	_	4	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	absorption	absorption	NN	_	8	ppmod	_	_
12	mainly	mainly	RB	_	13	adv	_	_
13	comes	come	VBZ	_	0	root	_	_
14	from	from	IN	_	15	case	_	_
15	studies	study	NNS	_	13	ppmod	_	_
16	that	that	WDT	_	19	dep	_	_
17	did	do	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	isolate	isolate	VB	_	15	relcl	_	_
20	the	the	DT	_	21	det	_	_
21	effect	effect	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	from	from	IN	_	25	case	_	_
25	that	that	DT	_	19	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	other	other	JJ	_	29	attr	_	_
28	dietary	dietary	JJ	_	29	attr	_	_
29	components	component	NNS	_	25	ppmod	_	_
30	,	,	,	_	19	p	_	_
31	because	because	IN	_	34	mark	_	_
32	it	it	PRP	_	34	dep	_	_
33	was	be	VBD	_	34	aux	_	_
34	detected	detect	VBN	_	19	comp	_	_
35	in	in	IN	_	37	case	_	_
36	single-meal	single-meal	JJ	_	37	attr	_	_
37	studies	study	NNS	_	34	ppmod	_	_
38	.	.	.	_	13	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	objective	objective	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	establish	establish	VB	_	3	comp	_	_
6	potential	potential	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	on	on	IN	_	11	case	_	_
11	absorption	absorption	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	and	and	CC	_	11	cc	_	_
17	the	the	DT	_	19	det	_	_
18	dose	dose	NN	_	19	com	_	_
19	response	response	NN	_	11	conj	_	_
20	for	for	IN	_	22	case	_	_
21	this	this	DT	_	22	det	_	_
22	effect	effect	NN	_	19	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	absence	absence	NN	_	5	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	a	a	DT	_	28	det	_	_
28	meal	meal	NN	_	25	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	Fifty-four	fifty-four	JJ	_	5	attr	_	_
2	healthy	healthy	JJ	_	4	adv	_	_
3	,	,	,	_	4	p	_	_
4	nonpregnant	nonpregnant	JJ	_	5	attr	_	_
5	women	woman	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	selected	select	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	participate	participate	VB	_	7	comp	_	_
10	in	in	IN	_	14	case	_	_
11	4	0	CD	_	14	num	_	_
12	drug1	drug0	JJ	_	14	attr	_	_
13	absorption	absorption	NN	_	14	com	_	_
14	studies	study	NNS	_	9	ppmod	_	_
15	using	use	VBG	_	14	acl	_	_
16	iron	iron	NN	_	18	attr	_	_
17	radioactive	radioactive	JJ	_	18	attr	_	_
18	tracers	tracer	NNS	_	15	obj	_	_
19	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	evaluated	evaluate	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	4	ppmod	_	_
8	between	between	IN	_	12	case	_	_
9	200	0	CD	_	12	num	_	_
10	and	and	CC	_	9	cc	_	_
11	1500	0	CD	_	9	conj	_	_
12	mg	mg	NN	_	7	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	absorption	absorption	NN	_	4	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	5	0	CD	_	17	num	_	_
17	mg	mg	NN	_	18	com	_	_
18	drug2	drug0	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	as	as	IN	_	21	case	_	_
21	drug3	drug0	NN	_	18	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	.	.	.	_	2	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	evaluated	evaluate	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	5	ppmod	_	_
9	between	between	IN	_	13	case	_	_
10	200	0	CD	_	13	num	_	_
11	and	and	CC	_	10	cc	_	_
12	800	0	CD	_	10	conj	_	_
13	mg	mg	NN	_	8	ppmod	_	_
14	on	on	IN	_	15	case	_	_
15	absorption	absorption	NN	_	5	ppmod	_	_
16	of	of	IN	_	22	case	_	_
17	5	0	CD	_	18	num	_	_
18	mg	mg	NN	_	22	attr	_	_
19	drug2	drug0	NN	_	22	attr	_	_
20	-LSB-as	-lsb-as	NN	_	22	attr	_	_
21	concentrated	concentrated	JJ	_	22	attr	_	_
22	RBC	rbc	NNS	_	15	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	CRBC	crbc	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	]	-rsb-	-RRB-	_	5	p	_	_
27	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	administered	administer	VBN	_	0	root	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	all	all	DT	_	8	det	_	_
8	studies	study	NNS	_	3	ppmod	_	_
9	and	and	CC	_	3	cc	_	_
10	drug3	drug0	NN	_	12	dep	_	_
11	were	be	VBD	_	12	aux	_	_
12	ingested	ingest	VBN	_	3	conj	_	_
13	on	on	IN	_	16	case	_	_
14	an	an	DT	_	16	det	_	_
15	empty	empty	JJ	_	16	attr	_	_
16	stomach	stomach	NN	_	12	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	doses	dose	NNS	_	5	dep	_	_
3	1000	0	CD	_	4	num	_	_
4	mg	mg	NN	_	2	appo	_	_
5	diminished	diminish	VBD	_	0	root	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	by	by	IN	_	10	case	_	_
9	an	an	DT	_	10	det	_	_
10	average	average	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	49.6	0	CD	_	10	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	.	.	.	_	5	p	_	_

1	A	a	DT	_	3	det	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	dose	dose	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	800	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	ppmod	_	_
7	diminished	diminish	VBD	_	0	root	_	_
8	absorption	absorption	NN	_	7	obj	_	_
9	of	of	IN	_	12	case	_	_
10	5	0	CD	_	11	num	_	_
11	mg	mg	NN	_	12	com	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	37.7	0	CD	_	8	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	conclusion	conclusion	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	we	we	PRP	_	5	dep	_	_
5	demonstrated	demonstrate	VBD	_	0	root	_	_
6	an	an	DT	_	8	det	_	_
7	isolated	isolate	VBN	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	as	as	IN	_	13	case	_	_
13	chloride	chloride	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	on	on	IN	_	16	case	_	_
16	absorption	absorption	NN	_	8	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	5	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	iron	iron	NN	_	19	ppmod	_	_
22	provided	provided	VBN	_	21	acl	_	_
23	as	as	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	as	as	IN	_	27	case	_	_
27	sulfate	sulfate	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	and	and	CC	_	24	cc	_	_
30	drug3	drug0	NN	_	35	attr	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	as	as	IN	_	33	case	_	_
33	CRBC	crbc	NN	_	30	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	drug3	drug0	NN	_	24	conj	_	_
36	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	at	at	IN	_	6	case	_	_
6	doses	dose	NNS	_	4	ppmod	_	_
7	higher	high	JJR	_	6	attr	_	_
8	than	than	IN	_	10	mark	_	_
9	previously	previously	RB	_	10	adv	_	_
10	reported	report	VBN	_	7	comp	_	_
11	from	from	IN	_	13	case	_	_
12	single-meal	single-meal	JJ	_	13	attr	_	_
13	studies	study	NNS	_	10	ppmod	_	_
14	,	,	,	_	4	p	_	_
15	starting	start	VBG	_	4	comp	_	_
16	at	at	IN	_	18	case	_	_
17	~800	~0	CD	_	18	num	_	_
18	mg	mg	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Synergistic	synergistic	JJ	_	2	attr	_	_
2	interaction	interaction	NN	_	7	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	0	root	_	_
8	sequence	sequence	NN	_	9	advnp	_	_
9	dependent	dependent	JJ	_	7	dep	_	_
10	in	in	IN	_	14	case	_	_
11	human	human	JJ	_	14	attr	_	_
12	non-small	non-small	NN	_	14	com	_	_
13	lung	lung	NN	_	14	com	_	_
14	cancer	cancer	NN	_	7	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	EGFR	egfr	NN	_	18	attr	_	_
17	TKIs-resistant	tkis-resistant	JJ	_	18	attr	_	_
18	mutation	mutation	NN	_	14	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Previous	previous	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	that	that	IN	_	10	mark	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	has	have	VBZ	_	10	lv	_	_
8	the	the	DT	_	10	det	_	_
9	anti-tumor	anti-tumor	JJ	_	10	attr	_	_
10	activity	activity	NN	_	4	comp	_	_
11	in	in	IN	_	16	case	_	_
12	human	human	JJ	_	16	attr	_	_
13	non-small	non-small	JJ	_	16	attr	_	_
14	cell	cell	NN	_	16	com	_	_
15	lung	lung	NN	_	16	com	_	_
16	cancer	cancer	NN	_	10	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	NSCLC	nsclc	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	aimed	aim	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	investigate	investigate	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	efficacy	efficacy	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	single	single	JJ	_	11	attr	_	_
11	use	use	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	that	that	DT	_	13	conj	_	_
16	of	of	IN	_	20	case	_	_
17	concurrent	concurrent	JJ	_	20	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	sequential	sequential	JJ	_	17	conj	_	_
20	administration	administration	NN	_	15	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	28	case	_	_
26	NSCLC	nsclc	NN	_	28	com	_	_
27	cell	cell	NN	_	28	com	_	_
28	lines	line	NNS	_	8	ppmod	_	_
29	that	that	WDT	_	30	dep	_	_
30	are	be	VBP	_	28	relcl	_	_
31	resistant	resistant	JJ	_	30	dep	_	_
32	to	to	TO	_	34	aux	_	_
33	EGFR	egfr	NN	_	34	com	_	_
34	TKIs	tkis	NN	_	31	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	NSCLC	nsclc	NN	_	3	com	_	_
2	cell	cell	NN	_	3	com	_	_
3	lines	line	NNS	_	12	dep	_	_
4	with	with	IN	_	7	case	_	_
5	EGFR	egfr	NN	_	7	com	_	_
6	T790M	t0m	NN	_	7	com	_	_
7	mutation	mutation	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	K-ras	k-ras	NN	_	10	com	_	_
10	mutation	mutation	NN	_	7	conj	_	_
11	were	be	VBD	_	12	aux	_	_
12	exposed	expose	VBN	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	either	either	CC	_	15	cc	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	or	or	CC	_	15	cc	_	_
19	both	both	DT	_	15	conj	_	_
20	based	base	VBN	_	19	acl	_	_
21	on	on	IN	_	24	case	_	_
22	various	various	JJ	_	24	attr	_	_
23	sequential	sequential	JJ	_	24	attr	_	_
24	administrations	administration	NNS	_	20	ppmod	_	_
25	.	.	.	_	12	p	_	_

1	After	after	IN	_	2	case	_	_
2	exposure	exposure	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	the	the	DT	_	6	det	_	_
5	cell	cell	NN	_	6	com	_	_
6	viability	viability	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	measured	measure	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	MTT	mtt	NN	_	11	com	_	_
11	assay	assay	NN	_	8	ppmod	_	_
12	,	,	,	_	8	p	_	_
13	cell	cell	NN	_	15	com	_	_
14	cycle	cycle	NN	_	15	com	_	_
15	distribution	distribution	NN	_	17	dep	_	_
16	was	be	VBD	_	17	aux	_	_
17	analyzed	analyze	VBN	_	8	conj	_	_
18	by	by	IN	_	20	case	_	_
19	flow	flow	NN	_	20	com	_	_
20	cytometry	cytometry	NN	_	17	ppmod	_	_
21	,	,	,	_	17	p	_	_
22	and	and	CC	_	17	cc	_	_
23	alterations	alteration	NNS	_	28	dep	_	_
24	in	in	IN	_	26	case	_	_
25	signaling	signaling	NN	_	26	com	_	_
26	pathway	pathway	NN	_	23	ppmod	_	_
27	were	be	VBD	_	28	aux	_	_
28	determined	determine	VBN	_	8	conj	_	_
29	by	by	IN	_	30	case	_	_
30	immunoblotting	immunoblotting	NN	_	28	ppmod	_	_
31	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	exhibited	exhibit	VBD	_	20	advcl	_	_
3	dose-dependent	dose-dependent	JJ	_	5	attr	_	_
4	growth	growth	NN	_	5	com	_	_
5	inhibition	inhibition	NN	_	2	obj	_	_
6	in	in	IN	_	9	case	_	_
7	NSCLC	nsclc	NN	_	9	com	_	_
8	cell	cell	NN	_	9	com	_	_
9	lines	line	NNS	_	2	ppmod	_	_
10	and	and	CC	_	2	cc	_	_
11	arrested	arrest	VBD	_	2	conj	_	_
12	cell	cell	NN	_	13	com	_	_
13	cycle	cycle	NN	_	11	obj	_	_
14	at	at	IN	_	16	case	_	_
15	G1	g0	NN	_	16	com	_	_
16	phase	phase	NN	_	11	ppmod	_	_
17	,	,	,	_	20	p	_	_
18	whereas	whereas	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	dep	_	_
20	arrested	arrest	VBD	_	0	root	_	_
21	at	at	IN	_	23	case	_	_
22	S	s	NN	_	23	com	_	_
23	phase	phase	NN	_	20	ppmod	_	_
24	.	.	.	_	20	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	single	single	JJ	_	5	attr	_	_
3	or	or	CC	_	2	cc	_	_
4	concurrent	concurrent	JJ	_	2	conj	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	has	have	VBZ	_	22	advcl	_	_
11	some	some	DT	_	13	det	_	_
12	anti-proliferative	anti-proliferative	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	10	obj	_	_
14	,	,	,	_	22	p	_	_
15	the	the	DT	_	17	det	_	_
16	sequential	sequential	JJ	_	17	attr	_	_
17	administrations	administration	NNS	_	22	dep	_	_
18	of	of	IN	_	20	case	_	_
19	both	both	DT	_	20	det	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	remarkably	remarkably	RB	_	22	adv	_	_
22	enhanced	enhance	VBD	_	0	root	_	_
23	anti-tumor	anti-tumor	JJ	_	24	attr	_	_
24	activity	activity	NN	_	22	obj	_	_
25	.	.	.	_	22	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	cells	cell	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	exposed	expose	VBN	_	13	advcl	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	followed	followed	VBN	_	4	comp	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	13	p	_	_
11	synergism	synergism	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	molecular	molecular	JJ	_	3	attr	_	_
3	basis	basis	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	synergism	synergism	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	that	that	IN	_	21	mark	_	_
9	the	the	DT	_	11	det	_	_
10	signaling	signaling	NN	_	11	com	_	_
11	pathways	pathway	NNS	_	21	dep	_	_
12	that	that	WDT	_	15	dep	_	_
13	were	be	VBD	_	15	aux	_	_
14	initially	initially	RB	_	15	adv	_	_
15	activated	activate	VBN	_	11	relcl	_	_
16	by	by	IN	_	18	case	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	exposure	exposure	NN	_	15	ppmod	_	_
19	were	be	VBD	_	21	aux	_	_
20	efficiently	efficiently	RB	_	21	adv	_	_
21	suppressed	suppress	VBN	_	7	comp	_	_
22	by	by	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	subsequent	subsequent	JJ	_	25	attr	_	_
25	exposure	exposure	NN	_	21	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	the	the	DT	_	5	det	_	_
5	reverse	reverse	NN	_	10	dep	_	_
6	of	of	IN	_	9	case	_	_
7	this	this	DT	_	9	det	_	_
8	sequential	sequential	JJ	_	9	attr	_	_
9	administration	administration	NN	_	5	ppmod	_	_
10	resulted	result	VBD	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	antagonism	antagonism	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	which	which	WDT	_	16	dep	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	12	relcl	_	_
17	due	due	JJ	_	16	dep	_	_
18	to	to	TO	_	20	aux	_	_
19	differential	differential	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	ppmod	_	_
21	on	on	IN	_	24	case	_	_
22	cell	cell	NN	_	24	com	_	_
23	cycle	cycle	NN	_	24	com	_	_
24	arrest	arrest	NN	_	20	ppmod	_	_
25	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	as	as	IN	_	5	case	_	_
3	a	a	DT	_	5	det	_	_
4	single	single	JJ	_	5	attr	_	_
5	agent	agent	NN	_	1	ppmod	_	_
6	exhibits	exhibit	VBZ	_	0	root	_	_
7	anti-proliferative	anti-proliferative	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	6	obj	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	6	adv	_	_
11	in	in	IN	_	14	case	_	_
12	NSCLC	nsclc	NN	_	14	com	_	_
13	cell	cell	NN	_	14	com	_	_
14	lines	line	NNS	_	6	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	EGFR	egfr	NN	_	17	com	_	_
17	T790M	t0m	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	K-ras	k-ras	NN	_	20	com	_	_
20	mutations	mutation	NNS	_	17	conj	_	_
21	but	but	CC	_	6	cc	_	_
22	the	the	DT	_	24	det	_	_
23	sequential	sequential	JJ	_	24	attr	_	_
24	administration	administration	NN	_	30	dep	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	followed	followed	VBN	_	26	acl	_	_
28	by	by	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	is	be	VBZ	_	6	conj	_	_
31	superior	superior	JJ	_	30	dep	_	_
32	to	to	TO	_	33	aux	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	followed	followed	VBN	_	33	acl	_	_
35	by	by	IN	_	36	case	_	_
36	drug5	drug0	NN	_	34	ppmod	_	_
37	and	and	CC	_	36	cc	_	_
38	concurrent	concurrent	JJ	_	39	attr	_	_
39	administration	administration	NN	_	36	conj	_	_
40	.	.	.	_	6	p	_	_

1	Determinants	determinant	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	sensitivity	sensitivity	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	induced	induce	VBD	_	0	root	_	_
7	apoptosis	apoptosis	NN	_	6	obj	_	_
8	in	in	IN	_	11	case	_	_
9	multiple	multiple	JJ	_	11	attr	_	_
10	myeloma	myeloma	NN	_	11	com	_	_
11	cells	cell	NNS	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	17	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	,	,	,	_	2	p	_	_
7	one	#crd#	CD	_	2	appo	_	_
8	of	of	IN	_	14	case	_	_
9	S-adenosylhomocysteine	s-adenosylhomocysteine	NN	_	14	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	AdoHcy	adohcy	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	hydrolase	hydrolase	NN	_	14	com	_	_
14	inhibitors	inhibitor	NNS	_	7	ppmod	_	_
15	,	,	,	_	2	p	_	_
16	has	have	VBZ	_	17	aux	_	_
17	shown	show	VBN	_	0	root	_	_
18	antitumor	antitumor	JJ	_	19	attr	_	_
19	activities	activity	NNS	_	17	obj	_	_
20	in	in	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	broad	broad	JJ	_	23	attr	_	_
23	range	range	NN	_	17	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	solid	solid	JJ	_	26	attr	_	_
26	tumors	tumor	NNS	_	23	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	acute	acute	JJ	_	30	attr	_	_
29	myeloid	myeloid	JJ	_	30	attr	_	_
30	leukemia	leukemia	NN	_	26	conj	_	_
31	.	.	.	_	17	p	_	_

1	Here	here	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	examined	examine	VBD	_	0	root	_	_
5	its	its	PRP$	_	6	poss	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	on	on	IN	_	13	case	_	_
8	multiple	multiple	JJ	_	9	attr	_	_
9	myeloma	myeloma	NN	_	13	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	MM	mm	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	cells	cell	NNS	_	6	ppmod	_	_
14	and	and	CC	_	4	cc	_	_
15	found	find	VBD	_	4	conj	_	_
16	that	that	IN	_	24	mark	_	_
17	,	,	,	_	24	p	_	_
18	at	at	IN	_	20	case	_	_
19	500	0	CD	_	20	num	_	_
20	nM	nm	NN	_	24	ppmod	_	_
21	,	,	,	_	24	p	_	_
22	it	it	PRP	_	24	dep	_	_
23	potently	potently	RB	_	24	adv	_	_
24	inhibited	inhibit	VBD	_	15	comp	_	_
25	growth	growth	NN	_	24	obj	_	_
26	and	and	CC	_	24	cc	_	_
27	induced	induce	VBD	_	24	conj	_	_
28	apoptosis	apoptosis	NN	_	27	obj	_	_
29	in	in	IN	_	35	case	_	_
30	2	0	CD	_	32	num	_	_
31	of	of	IN	_	32	case	_	_
32	8	0	CD	_	35	num	_	_
33	MM	mm	NN	_	35	com	_	_
34	cell	cell	NN	_	35	com	_	_
35	lines	line	NNS	_	28	ppmod	_	_
36	.	.	.	_	4	p	_	_

1	RNA	rna	NN	_	9	dep	_	_
2	from	from	IN	_	7	case	_	_
3	un-treated	un-treated	JJ	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	JJ	_	3	conj	_	_
6	treated	treated	JJ	_	7	attr	_	_
7	cells	cell	NNS	_	1	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	profiled	profile	VBN	_	0	root	_	_
10	by	by	IN	_	15	case	_	_
11	Affymetrix	affymetrix	NN	_	15	attr	_	_
12	HG-U133	hg-u0	NN	_	15	attr	_	_
13	Plus	plus	NN	_	15	attr	_	_
14	2.0	0	CD	_	15	num	_	_
15	microarray	microarray	NN	_	9	ppmod	_	_
16	and	and	CC	_	9	cc	_	_
17	genes	gene	NNS	_	26	dep	_	_
18	with	with	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	significant	significant	JJ	_	21	attr	_	_
21	change	change	NN	_	17	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	gene	gene	NN	_	24	com	_	_
24	expression	expression	NN	_	21	ppmod	_	_
25	were	be	VBD	_	26	aux	_	_
26	determined	determine	VBN	_	9	conj	_	_
27	by	by	IN	_	29	case	_	_
28	significance	significance	NN	_	29	com	_	_
29	analysis	analysis	NN	_	26	ppmod	_	_
30	of	of	IN	_	35	case	_	_
31	microarray	microarray	NN	_	35	attr	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	SAM	sam	NN	_	35	attr	_	_
34	)	-rrb-	-RRB-	_	35	p	_	_
35	testing	testing	NN	_	29	ppmod	_	_
36	.	.	.	_	9	p	_	_

1	ALOX5	alox0	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	most	most	RBS	_	5	adv	_	_
5	down-regulated	down-regulated	VBN	_	6	attr	_	_
6	gene	gene	NN	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	5.8-fold	0-fold	RB	_	2	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	in	in	IN	_	12	case	_	_
11	sensitive	sensitive	JJ	_	12	attr	_	_
12	cells	cell	NNS	_	2	ppmod	_	_
13	and	and	CC	_	2	cc	_	_
14	was	be	VBD	_	15	aux	_	_
15	expressed	express	VBN	_	2	conj	_	_
16	at	at	IN	_	18	case	_	_
17	low	low	JJ	_	18	attr	_	_
18	level	level	NN	_	15	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	resistant	resistant	JJ	_	21	attr	_	_
21	cells	cell	NNS	_	15	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	corroborated	corroborate	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	quantitative	quantitative	JJ	_	7	attr	_	_
7	RT-PCR	rt-pcr	NN	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	Western-blot	western-blot	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	7	dep	_	_
3	indicated	indicate	VBD	_	7	aux	_	_
4	ALOX5	alox0	NN	_	7	obj	_	_
5	was	be	VBD	_	7	aux	_	_
6	highly	highly	RB	_	7	adv	_	_
7	expressed	express	VBN	_	0	root	_	_
8	only	only	RB	_	7	adv	_	_
9	in	in	IN	_	12	case	_	_
10	sensitive	sensitive	JJ	_	12	attr	_	_
11	cell	cell	NN	_	12	com	_	_
12	line	line	NN	_	7	ppmod	_	_
13	H929	h0	CD	_	12	num	_	_
14	and	and	CC	_	7	cc	_	_
15	greatly	greatly	RB	_	16	adv	_	_
16	decreased	decrease	VBD	_	7	conj	_	_
17	upon	upon	IN	_	19	case	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	treatment	treatment	NN	_	16	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	Ectopic	ectopic	JJ	_	2	attr	_	_
2	expression	expression	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	ALOX5	alox0	NN	_	2	ppmod	_	_
5	reduced	reduce	VBD	_	0	root	_	_
6	sensitivity	sensitivity	NN	_	5	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	H929	h0	NN	_	11	com	_	_
11	cells	cell	NNS	_	5	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	Furthermore	furthermore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	down-regulation	down-regulation	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	ALOX5	alox0	NN	_	3	ppmod	_	_
6	by	by	IN	_	8	case	_	_
7	RNA	rna	NN	_	8	com	_	_
8	interference	interference	NN	_	3	ppmod	_	_
9	could	could	MD	_	11	modal	_	_
10	also	also	RB	_	11	adv	_	_
11	induce	induce	VB	_	0	root	_	_
12	apoptosis	apoptosis	NN	_	11	obj	_	_
13	in	in	IN	_	14	case	_	_
14	H929	h0	NN	_	11	ppmod	_	_
15	.	.	.	_	11	p	_	_

1	Gene	gene	NN	_	3	com	_	_
2	expression	expression	NN	_	3	com	_	_
3	analysis	analysis	NN	_	11	dep	_	_
4	on	on	IN	_	7	case	_	_
5	MM	mm	NN	_	7	com	_	_
6	patient	patient	NN	_	7	com	_	_
7	dataset	dataset	NN	_	3	ppmod	_	_
8	indicated	indicate	VBD	_	11	aux	_	_
9	ALOX5	alox0	NN	_	10	com	_	_
10	expression	expression	NN	_	11	obj	_	_
11	was	be	VBD	_	0	root	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	higher	high	JJR	_	11	dep	_	_
14	in	in	IN	_	16	case	_	_
15	MM	mm	NN	_	16	com	_	_
16	patients	patient	NNS	_	11	ppmod	_	_
17	compared	compare	VBN	_	21	adv	_	_
18	to	to	TO	_	21	aux	_	_
19	normal	normal	JJ	_	21	attr	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	cells	cell	NNS	_	11	ppmod	_	_
22	.	.	.	_	11	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	found	find	VBD	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	Bcl-2	bcl-0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	overexpressed	overexpressed	VBN	_	3	comp	_	_
8	in	in	IN	_	11	case	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	insensitive	insensitive	JJ	_	11	attr	_	_
11	cells	cell	NNS	_	7	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	and	and	CC	_	7	cc	_	_
14	cotreatment	cotreatment	NN	_	26	dep	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	16	p	_	_
20	a	a	DT	_	23	det	_	_
21	Bcl-2	bcl-0	NN	_	23	com	_	_
22	family	family	NN	_	23	com	_	_
23	inhibitor	inhibitor	NN	_	16	appo	_	_
24	,	,	,	_	16	p	_	_
25	synergistically	synergistically	RB	_	26	adv	_	_
26	inhibited	inhibit	VBD	_	7	conj	_	_
27	growth	growth	NN	_	26	obj	_	_
28	and	and	CC	_	26	cc	_	_
29	induced	induce	VBD	_	26	conj	_	_
30	apoptosis	apoptosis	NN	_	29	obj	_	_
31	of	of	IN	_	35	case	_	_
32	drug4	drug0	NN	_	35	attr	_	_
33	insensitive	insensitive	JJ	_	35	attr	_	_
34	MM	mm	NN	_	35	com	_	_
35	cells	cell	NNS	_	30	ppmod	_	_
36	.	.	.	_	3	p	_	_

1	Taken	take	VBN	_	6	advcl	_	_
2	together	together	RB	_	1	adv	_	_
3	,	,	,	_	6	p	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	6	dep	_	_
6	shows	show	VBZ	_	0	root	_	_
7	one	#crd#	CD	_	6	obj	_	_
8	of	of	IN	_	9	case	_	_
9	mechanisms	mechanism	NNS	_	7	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	efficacy	efficacy	NN	_	9	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	MM	mm	JJ	_	16	attr	_	_
16	correlates	correlate	NNS	_	6	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	its	its	PRP$	_	19	poss	_	_
19	ability	ability	NN	_	16	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	down-regulate	down-regulate	VB	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	ALOX5	alox0	NN	_	24	com	_	_
24	levels	level	NNS	_	21	obj	_	_
25	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	insensitivity	insensitivity	NN	_	8	dep	_	_
6	might	might	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	overexpression	overexpression	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	Bcl-2	bcl-0	NN	_	10	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	the	the	DT	_	16	det	_	_
16	combination	combination	NN	_	23	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	could	could	MD	_	23	modal	_	_
22	synergistically	synergistically	RB	_	23	adv	_	_
23	induced	induce	VBD	_	8	conj	_	_
24	apoptosis	apoptosis	NN	_	23	obj	_	_
25	.	.	.	_	8	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	exploited	exploit	VBN	_	3	comp	_	_
9	therapeutically	therapeutically	RB	_	8	adv	_	_
10	for	for	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	subset	subset	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	MM	mm	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interaction	interaction	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	infant	infant	NN	_	8	com	_	_
7	colic	colic	NN	_	8	com	_	_
8	drops	drops	NN	_	2	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	Forest	forest	NNP	_	1	prn	_	_
4	Laboratories	laboratory	NNS	_	3	appo	_	_
5	UK	uk	NNP	_	9	attr	_	_
6	,	,	,	_	9	p	_	_
7	Kent	kent	NNP	_	9	attr	_	_
8	,	,	,	_	9	p	_	_
9	UK	uk	NNP	_	3	appo	_	_
10	)	-rrb-	-RRB-	_	3	p	_	_
11	is	be	VBZ	_	0	root	_	_
12	a	a	DT	_	16	det	_	_
13	widely	widely	RB	_	14	adv	_	_
14	available	available	JJ	_	16	attr	_	_
15	over-the-counter	over-the-counter	NN	_	16	com	_	_
16	preparation	preparation	NN	_	11	obj	_	_
17	used	use	VBN	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	relieve	relieve	VBP	_	17	comp	_	_
20	colic	colic	NN	_	21	com	_	_
21	symptoms	symptom	NNS	_	19	obj	_	_
22	in	in	IN	_	23	case	_	_
23	neonates	neonate	NNS	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	infants	infant	NNS	_	23	conj	_	_
26	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	active	active	JJ	_	3	attr	_	_
3	ingredient	ingredient	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	.	.	.	_	4	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	7	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	documented	document	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	current	current	JJ	_	11	attr	_	_
11	summary	summary	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	product	product	NN	_	14	com	_	_
14	characteristics	characteristic	NNS	_	11	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	authors	author	NNS	_	3	dep	_	_
3	report	report	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	case	case	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	an	an	DT	_	8	det	_	_
8	infant	infant	NN	_	5	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	confirmed	confirm	VBN	_	12	attr	_	_
11	congenital	congenital	JJ	_	12	attr	_	_
12	hypothyroidism	hypothyroidism	NN	_	8	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	drug1	drug0	NN	_	8	ppmod	_	_
15	who	who	WP	_	16	dep	_	_
16	experienced	experience	VBN	_	14	relcl	_	_
17	a	a	DT	_	20	det	_	_
18	possible	possible	JJ	_	20	attr	_	_
19	drug	drug	NN	_	20	com	_	_
20	interaction	interaction	NN	_	16	obj	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	Despite	despite	IN	_	4	case	_	_
2	adequate	adequate	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dosage	dosage	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	thyroid	thyroid	NN	_	8	com	_	_
7	stimulating	stimulating	NN	_	8	com	_	_
8	hormone	hormone	NN	_	12	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	TSH	tsh	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	was	be	VBD	_	0	root	_	_
13	high	high	JJ	_	12	dep	_	_
14	,	,	,	_	12	p	_	_
15	suggesting	suggest	VBG	_	12	comp	_	_
16	undertreatment	undertreatment	NN	_	15	obj	_	_
17	.	.	.	_	12	p	_	_

1	Questioning	questioning	NN	_	2	dep	_	_
2	revealed	reveal	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	child	child	NN	_	2	obj	_	_
5	was	be	VBD	_	4	acl	_	_
6	taking	take	VBG	_	8	adv	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	drops	drops	NN	_	5	ppmod	_	_
9	before	before	IN	_	10	mark	_	_
10	feeds	feed	VBZ	_	5	comp	_	_
11	while	while	IN	_	13	case	_	_
12	on	on	IN	_	13	case	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	colic	colic	NN	_	3	com	_	_
3	drops	drops	NN	_	6	dep	_	_
4	were	be	VBD	_	6	aux	_	_
5	immediately	immediately	RB	_	6	adv	_	_
6	discontinued	discontinue	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	TSH	tsh	NN	_	10	dep	_	_
9	promptly	promptly	RB	_	10	adv	_	_
10	normalised	normalise	VBD	_	6	conj	_	_
11	with	with	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	reduction	reduction	NN	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	thyroxine	thyroxine	NN	_	16	com	_	_
16	requirement	requirement	NN	_	13	ppmod	_	_
17	to	to	TO	_	21	aux	_	_
18	an	an	DT	_	21	det	_	_
19	age	age	NN	_	21	attr	_	_
20	appropriate	appropriate	JJ	_	21	attr	_	_
21	dosage	dosage	NN	_	13	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interaction	interaction	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	previously	previously	RB	_	10	adv	_	_
12	and	and	CC	_	10	cc	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	listed	list	VBN	_	10	conj	_	_
16	in	in	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	British	british	NNP	_	20	com	_	_
19	National	national	NNP	_	20	com	_	_
20	Formulary	formulary	NN	_	15	ppmod	_	_
21	for	for	IN	_	22	case	_	_
22	Children	child	NNS	_	20	ppmod	_	_
23	.	.	.	_	10	p	_	_

1	Clinicians	clinician	NNS	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	parents	parent	NNS	_	1	conj	_	_
4	need	need	VBP	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	aware	aware	NN	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	this	this	DT	_	10	det	_	_
10	interaction	interaction	NN	_	7	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	avoid	avoid	VB	_	7	acl	_	_
13	unnecessary	unnecessary	JJ	_	14	attr	_	_
14	undertreatment	undertreatment	NN	_	12	obj	_	_
15	and	and	CC	_	12	cc	_	_
16	prevent	prevent	VB	_	12	conj	_	_
17	potential	potential	JJ	_	20	attr	_	_
18	long-term	long-term	JJ	_	20	attr	_	_
19	neurological	neurological	JJ	_	20	attr	_	_
20	sequelae	sequelae	NN	_	16	obj	_	_
21	.	.	.	_	4	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	locomotor	locomotor	NN	_	3	com	_	_
3	sensitization	sensitization	NN	_	15	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	conditioned	conditioned	JJ	_	7	attr	_	_
6	place	place	NN	_	7	com	_	_
7	preference	preference	NN	_	3	conj	_	_
8	in	in	IN	_	13	case	_	_
9	adolescent	adolescent	JJ	_	13	attr	_	_
10	male	male	JJ	_	13	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	female	female	JJ	_	10	conj	_	_
13	rats	rat	NNS	_	3	ppmod	_	_
14	neonatally	neonatally	RB	_	15	adv	_	_
15	treated	treat	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	15	p	_	_

1	Neonatal	neonatal	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	treatment	treatment	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	produce	produce	VB	_	6	comp	_	_
9	an	an	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	15	case	_	_
12	dopamine	dopamine	NN	_	14	attr	_	_
13	D2-like	d0-like	JJ	_	14	attr	_	_
14	receptor	receptor	NN	_	15	com	_	_
15	sensitivity	sensitivity	NN	_	10	ppmod	_	_
16	that	that	WDT	_	17	dep	_	_
17	persists	persist	VBZ	_	10	relcl	_	_
18	throughout	throughout	IN	_	22	case	_	_
19	the	the	DT	_	20	det	_	_
20	subject	subject	NN	_	22	poss	_	_
21	's	's	POS	_	20	case	_	_
22	lifetime	lifetime	NN	_	17	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	objective	objective	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	analyze	analyze	VB	_	3	comp	_	_
6	the	the	DT	_	7	det	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	neonatal	neonatal	JJ	_	11	attr	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	treatment	treatment	NN	_	7	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	effects	effect	NNS	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	adolescent	adolescent	JJ	_	18	attr	_	_
18	rats	rat	NNS	_	13	ppmod	_	_
19	using	use	VBG	_	18	acl	_	_
20	locomotor	locomotor	NN	_	21	com	_	_
21	sensitization	sensitization	NN	_	26	attr	_	_
22	and	and	CC	_	21	cc	_	_
23	conditioned	conditioned	JJ	_	25	attr	_	_
24	place	place	NN	_	25	com	_	_
25	preference	preference	NN	_	21	conj	_	_
26	procedures	procedure	NNS	_	19	obj	_	_
27	.	.	.	_	3	p	_	_

1	Sprague-Dawley	sprague-dawley	NN	_	2	com	_	_
2	rats	rat	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	treated	treat	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	1	0	CD	_	9	num	_	_
9	mg/kg	mg/kg	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	or	or	CC	_	6	cc	_	_
12	saline	saline	NN	_	6	conj	_	_
13	from	from	IN	_	15	case	_	_
14	postnatal	postnatal	JJ	_	15	attr	_	_
15	days	day	NNS	_	4	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	P	p	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	1	0	CD	_	15	num	_	_
20	to	to	TO	_	19	cc	_	_
21	P11	p0	CD	_	19	conj	_	_
22	and	and	CC	_	4	cc	_	_
23	raised	raise	VBN	_	4	conj	_	_
24	to	to	TO	_	25	aux	_	_
25	adolescence	adolescence	NN	_	23	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	For	for	IN	_	3	case	_	_
2	locomotor	locomotor	NN	_	3	com	_	_
3	sensitization	sensitization	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	subjects	subject	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	given	give	VBN	_	0	root	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	1	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	or	or	CC	_	8	cc	_	_
14	saline	saline	NN	_	17	attr	_	_
15	every	every	DT	_	17	det	_	_
16	second	#ord#	JJ	_	17	attr	_	_
17	day	day	NN	_	8	conj	_	_
18	from	from	IN	_	19	case	_	_
19	P35	p0	NN	_	7	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	P47	p0	NN	_	7	ppmod	_	_
22	and	and	CC	_	7	cc	_	_
23	were	be	VBD	_	24	aux	_	_
24	placed	place	VBN	_	7	conj	_	_
25	into	into	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	locomotor	locomotor	JJ	_	28	attr	_	_
28	arena	arena	NN	_	24	ppmod	_	_
29	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	female	female	JJ	_	3	attr	_	_
3	rats	rat	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	neonatal	neonatal	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	treatment	treatment	NN	_	8	dep	_	_
8	enhanced	enhance	VBD	_	0	root	_	_
9	drug2	drug0	NN	_	11	com	_	_
10	locomotor	locomotor	NN	_	11	com	_	_
11	sensitization	sensitization	NN	_	8	obj	_	_
12	compared	compare	VBN	_	16	adv	_	_
13	with	with	IN	_	16	case	_	_
14	drug3	drug0	CD	_	16	num	_	_
15	-free	-free	JJ	_	16	attr	_	_
16	controls	control	NNS	_	8	ppmod	_	_
17	sensitized	sensitize	VBN	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Male	male	JJ	_	2	attr	_	_
2	rats	rat	NNS	_	3	dep	_	_
3	demonstrated	demonstrate	VBD	_	0	root	_	_
4	sensitization	sensitization	NN	_	3	obj	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	although	although	IN	_	11	mark	_	_
9	this	this	DT	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	muted	mute	VBN	_	3	comp	_	_
12	compared	compare	VBN	_	15	adv	_	_
13	with	with	IN	_	15	case	_	_
14	female	female	JJ	_	15	attr	_	_
15	rats	rat	NNS	_	11	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	and	and	CC	_	11	cc	_	_
18	were	be	VBD	_	19	aux	_	_
19	unaffected	unaffected	VBN	_	11	conj	_	_
20	by	by	IN	_	22	case	_	_
21	neonatal	neonatal	JJ	_	22	attr	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	For	for	IN	_	4	case	_	_
2	conditioned	conditioned	JJ	_	4	attr	_	_
3	place	place	NN	_	4	com	_	_
4	preference	preference	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	subjects	subject	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	conditioned	condition	VBN	_	0	root	_	_
9	for	for	IN	_	12	case	_	_
10	8	0	CD	_	12	num	_	_
11	consecutive	consecutive	JJ	_	12	attr	_	_
12	days	day	NNS	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	P32-39	p0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	1	0	CD	_	20	num	_	_
20	mg/kg	mg/kg	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	or	or	CC	_	17	cc	_	_
23	saline	saline	NN	_	17	conj	_	_
24	and	and	CC	_	8	cc	_	_
25	a	a	DT	_	28	det	_	_
26	drug-free	drug-free	JJ	_	28	attr	_	_
27	preference	preference	NN	_	28	com	_	_
28	test	test	NN	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	conducted	conduct	VBN	_	8	conj	_	_
31	at	at	IN	_	32	case	_	_
32	P40	p0	NN	_	30	ppmod	_	_
33	.	.	.	_	8	p	_	_

1	Rats	rat	NNS	_	30	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	8	case	_	_
4	neonatal	neonatal	JJ	_	8	attr	_	_
5	drug1	drug0	JJ	_	8	attr	_	_
6	enhanced	enhance	VBN	_	8	attr	_	_
7	time	time	NN	_	8	com	_	_
8	spent	spent	NN	_	2	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	drug2	drug0	JJ	_	13	attr	_	_
12	-paired	-paired	JJ	_	13	attr	_	_
13	context	context	NN	_	8	ppmod	_	_
14	compared	compare	VBN	_	18	adv	_	_
15	with	with	IN	_	18	case	_	_
16	drug3	drug0	CD	_	18	num	_	_
17	-free	-free	JJ	_	18	attr	_	_
18	controls	control	NNS	_	2	ppmod	_	_
19	conditioned	condition	VBN	_	18	acl	_	_
20	with	with	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	1	p	_	_
23	but	but	CC	_	1	cc	_	_
24	only	only	RB	_	23	com	_	_
25	female	female	JJ	_	26	attr	_	_
26	controls	control	NNS	_	1	conj	_	_
27	conditioned	condition	VBN	_	1	acl	_	_
28	with	with	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	spent	spend	VBP	_	0	root	_	_
31	more	more	JJR	_	32	attr	_	_
32	time	time	NN	_	30	obj	_	_
33	in	in	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	drug-paired	drug-paired	JJ	_	36	attr	_	_
36	context	context	NN	_	30	ppmod	_	_
37	compared	compare	VBN	_	40	adv	_	_
38	with	with	IN	_	40	case	_	_
39	saline-treated	saline-treated	JJ	_	40	attr	_	_
40	controls	control	NNS	_	30	ppmod	_	_
41	.	.	.	_	30	p	_	_

1	Increased	increase	VBN	_	5	attr	_	_
2	D	d	NN	_	4	attr	_	_
3	-like	-like	JJ	_	4	attr	_	_
4	receptor	receptor	NN	_	5	com	_	_
5	sensitivity	sensitivity	NN	_	6	dep	_	_
6	appears	appear	VBZ	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	have	have	VB	_	9	aux	_	_
9	enhanced	enhance	VBD	_	6	comp	_	_
10	the	the	DT	_	12	det	_	_
11	behavioral	behavioral	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	6	p	_	_
16	but	but	CC	_	6	cc	_	_
17	these	these	DT	_	18	det	_	_
18	effects	effect	NNS	_	19	dep	_	_
19	were	be	VBD	_	6	conj	_	_
20	more	more	RBR	_	21	adv	_	_
21	prevalent	prevalent	JJ	_	19	dep	_	_
22	in	in	IN	_	25	case	_	_
23	adolescent	adolescent	JJ	_	25	attr	_	_
24	female	female	JJ	_	25	attr	_	_
25	rats	rat	NNS	_	19	ppmod	_	_
26	compared	compare	VBN	_	29	adv	_	_
27	with	with	IN	_	29	case	_	_
28	male	male	JJ	_	29	attr	_	_
29	rats	rat	NNS	_	19	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	6	case	_	_
3	drug1	drug0	NN	_	6	attr	_	_
4	-mediated	-mediated	JJ	_	6	attr	_	_
5	CYP3A4	cyp0a0	NN	_	6	com	_	_
6	inhibition	inhibition	NN	_	1	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug3	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	11	p	_	_
16	an	an	DT	_	19	det	_	_
17	orally	orally	RB	_	18	adv	_	_
18	active	active	JJ	_	19	attr	_	_
19	drug4	drug0	NN	_	11	appo	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	partly	partly	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	4	adv	_	_
9	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	evaluated	evaluate	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	a	a	DT	_	10	det	_	_
8	potent	potent	JJ	_	10	attr	_	_
9	CYP3A	cyp0a	NN	_	10	com	_	_
10	inhibitor	inhibitor	NN	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug1	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	safety	safety	NN	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	16	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Patients	patient	NNS	_	2	dep	_	_
2	received	receive	VBD	_	0	root	_	_
3	a	a	DT	_	7	det	_	_
4	single	single	JJ	_	7	attr	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	dose	dose	NN	_	2	obj	_	_
8	on	on	IN	_	9	case	_	_
9	day	day	NN	_	7	ppmod	_	_
10	1	0	CD	_	9	num	_	_
11	,	,	,	_	7	p	_	_
12	followed	followed	VBN	_	7	acl	_	_
13	by	by	IN	_	17	case	_	_
14	4	0	CD	_	17	num	_	_
15	days	day	NNS	_	17	com	_	_
16	wash-out	wash-out	NN	_	17	com	_	_
17	period	period	NN	_	12	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	On	on	IN	_	2	case	_	_
2	days	day	NNS	_	7	ppmod	_	_
3	5-9	0	CD	_	2	num	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	On	on	IN	_	2	case	_	_
2	day	day	NN	_	10	ppmod	_	_
3	8	0	CD	_	2	num	_	_
4	,	,	,	_	10	p	_	_
5	a	a	DT	_	8	det	_	_
6	single	single	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	dose	dose	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	co-administered	co-administered	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	administered	administer	VBN	_	0	root	_	_
4	as	as	IN	_	6	case	_	_
5	single	single	JJ	_	6	attr	_	_
6	agent	agent	NN	_	3	ppmod	_	_
7	three	#crd#	CD	_	8	num	_	_
8	times	time	NNS	_	6	appo	_	_
9	a	a	DT	_	10	det	_	_
10	week	week	NN	_	8	appo	_	_
11	on	on	IN	_	12	case	_	_
12	day	day	NN	_	10	ppmod	_	_
13	15	0	CD	_	12	num	_	_
14	and	and	CC	_	12	cc	_	_
15	onward	onward	CD	_	12	conj	_	_
16	.	.	.	_	3	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	presence	presence	NN	_	5	advnp	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	was	be	VBD	_	0	root	_	_
9	1.6-	0-	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	1.8-fold	0-fold	JJ	_	12	attr	_	_
12	increase	increase	NN	_	9	conj	_	_
13	in	in	IN	_	14	case	_	_
14	C	c	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	max	max	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	and	and	CC	_	14	cc	_	_
19	AUC	auc	NN	_	14	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	12	p	_	_
23	respectively	respectively	RB	_	9	conj	_	_
24	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	substantial	substantial	JJ	_	3	attr	_	_
3	change	change	NN	_	12	dep	_	_
4	in	in	IN	_	5	case	_	_
5	T	t	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	max	max	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	or	or	CC	_	5	cc	_	_
10	half-life	half-life	NN	_	5	conj	_	_
11	was	be	VBD	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	No	no	DT	_	2	det	_	_
2	difference	difference	NN	_	22	dep	_	_
3	in	in	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	-pharmacokinetics	-pharmacokinetics	NNS	_	2	ppmod	_	_
6	between	between	IN	_	7	case	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	carrying	carry	VBG	_	7	acl	_	_
9	CYP3A5	cyp0a0	NN	_	12	com	_	_
10	*	*	NN	_	12	com	_	_
11	1/	0/	NN	_	12	com	_	_
12	*	*	NN	_	20	attr	_	_
13	3	0	CD	_	12	num	_	_
14	and	and	CC	_	12	cc	_	_
15	CYP3A5	cyp0a0	NN	_	18	com	_	_
16	*	*	NN	_	18	com	_	_
17	3/	0/	NN	_	18	com	_	_
18	*	*	NN	_	12	conj	_	_
19	3	0	CD	_	18	num	_	_
20	alleles	allele	NNS	_	8	obj	_	_
21	was	be	VBD	_	22	aux	_	_
22	observed	observe	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	Most	most	RBS	_	2	com	_	_
2	frequently	frequently	RB	_	3	adv	_	_
3	reported	report	VBN	_	5	attr	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	events	event	NNS	_	6	dep	_	_
6	were	be	VBD	_	0	root	_	_
7	gastrointestinal	gastrointestinal	JJ	_	8	adv	_	_
8	related	related	JJ	_	6	dep	_	_
9	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	asymptomatic	asymptomatic	JJ	_	4	attr	_	_
4	hypophosphatemia	hypophosphatemia	NN	_	2	obj	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	64	0	CD	_	4	num	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	6	p	_	_
9	,	,	,	_	2	p	_	_
10	and	and	CC	_	2	cc	_	_
11	urine	urine	NN	_	12	com	_	_
12	analysis	analysis	NN	_	13	dep	_	_
13	suggested	suggest	VBD	_	2	conj	_	_
14	renal	renal	JJ	_	16	attr	_	_
15	phosphate	phosphate	NN	_	16	com	_	_
16	wasting	wasting	NN	_	13	obj	_	_
17	.	.	.	_	2	p	_	_

1	Co-administration	co-administration	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	CYP3A	cyp0a	NN	_	6	com	_	_
6	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	feasible	feasible	JJ	_	7	dep	_	_
9	as	as	IN	_	19	mark	_	_
10	the	the	DT	_	12	det	_	_
11	observed	observe	VBN	_	12	attr	_	_
12	increase	increase	NN	_	19	dep	_	_
13	in	in	IN	_	16	case	_	_
14	drug2	drug0	NN	_	16	com	_	_
15	PK	pk	NN	_	16	com	_	_
16	parameters	parameter	NNS	_	12	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	considered	consider	VBD	_	7	comp	_	_
20	clinically	clinically	RB	_	21	adv	_	_
21	relevant	relevant	JJ	_	19	dep	_	_
22	.	.	.	_	7	p	_	_

1	Considering	consider	VBG	_	31	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	variability	variability	NN	_	1	obj	_	_
4	in	in	IN	_	5	case	_	_
5	exposure	exposure	NN	_	3	ppmod	_	_
6	following	follow	VBG	_	8	adv	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	inhibition	inhibition	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	the	the	DT	_	11	det	_	_
11	fact	fact	NN	_	8	conj	_	_
12	that	that	IN	_	19	mark	_	_
13	chronic	chronic	JJ	_	14	attr	_	_
14	dosing	dosing	NN	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	studied	study	VBN	_	11	acl	_	_
20	with	with	IN	_	22	case	_	_
21	CYP3A	cyp0a	NN	_	22	com	_	_
22	inhibitors	inhibitor	NNS	_	19	ppmod	_	_
23	,	,	,	_	31	p	_	_
24	close	close	JJ	_	25	attr	_	_
25	monitoring	monitoring	NN	_	31	dep	_	_
26	of	of	IN	_	30	case	_	_
27	drug2	drug0	NN	_	28	advnp	_	_
28	-related	-related	JJ	_	30	attr	_	_
29	adverse	adverse	JJ	_	30	attr	_	_
30	events	event	NNS	_	25	ppmod	_	_
31	is	be	VBZ	_	0	root	_	_
32	necessary	necessary	JJ	_	31	dep	_	_
33	.	.	.	_	31	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	CYP	cyp	NN	_	4	com	_	_
4	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	metabolism	metabolism	NN	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	toxicity	toxicity	NN	_	7	conj	_	_
10	in	in	IN	_	13	case	_	_
11	rat	rat	NN	_	13	com	_	_
12	liver	liver	NN	_	13	com	_	_
13	slices	slice	NNS	_	7	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	present	present	VBP	_	0	root	_	_
3	a	a	DT	_	7	det	_	_
4	comprehensive	comprehensive	JJ	_	7	attr	_	_
5	in	in	FW	_	6	adv	_	_
6	vitro	vitro	FW	_	7	attr	_	_
7	approach	approach	NN	_	2	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	assessing	assess	VBG	_	7	ppmod	_	_
10	metabolism-mediated	metabolism-mediated	JJ	_	11	attr	_	_
11	hepatotoxicity	hepatotoxicity	NN	_	9	obj	_	_
12	using	use	VBG	_	11	acl	_	_
13	male	male	JJ	_	17	attr	_	_
14	Sprague-Dawley	sprague-dawley	NN	_	17	com	_	_
15	rat	rat	NN	_	17	com	_	_
16	liver	liver	NN	_	17	com	_	_
17	slices	slice	NNS	_	12	obj	_	_
18	incubated	incubate	VBN	_	17	acl	_	_
19	with	with	IN	_	23	case	_	_
20	the	the	DT	_	23	det	_	_
21	well	well	RB	_	22	adv	_	_
22	characterized	characterize	VBN	_	23	attr	_	_
23	hepatotoxicant	hepatotoxicant	NN	_	18	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	drug1	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	inhibitors	inhibitor	NNS	_	23	conj	_	_
29	of	of	IN	_	35	case	_	_
30	cytochrome	cytochrome	NN	_	31	com	_	_
31	P450	p0	NN	_	35	attr	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	CYP	cyp	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	enzymes	enzyme	NNS	_	28	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	approach	approach	NN	_	3	dep	_	_
3	combines	combine	VBZ	_	0	root	_	_
4	liquid	liquid	JJ	_	7	attr	_	_
5	chromatography	chromatography	NN	_	7	com	_	_
6	mass	mass	NN	_	7	com	_	_
7	spectrometry	spectrometry	NN	_	13	attr	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	LC	lc	CD	_	10	num	_	_
10	MS	ms	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	detection	detection	NN	_	13	com	_	_
13	methods	method	NNS	_	3	obj	_	_
14	with	with	IN	_	17	case	_	_
15	multiple	multiple	JJ	_	17	attr	_	_
16	toxicity	toxicity	NN	_	17	com	_	_
17	endpoints	endpoint	NNS	_	3	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	enable	enable	VB	_	3	comp	_	_
20	identification	identification	NN	_	19	obj	_	_
21	of	of	IN	_	24	case	_	_
22	critical	critical	JJ	_	24	attr	_	_
23	metabolic	metabolic	JJ	_	24	attr	_	_
24	pathways	pathway	NNS	_	20	ppmod	_	_
25	for	for	IN	_	26	case	_	_
26	hepatotoxicity	hepatotoxicity	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	incubations	incubation	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	performed	performed	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absence	absence	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	presence	presence	NN	_	7	conj	_	_
10	of	of	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	non-specific	non-specific	JJ	_	14	attr	_	_
13	CYP	cyp	NN	_	14	com	_	_
14	inhibitor	inhibitor	NN	_	7	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug1	drug0	NN	_	14	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug2	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	16	cc	_	_
21	isoform-specific	isoform-specific	JJ	_	22	attr	_	_
22	inhibitors	inhibitor	NNS	_	14	conj	_	_
23	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	metabolite	metabolite	NN	_	3	com	_	_
3	profile	profile	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	rat	rat	NN	_	9	com	_	_
8	liver	liver	NN	_	9	com	_	_
9	slices	slice	NNS	_	3	ppmod	_	_
10	shares	share	VBZ	_	0	root	_	_
11	some	some	DT	_	12	det	_	_
12	features	feature	NNS	_	10	obj	_	_
13	of	of	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	in	in	FW	_	16	adv	_	_
16	vivo	vivo	FW	_	17	attr	_	_
17	profile	profile	NN	_	12	ppmod	_	_
18	,	,	,	_	10	p	_	_
19	but	but	CC	_	10	cc	_	_
20	also	also	RB	_	24	adv	_	_
21	had	have	VBD	_	24	lv	_	_
22	a	a	DT	_	24	det	_	_
23	major	major	JJ	_	24	attr	_	_
24	difference	difference	NN	_	10	conj	_	_
25	in	in	IN	_	26	case	_	_
26	that	that	WDT	_	33	ppmod	_	_
27	epoxide	epoxide	NN	_	30	com	_	_
28	dihydrodiol	dihydrodiol	NN	_	30	com	_	_
29	hydrolysis	hydrolysis	NN	_	30	com	_	_
30	products	product	NNS	_	33	dep	_	_
31	were	be	VBD	_	33	aux	_	_
32	not	not	RB	_	33	neg	_	_
33	observed	observe	VBN	_	24	relcl	_	_
34	to	to	TO	_	37	aux	_	_
35	a	a	DT	_	37	det	_	_
36	measurable	measurable	JJ	_	37	attr	_	_
37	extent	extent	NN	_	33	ppmod	_	_
38	.	.	.	_	10	p	_	_

1	As	as	IN	_	2	case	_	_
2	examples	example	NNS	_	25	ppmod	_	_
3	of	of	IN	_	9	case	_	_
4	our	our	PRP$	_	9	poss	_	_
5	liver	liver	NN	_	9	com	_	_
6	slice	slice	NN	_	9	com	_	_
7	metabolite	metabolite	NN	_	9	com	_	_
8	identification	identification	NN	_	9	com	_	_
9	procedure	procedure	NN	_	2	ppmod	_	_
10	,	,	,	_	25	p	_	_
11	a	a	DT	_	14	det	_	_
12	minor	minor	JJ	_	14	attr	_	_
13	glutathione	glutathione	NN	_	14	com	_	_
14	adduct	adduct	NN	_	25	dep	_	_
15	and	and	CC	_	14	cc	_	_
16	previously	previously	RB	_	17	adv	_	_
17	unreported	unreported	VBN	_	21	attr	_	_
18	7-O-desmethyl	0-o-desmethyl	JJ	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	glucuronidated	glucuronidated	JJ	_	18	conj	_	_
21	metabolites	metabolite	NNS	_	14	conj	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	are	be	VBP	_	25	aux	_	_
25	reported	report	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	induced	induce	VBD	_	0	root	_	_
3	hepatocellular	hepatocellular	JJ	_	4	attr	_	_
4	necrosis	necrosis	NN	_	2	obj	_	_
5	in	in	IN	_	10	case	_	_
6	a	a	DT	_	10	det	_	_
7	dose-	dose-	NN	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	time-dependent	time-dependent	JJ	_	7	conj	_	_
10	manner	manner	NN	_	2	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	toxicity	toxicity	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	increased	increase	VBD	_	2	conj	_	_
9	exposure	exposure	NN	_	8	obj	_	_
10	to	to	TO	_	12	aux	_	_
11	parent	parent	NN	_	12	com	_	_
12	compound	compound	NN	_	9	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	decreased	decrease	VBD	_	2	conj	_	_
16	metabolite	metabolite	NN	_	17	com	_	_
17	levels	level	NNS	_	15	obj	_	_
18	in	in	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	dose-dependent	dose-dependent	JJ	_	21	attr	_	_
21	manner	manner	NN	_	15	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	Of	of	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	isoform-specific	isoform-specific	JJ	_	5	attr	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	inhibitors	inhibitor	NNS	_	18	ppmod	_	_
6	tested	test	VBN	_	5	acl	_	_
7	for	for	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	effect	effect	NN	_	6	ppmod	_	_
10	on	on	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	drug1	drug0	NN	_	14	com	_	_
13	metabolite	metabolite	NN	_	14	com	_	_
14	profile	profile	NN	_	9	ppmod	_	_
15	,	,	,	_	18	p	_	_
16	only	only	RB	_	17	adv	_	_
17	drug2	drug0	NN	_	18	dep	_	_
18	was	be	VBD	_	0	root	_	_
19	noticeably	noticeably	RB	_	18	adv	_	_
20	effective	effective	JJ	_	18	dep	_	_
21	,	,	,	_	18	p	_	_
22	indicating	indicate	VBG	_	18	comp	_	_
23	a	a	DT	_	24	det	_	_
24	role	role	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	CYPs	cyps	NNS	_	24	ppmod	_	_
27	2A6	0a0	NN	_	26	attr	_	_
28	,	,	,	_	27	p	_	_
29	2C9	0c0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	2Cl9	0cl0	NN	_	27	conj	_	_
32	,	,	,	_	31	p	_	_
33	and	and	CC	_	31	cc	_	_
34	2E1	0e0	NN	_	27	conj	_	_
35	.	.	.	_	18	p	_	_

1	With	with	IN	_	4	case	_	_
2	respect	respect	NN	_	4	advnp	_	_
3	to	to	TO	_	4	aux	_	_
4	toxicity	toxicity	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	the	the	DT	_	7	det	_	_
7	order	order	NN	_	12	dep	_	_
8	of	of	IN	_	11	case	_	_
9	CYP	cyp	NN	_	11	com	_	_
10	inhibitor	inhibitor	NN	_	11	com	_	_
11	effectiveness	effectiveness	NN	_	7	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	drug1	drug0	NN	_	19	com	_	_
14	>	>	NN	_	19	com	_	_
15	drug2	drug0	NN	_	19	com	_	_
16	~	~	NN	_	19	com	_	_
17	drug3	drug0	NN	_	19	com	_	_
18	>	>	NN	_	19	com	_	_
19	drug4	drug0	NN	_	12	obj	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	had	have	VBD	_	0	root	_	_
5	no	no	DT	_	6	det	_	_
6	effect	effect	NN	_	4	obj	_	_
7	,	,	,	_	4	p	_	_
8	while	while	IN	_	10	mark	_	_
9	drug3	drug0	NN	_	10	dep	_	_
10	appeared	appear	VBD	_	4	comp	_	_
11	to	to	TO	_	12	aux	_	_
12	augment	augment	VB	_	10	comp	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	toxicity	toxicity	NN	_	12	obj	_	_
15	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	rat	rat	NN	_	7	com	_	_
6	liver	liver	NN	_	7	com	_	_
7	slices	slice	NNS	_	10	dep	_	_
8	do	do	VBP	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	reproduce	reproduce	VB	_	3	comp	_	_
11	the	the	DT	_	15	det	_	_
12	reported	report	VBN	_	15	attr	_	_
13	in	in	FW	_	14	adv	_	_
14	vivo	vivo	FW	_	15	attr	_	_
15	biotransformation	biotransformation	NN	_	10	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	10	cc	_	_
19	therefore	therefore	RB	_	22	adv	_	_
20	may	may	MD	_	22	modal	_	_
21	not	not	RB	_	22	neg	_	_
22	be	be	VB	_	10	conj	_	_
23	an	an	DT	_	25	det	_	_
24	appropriate	appropriate	JJ	_	25	attr	_	_
25	model	model	NN	_	22	obj	_	_
26	for	for	IN	_	28	case	_	_
27	drug2	drug0	NN	_	28	com	_	_
28	metabolism	metabolism	NN	_	25	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	these	these	DT	_	4	det	_	_
4	results	result	NNS	_	5	dep	_	_
5	provide	provide	VBP	_	0	root	_	_
6	an	an	DT	_	7	det	_	_
7	example	example	NN	_	5	obj	_	_
8	of	of	IN	_	23	case	_	_
9	how	how	WRB	_	23	adv	_	_
10	small	small	JJ	_	12	attr	_	_
11	molecule	molecule	NN	_	12	com	_	_
12	manipulation	manipulation	NN	_	23	dep	_	_
13	of	of	IN	_	15	case	_	_
14	CYP	cyp	NN	_	15	com	_	_
15	activity	activity	NN	_	12	ppmod	_	_
16	in	in	IN	_	20	case	_	_
17	an	an	DT	_	20	det	_	_
18	in	in	FW	_	19	adv	_	_
19	vitro	vitro	FW	_	20	attr	_	_
20	model	model	NN	_	12	ppmod	_	_
21	can	can	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	used	use	VBN	_	7	ppmod	_	_
24	to	to	TO	_	25	aux	_	_
25	confirm	confirm	VB	_	23	comp	_	_
26	metabolism-mediated	metabolism-mediated	JJ	_	27	attr	_	_
27	toxicity	toxicity	NN	_	25	obj	_	_
28	.	.	.	_	5	p	_	_

1	Glycosidic	glycosidic	JJ	_	2	attr	_	_
2	enzymes	enzyme	NNS	_	3	dep	_	_
3	enhance	enhance	VBP	_	0	root	_	_
4	retinal	retinal	NN	_	5	com	_	_
5	transduction	transduction	NN	_	3	obj	_	_
6	following	follow	VBG	_	8	adv	_	_
7	intravitreal	intravitreal	JJ	_	8	attr	_	_
8	delivery	delivery	NN	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	To	to	TO	_	2	aux	_	_
2	determine	determine	VB	_	0	root	_	_
3	whether	whether	IN	_	11	mark	_	_
4	the	the	DT	_	5	det	_	_
5	co-injection	co-injection	NN	_	11	dep	_	_
6	of	of	IN	_	10	case	_	_
7	extracellular	extracellular	JJ	_	10	attr	_	_
8	matrix	matrix	NN	_	10	com	_	_
9	degrading	degrading	NN	_	10	com	_	_
10	enzymes	enzyme	NNS	_	5	ppmod	_	_
11	improves	improve	VBZ	_	2	comp	_	_
12	retinal	retinal	NN	_	13	com	_	_
13	transduction	transduction	NN	_	11	obj	_	_
14	following	follow	VBG	_	16	adv	_	_
15	intravitreal	intravitreal	JJ	_	16	attr	_	_
16	delivery	delivery	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug2	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	containing	contain	VBG	_	1	acl	_	_
3	cDNA	cdna	NN	_	2	obj	_	_
4	encoding	encode	VBG	_	3	acl	_	_
5	enhanced	enhance	VBN	_	8	attr	_	_
6	green	green	JJ	_	8	attr	_	_
7	fluorescent	fluorescent	JJ	_	8	attr	_	_
8	protein	protein	NN	_	4	obj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	GFP	gfp	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	4	p	_	_
13	under	under	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	control	control	NN	_	4	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	chicken	chicken	NN	_	20	com	_	_
19	-actin	-actin	NN	_	20	com	_	_
20	promoter	promoter	NN	_	15	ppmod	_	_
21	,	,	,	_	4	p	_	_
22	was	be	VBD	_	23	aux	_	_
23	delivered	deliver	VBN	_	0	root	_	_
24	by	by	IN	_	26	case	_	_
25	intravitreal	intravitreal	JJ	_	26	attr	_	_
26	injection	injection	NN	_	23	ppmod	_	_
27	to	to	TO	_	29	aux	_	_
28	adult	adult	JJ	_	29	attr	_	_
29	mice	mouse	NNS	_	26	ppmod	_	_
30	in	in	IN	_	31	case	_	_
31	conjunction	conjunction	NN	_	26	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	enzymes	enzyme	NNS	_	31	ppmod	_	_
34	including	include	VBG	_	35	adv	_	_
35	drug2	drug0	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	drug3	drug0	NN	_	35	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug4	drug0	NN	_	35	conj	_	_
40	,	,	,	_	39	p	_	_
41	or	or	CC	_	39	cc	_	_
42	drug5	drug0	NN	_	35	conj	_	_
43	.	.	.	_	23	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	weeks	week	NNS	_	3	advnp	_	_
3	later	later	RB	_	8	adv	_	_
4	,	,	,	_	8	p	_	_
5	retinal	retinal	JJ	_	6	attr	_	_
6	flatmounts	flatmounts	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	examined	examine	VBN	_	0	root	_	_
9	for	for	IN	_	11	case	_	_
10	GFP	gfp	NN	_	11	com	_	_
11	expression	expression	NN	_	8	ppmod	_	_
12	using	use	VBG	_	11	acl	_	_
13	confocal	confocal	JJ	_	14	attr	_	_
14	microscopy	microscopy	NN	_	12	obj	_	_
15	.	.	.	_	8	p	_	_

1	Without	without	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	addition	addition	NN	_	9	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	enzymes	enzyme	NNS	_	3	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	transduction	transduction	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	limited	limit	VBN	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	occasional	occasional	JJ	_	12	attr	_	_
12	cells	cell	NNS	_	9	ppmod	_	_
13	in	in	IN	_	18	case	_	_
14	the	the	DT	_	18	det	_	_
15	retinal	retinal	JJ	_	18	attr	_	_
16	ganglion	ganglion	NN	_	18	com	_	_
17	cell	cell	NN	_	18	com	_	_
18	layer	layer	NN	_	12	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	addition	addition	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	greatly	greatly	RB	_	8	adv	_	_
8	enhanced	enhance	VBD	_	0	root	_	_
9	transduction	transduction	NN	_	8	obj	_	_
10	of	of	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	retinal	retinal	JJ	_	15	attr	_	_
13	ganglion	ganglion	NN	_	15	com	_	_
14	cell	cell	NN	_	15	com	_	_
15	layer	layer	NN	_	9	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	increased	increase	VBD	_	8	conj	_	_
18	the	the	DT	_	19	det	_	_
19	depth	depth	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	transduction	transduction	NN	_	19	ppmod	_	_
22	into	into	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	outer	outer	JJ	_	25	attr	_	_
25	retina	retina	NN	_	19	ppmod	_	_
26	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	limited	limited	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	and	and	CC	_	2	cc	_	_
7	drug2	drug0	NN	_	8	dep	_	_
8	was	be	VBD	_	2	conj	_	_
9	ineffective	ineffective	JJ	_	8	dep	_	_
10	.	.	.	_	2	p	_	_

1	Electroretinograms	electroretinogram	NNS	_	2	dep	_	_
2	survived	survive	VBD	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	higher	high	JJR	_	5	attr	_	_
5	concentrations	concentration	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	than	than	IN	_	12	mark	_	_
11	were	be	VBD	_	12	aux	_	_
12	required	require	VBN	_	2	comp	_	_
13	for	for	IN	_	16	case	_	_
14	optimal	optimal	JJ	_	16	attr	_	_
15	retinal	retinal	JJ	_	16	attr	_	_
16	transduction	transduction	NN	_	12	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	-mediated	-mediated	JJ	_	4	attr	_	_
3	retinal	retinal	NN	_	4	com	_	_
4	transduction	transduction	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	improved	improve	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	co-injection	co-injection	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	6	p	_	_

1	Improved	improved	JJ	_	3	attr	_	_
2	transduction	transduction	NN	_	3	com	_	_
3	efficiency	efficiency	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	allow	allow	VB	_	0	root	_	_
6	intravitreal	intravitreal	JJ	_	7	attr	_	_
7	injection	injection	NN	_	5	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	become	become	VB	_	5	comp	_	_
10	the	the	DT	_	12	det	_	_
11	preferred	preferred	JJ	_	12	attr	_	_
12	route	route	NN	_	9	obj	_	_
13	for	for	IN	_	14	case	_	_
14	delivering	deliver	VBG	_	12	ppmod	_	_
15	gene	gene	NN	_	16	com	_	_
16	therapy	therapy	NN	_	14	obj	_	_
17	to	to	TO	_	23	aux	_	_
18	both	both	CC	_	23	cc	_	_
19	the	the	DT	_	23	det	_	_
20	inner	inner	JJ	_	23	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	outer	outer	JJ	_	20	conj	_	_
23	retina	retina	NNS	_	14	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	advnp	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	drug2	drug0	NN	_	5	advnp	_	_
4	)	-rrb-	-RRB-	_	5	p	_	_
5	--better	--better	JJ	_	0	root	_	_
6	than	than	IN	_	7	case	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug4	drug0	NN	_	5	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	FDA	fda	NN	_	3	dep	_	_
3	has	have	VBZ	_	0	root	_	_
4	approved	approved	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	-AstraZeneca	-astrazeneca	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	5	p	_	_
11	an	an	DT	_	13	det	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	5	appo	_	_
14	,	,	,	_	5	p	_	_
15	for	for	IN	_	16	case	_	_
16	use	use	NN	_	3	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	low-dose	low-dose	JJ	_	19	attr	_	_
19	drug4	drug0	NN	_	16	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	reduce	reduce	VB	_	16	acl	_	_
22	the	the	DT	_	23	det	_	_
23	rate	rate	NN	_	21	obj	_	_
24	of	of	IN	_	27	case	_	_
25	thrombotic	thrombotic	JJ	_	27	attr	_	_
26	cardiovascular	cardiovascular	JJ	_	27	attr	_	_
27	events	event	NNS	_	23	ppmod	_	_
28	in	in	IN	_	29	case	_	_
29	patients	patient	NNS	_	27	ppmod	_	_
30	with	with	IN	_	33	case	_	_
31	acute	acute	JJ	_	33	attr	_	_
32	coronary	coronary	JJ	_	33	attr	_	_
33	syndrome	syndrome	NN	_	29	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	ACS	acs	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	will	will	MD	_	3	modal	_	_
3	compete	compete	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	and	and	CC	_	5	cc	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug4	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	for	for	IN	_	16	case	_	_
15	such	such	JJ	_	16	attr	_	_
16	use	use	NN	_	3	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	expected	expect	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	become	become	VB	_	3	comp	_	_
6	available	available	JJ	_	5	dep	_	_
7	generically	generically	RB	_	6	adv	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	US	us	PRP	_	5	ppmod	_	_
11	within	within	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	next	next	JJ	_	15	attr	_	_
14	few	few	JJ	_	15	attr	_	_
15	months	month	NNS	_	5	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	role	role	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	p27	p0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	Kip1	kip0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	in	in	IN	_	12	case	_	_
9	drug1	drug0	JJ	_	12	attr	_	_
10	-enhanced	-enhanced	JJ	_	12	attr	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	cytotoxicity	cytotoxicity	NN	_	2	ppmod	_	_
13	in	in	IN	_	17	case	_	_
14	human	human	JJ	_	17	attr	_	_
15	ovarian	ovarian	JJ	_	17	attr	_	_
16	cancer	cancer	NN	_	17	com	_	_
17	cells	cell	NNS	_	12	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Less	less	JJR	_	3	attr	_	_
2	than	than	IN	_	1	com	_	_
3	50	0	CD	_	8	num	_	_
4	%	%	NN	_	3	meta	_	_
5	of	of	IN	_	7	case	_	_
6	ovarian	ovarian	JJ	_	7	attr	_	_
7	cancers	cancer	NNS	_	3	ppmod	_	_
8	respond	respond	VBP	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Effective	effective	JJ	_	2	attr	_	_
2	strategies	strategy	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	needed	need	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	enhance	enhance	VB	_	4	comp	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	sensitivity	sensitivity	NN	_	6	obj	_	_
9	.	.	.	_	4	p	_	_

1	A	a	DT	_	2	det	_	_
2	library	library	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	silencing	silencing	JJ	_	5	attr	_	_
5	RNAs	rna	NNS	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	siRNAs	sirnas	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	was	be	VBD	_	10	aux	_	_
10	used	use	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	identify	identify	VB	_	10	comp	_	_
13	kinases	kinase	NNS	_	12	obj	_	_
14	that	that	WDT	_	15	dep	_	_
15	regulate	regulate	VBP	_	13	relcl	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	sensitivity	sensitivity	NN	_	15	obj	_	_
18	in	in	IN	_	23	case	_	_
19	human	human	JJ	_	23	attr	_	_
20	ovarian	ovarian	JJ	_	23	attr	_	_
21	cancer	cancer	NN	_	23	attr	_	_
22	SKOv3	skov0	JJ	_	23	attr	_	_
23	cells	cell	NNS	_	15	ppmod	_	_
24	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	18	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	an	an	DT	_	7	det	_	_
7	inhibitor	inhibitor	NN	_	4	appo	_	_
8	of	of	IN	_	9	case	_	_
9	Src	src	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	Abl	abl	NN	_	12	com	_	_
12	kinases	kinase	NNS	_	9	conj	_	_
13	,	,	,	_	4	p	_	_
14	on	on	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	sensitivity	sensitivity	NN	_	2	ppmod	_	_
17	was	be	VBD	_	18	aux	_	_
18	measured	measure	VBN	_	0	root	_	_
19	in	in	IN	_	22	case	_	_
20	ovarian	ovarian	JJ	_	22	attr	_	_
21	cancer	cancer	NN	_	22	com	_	_
22	cells	cell	NNS	_	18	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	HEY	hey	NN	_	25	com	_	_
25	xenografts	xenograft	NNS	_	22	conj	_	_
26	.	.	.	_	18	p	_	_

1	The	the	DT	_	2	det	_	_
2	roles	role	NNS	_	21	dep	_	_
3	of	of	IN	_	4	case	_	_
4	p27	p0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	Kip1	kip0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	4	p	_	_
9	Bcl-2	bcl-0	NN	_	4	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	Cdk1	cdk0	NN	_	4	conj	_	_
13	in	in	IN	_	14	case	_	_
14	apoptosis	apoptosis	NN	_	2	ppmod	_	_
15	induced	induce	VBN	_	14	acl	_	_
16	by	by	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	were	be	VBD	_	21	aux	_	_
21	assessed	assess	VBN	_	0	root	_	_
22	using	use	VBG	_	21	comp	_	_
23	a	a	DT	_	29	det	_	_
24	terminal	terminal	JJ	_	29	attr	_	_
25	deoxynucleotidyl	deoxynucleotidyl	NN	_	29	attr	_	_
26	transferase-mediated	transferase-mediated	JJ	_	29	attr	_	_
27	dUTP	dutp	NN	_	29	com	_	_
28	nick-end	nick-end	NN	_	29	com	_	_
29	labeling	labeling	NN	_	33	attr	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	TUNEL	tunel	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	assay	assay	NN	_	22	obj	_	_
34	,	,	,	_	33	p	_	_
35	siRNA	sirna	NN	_	36	com	_	_
36	knockdown	knockdown	NN	_	33	conj	_	_
37	of	of	IN	_	39	case	_	_
38	gene	gene	NN	_	39	com	_	_
39	expression	expression	NN	_	36	ppmod	_	_
40	,	,	,	_	36	p	_	_
41	transfection	transfection	NN	_	33	conj	_	_
42	with	with	IN	_	43	case	_	_
43	Bcl-2	bcl-0	NN	_	41	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	Cdk1	cdk0	NN	_	47	com	_	_
46	expression	expression	NN	_	47	com	_	_
47	vectors	vector	NNS	_	43	conj	_	_
48	,	,	,	_	41	p	_	_
49	and	and	CC	_	41	cc	_	_
50	flow	flow	NN	_	51	com	_	_
51	cytometry	cytometry	NN	_	33	conj	_	_
52	.	.	.	_	21	p	_	_

1	All	all	DT	_	3	det	_	_
2	statistical	statistical	JJ	_	3	attr	_	_
3	tests	test	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	two-sided	two-sided	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	Src	src	NN	_	2	com	_	_
2	family	family	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	Abl	abl	NN	_	5	com	_	_
5	kinases	kinase	NNS	_	2	conj	_	_
6	were	be	VBD	_	7	aux	_	_
7	identified	identify	VBN	_	0	root	_	_
8	as	as	IN	_	9	case	_	_
9	modulators	modulator	NNS	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	sensitivity	sensitivity	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	SKOv3	skov0	JJ	_	15	attr	_	_
15	cells	cell	NNS	_	9	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	siRNA	sirna	NN	_	3	com	_	_
3	knockdown	knockdown	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	Src	src	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	Fyn	fyn	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	Abl1	abl0	NN	_	5	conj	_	_
11	enhanced	enhance	VBD	_	0	root	_	_
12	drug1	drug0	NN	_	13	advnp	_	_
13	-mediated	-mediated	JJ	_	15	attr	_	_
14	growth	growth	NN	_	15	com	_	_
15	inhibition	inhibition	NN	_	11	obj	_	_
16	in	in	IN	_	19	case	_	_
17	ovarian	ovarian	JJ	_	19	attr	_	_
18	cancer	cancer	NN	_	19	com	_	_
19	cells	cell	NNS	_	11	ppmod	_	_
20	compared	compare	VBN	_	24	adv	_	_
21	with	with	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	control	control	NN	_	24	com	_	_
24	siRNA	sirna	NN	_	11	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	HEY	hey	NN	_	2	com	_	_
2	cells	cell	NNS	_	8	dep	_	_
3	treated	treat	VBN	_	2	acl	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	plus	plus	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	formed	form	VBD	_	0	root	_	_
9	fewer	few	JJR	_	10	attr	_	_
10	colonies	colony	NNS	_	8	obj	_	_
11	than	than	IN	_	12	mark	_	_
12	did	do	VBD	_	8	comp	_	_
13	cells	cell	NNS	_	12	obj	_	_
14	treated	treat	VBN	_	13	acl	_	_
15	with	with	IN	_	17	case	_	_
16	either	either	DT	_	17	det	_	_
17	agent	agent	NN	_	14	ppmod	_	_
18	alone	alone	RB	_	17	adv	_	_
19	.	.	.	_	8	p	_	_

1	Treatment	treatment	NN	_	10	dep	_	_
2	of	of	IN	_	5	case	_	_
3	HEY	hey	NN	_	5	attr	_	_
4	xenograft-bearing	xenograft-bearing	JJ	_	5	attr	_	_
5	mice	mouse	NNS	_	1	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	1	ppmod	_	_
8	plus	plus	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	inhibited	inhibit	VBD	_	0	root	_	_
11	tumor	tumor	NN	_	12	com	_	_
12	growth	growth	NN	_	10	obj	_	_
13	more	more	JJR	_	12	attr	_	_
14	than	than	IN	_	15	case	_	_
15	treatment	treatment	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	either	either	DT	_	18	det	_	_
18	agent	agent	NN	_	15	ppmod	_	_
19	alone	alone	RB	_	18	adv	_	_
20	(	-lrb-	-LRB-	_	55	p	_	_
21	average	average	JJ	_	23	attr	_	_
22	tumor	tumor	NN	_	23	com	_	_
23	volume	volume	NN	_	55	dep	_	_
24	per	per	IN	_	25	case	_	_
25	mouse	mouse	NN	_	23	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	+	+	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	25	conj	_	_
30	vs	vs	CC	_	23	cc	_	_
31	drug5	drug0	NN	_	23	conj	_	_
32	:	:	:	_	47	p	_	_
33	0.28	0	CD	_	36	num	_	_
34	vs.	vs.	CC	_	36	cc	_	_
35	0.81	0	CD	_	36	num	_	_
36	cm3	cm0	NN	_	47	dep	_	_
37	,	,	,	_	36	p	_	_
38	difference	difference	NN	_	41	attr	_	_
39	=	=	JJ	_	41	attr	_	_
40	0.53	0	CD	_	41	num	_	_
41	cm3	cm0	NN	_	36	conj	_	_
42	,	,	,	_	47	p	_	_
43	95	0	CD	_	47	num	_	_
44	%	%	NN	_	47	meta	_	_
45	confidence	confidence	NN	_	47	com	_	_
46	interval	interval	NN	_	47	com	_	_
47	-LSB-CI	-lsb-ci	NN	_	23	prn	_	_
48	]	-rsb-	-RRB-	_	47	p	_	_
49	=	=	JJ	_	23	attr	_	_
50	0.44	0	CD	_	53	num	_	_
51	to	to	TO	_	50	cc	_	_
52	0.62	0	CD	_	50	conj	_	_
53	cm3	cm0	NN	_	49	advnp	_	_
54	,	,	,	_	55	p	_	_
55	P	p	NN	_	10	prn	_	_
56	=	=	JJ	_	55	attr	_	_
57	.014	0	CD	_	55	num	_	_
58	)	-rrb-	-RRB-	_	55	p	_	_
59	;	;	:	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	+	+	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	vs	vs	CC	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	:	:	:	_	3	p	_	_
3	0.28	0	CD	_	0	root	_	_
4	vs	vs	CC	_	3	cc	_	_
5	.	.	.	_	3	p	_	_

1	0.55	0	CD	_	2	num	_	_
2	cm3	cm0	NN	_	5	dep	_	_
3	,	,	,	_	5	p	_	_
4	difference	difference	NN	_	5	dep	_	_
5	=	=	JJ	_	0	root	_	_
6	0.27	0	CD	_	5	obj	_	_
7	cm3	cm0	CD	_	6	num	_	_
8	,	,	,	_	11	p	_	_
9	95	0	CD	_	11	num	_	_
10	%	%	NN	_	9	meta	_	_
11	CI	ci	NN	_	6	prn	_	_
12	=	=	JJ	_	11	attr	_	_
13	0.21	0	CD	_	16	num	_	_
14	to	to	TO	_	13	cc	_	_
15	0.33	0	CD	_	13	conj	_	_
16	cm3	cm0	NN	_	12	advnp	_	_
17	,	,	,	_	11	p	_	_
18	P	p	NN	_	19	dep	_	_
19	=	=	JJ	_	11	advcl	_	_
20	.035	0	CD	_	19	obj	_	_
21	)	-rrb-	-RRB-	_	11	p	_	_
22	.	.	.	_	5	p	_	_

1	Combined	combined	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	3	dep	_	_
3	induced	induce	VBD	_	0	root	_	_
4	more	more	RBR	_	5	adv	_	_
5	TUNEL-positive	tunel-positive	JJ	_	7	attr	_	_
6	apoptotic	apoptotic	JJ	_	7	attr	_	_
7	cells	cell	NNS	_	3	obj	_	_
8	than	than	IN	_	9	mark	_	_
9	did	do	VBD	_	3	comp	_	_
10	either	either	DT	_	11	det	_	_
11	agent	agent	NN	_	9	obj	_	_
12	alone	alone	RB	_	11	adv	_	_
13	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	siRNA	sirna	NN	_	3	com	_	_
3	knockdown	knockdown	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	p27	p0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	Kip1	kip0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	decreased	decrease	VBD	_	0	root	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	-	-	:	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug2	drug0	NN	_	14	advnp	_	_
14	-induced	-induced	JJ	_	15	attr	_	_
15	apoptosis	apoptosis	NN	_	10	conj	_	_
16	compared	compare	VBN	_	21	adv	_	_
17	with	with	IN	_	21	case	_	_
18	a	a	DT	_	21	det	_	_
19	negative	negative	JJ	_	21	attr	_	_
20	control	control	NN	_	21	com	_	_
21	siRNA	sirna	NN	_	9	ppmod	_	_
22	(	-lrb-	-LRB-	_	58	p	_	_
23	sub-G1	sub-g0	NN	_	24	com	_	_
24	fraction	fraction	NN	_	58	dep	_	_
25	,	,	,	_	24	p	_	_
26	control	control	NN	_	27	com	_	_
27	siRNA	sirna	NN	_	24	conj	_	_
28	vs.	vs.	CC	_	27	cc	_	_
29	p27	p0	NN	_	33	attr	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	Kip1	kip0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	siRNA	sirna	NN	_	24	conj	_	_
34	:	:	:	_	58	p	_	_
35	42.5	0	CD	_	58	num	_	_
36	%	%	NN	_	35	meta	_	_
37	vs.	vs.	CC	_	35	cc	_	_
38	20.1	0	CD	_	35	conj	_	_
39	%	%	NN	_	38	meta	_	_
40	,	,	,	_	58	p	_	_
41	difference	difference	NN	_	48	attr	_	_
42	=	=	JJ	_	48	attr	_	_
43	22.4	0	CD	_	48	num	_	_
44	%	%	NN	_	48	meta	_	_
45	,	,	,	_	48	p	_	_
46	95	0	CD	_	48	num	_	_
47	%	%	NN	_	48	meta	_	_
48	CI	ci	NN	_	58	dep	_	_
49	=	=	JJ	_	48	attr	_	_
50	20.1	0	CD	_	48	num	_	_
51	%	%	NN	_	48	meta	_	_
52	to	to	TO	_	48	attr	_	_
53	24.7	0	CD	_	48	num	_	_
54	%	%	NN	_	48	meta	_	_
55	,	,	,	_	58	p	_	_
56	P	p	NN	_	58	attr	_	_
57	=	=	JJ	_	58	attr	_	_
58	.017	0	NN	_	21	num	_	_
59	)	-rrb-	-RRB-	_	58	p	_	_
60	.	.	.	_	9	p	_	_

1	Studies	study	NNS	_	12	dep	_	_
2	with	with	IN	_	4	case	_	_
3	forced	force	VBN	_	4	attr	_	_
4	expression	expression	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	siRNA	sirna	NN	_	7	com	_	_
7	knockdown	knockdown	NN	_	4	conj	_	_
8	of	of	IN	_	9	case	_	_
9	Bcl-2	bcl-0	NN	_	4	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	Cdk1	cdk0	NN	_	9	conj	_	_
12	suggest	suggest	VBP	_	0	root	_	_
13	that	that	IN	_	22	mark	_	_
14	drug1	drug0	NN	_	16	attr	_	_
15	-mediated	-mediated	JJ	_	16	attr	_	_
16	induction	induction	NN	_	22	dep	_	_
17	of	of	IN	_	18	case	_	_
18	p27	p0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	Kip1	kip0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	enhanced	enhance	VBD	_	12	comp	_	_
23	drug2	drug0	NN	_	25	attr	_	_
24	-induced	-induced	JJ	_	25	attr	_	_
25	apoptosis	apoptosis	NN	_	22	obj	_	_
26	by	by	IN	_	28	case	_	_
27	negatively	negatively	RB	_	28	adv	_	_
28	regulating	regulate	VBG	_	22	ppmod	_	_
29	Bcl-2	bcl-0	NN	_	28	obj	_	_
30	and	and	CC	_	29	cc	_	_
31	Cdk1	cdk0	NN	_	32	com	_	_
32	expression	expression	NN	_	29	conj	_	_
33	.	.	.	_	12	p	_	_

1	Inhibition	inhibition	NN	_	13	dep	_	_
2	of	of	IN	_	4	case	_	_
3	Src	src	NN	_	4	com	_	_
4	family	family	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	Abl	abl	NN	_	7	com	_	_
7	kinases	kinase	NNS	_	4	conj	_	_
8	with	with	IN	_	10	case	_	_
9	either	either	CC	_	10	cc	_	_
10	siRNAs	sirnas	NN	_	1	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug1	drug0	NN	_	10	conj	_	_
13	enhances	enhance	VBZ	_	0	root	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	sensitivity	sensitivity	NN	_	13	obj	_	_
16	of	of	IN	_	19	case	_	_
17	ovarian	ovarian	JJ	_	19	attr	_	_
18	cancer	cancer	NN	_	19	com	_	_
19	cells	cell	NNS	_	15	ppmod	_	_
20	through	through	IN	_	26	case	_	_
21	p27	p0	NN	_	25	advnp	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	Kip1	kip0	NN	_	25	advnp	_	_
24	)	-rrb-	-RRB-	_	25	p	_	_
25	-mediated	-mediated	JJ	_	26	attr	_	_
26	suppression	suppression	NN	_	13	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	Bcl-2	bcl-0	NN	_	26	ppmod	_	_
29	and	and	CC	_	28	cc	_	_
30	Cdk1	cdk0	NN	_	31	com	_	_
31	expression	expression	NN	_	28	conj	_	_
32	.	.	.	_	13	p	_	_

1	Influence	influence	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	induced	induce	VBD	_	0	root	_	_
7	antinociception	antinociception	NN	_	6	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	its	its	PRP$	_	10	poss	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	7	conj	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	CAS	cas	NN	_	4	com	_	_
4	94-62-2	0	NN	_	1	num	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	,	,	,	_	8	p	_	_
7	an	an	DT	_	8	det	_	_
8	alkaloid	alkaloid	NN	_	0	root	_	_
9	obtained	obtain	VBN	_	8	acl	_	_
10	from	from	IN	_	12	case	_	_
11	Piper	piper	NN	_	12	com	_	_
12	nigrum	nigrum	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	P	p	NN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	longum	longum	FW	_	3	dep	_	_
2	,	,	,	_	1	p	_	_
3	is	be	VBZ	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	known	known	JJ	_	6	attr	_	_
6	inhibitor	inhibitor	NN	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	various	various	JJ	_	9	attr	_	_
9	enzymes	enzyme	NNS	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	CYP	cyp	NN	_	12	com	_	_
12	isozymes	isozymes	NNS	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	responsible	responsible	JJ	_	9	attr	_	_
15	for	for	IN	_	16	case	_	_
16	biotransformation	biotransformation	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	By	by	IN	_	2	case	_	_
2	inhibiting	inhibit	VBG	_	9	ppmod	_	_
3	the	the	DT	_	4	det	_	_
4	metabolism	metabolism	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	improves	improve	VBZ	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	bioavailability	bioavailability	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	11	ppmod	_	_
5	drug1	drug0	NN	_	11	dep	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	10	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	significantly	significantly	RB	_	11	adv	_	_
11	increased	increase	VBD	_	0	root	_	_
12	the	the	DT	_	15	det	_	_
13	dose-dependent	dose-dependent	JJ	_	15	attr	_	_
14	antinociceptive	antinociceptive	JJ	_	15	attr	_	_
15	activity	activity	NN	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NNS	_	15	ppmod	_	_
18	evaluated	evaluate	VBN	_	17	acl	_	_
19	by	by	IN	_	22	case	_	_
20	both	both	CC	_	22	cc	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	writhing	writhing	NN	_	18	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	formalin	formalin	NN	_	25	com	_	_
25	test	test	NN	_	22	conj	_	_
26	,	,	,	_	11	p	_	_
27	when	when	WRB	_	30	adv	_	_
28	it	it	PRP	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	administered	administer	VBN	_	11	comp	_	_
31	with	with	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentration	concentration	NN	_	6	dep	_	_
4	was	be	VBD	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	increased	increase	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	it	it	PRP	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	administered	administer	VBN	_	6	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	The	the	DT	_	4	det	_	_
2	synergistic	synergistic	JJ	_	4	attr	_	_
3	antinociception	antinociception	NN	_	4	com	_	_
4	activity	activity	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	when	when	WRB	_	8	adv	_	_
8	administered	administer	VBN	_	4	relcl	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	can	can	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	attributed	attribute	VBN	_	0	root	_	_
14	to	to	TO	_	17	aux	_	_
15	increased	increase	VBN	_	17	attr	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentration	concentration	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	From	from	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	7	ppmod	_	_
4	it	it	PRP	_	7	dep	_	_
5	can	can	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	concluded	conclude	VBN	_	0	root	_	_
8	that	that	IN	_	12	mark	_	_
9	drug1	drug0	NN	_	12	dep	_	_
10	can	can	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	used	use	VBN	_	7	comp	_	_
13	as	as	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	bioenhancer	bioenhancer	NN	_	12	ppmod	_	_
16	along	along	IN	_	18	case	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Prevention	prevention	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	emergence	emergence	NN	_	4	com	_	_
4	agitation	agitation	NN	_	1	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	seven	#crd#	CD	_	7	num	_	_
7	children	child	NNS	_	1	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	low-dose	low-dose	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	8	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	15	attr	_	_
13	total	total	JJ	_	15	attr	_	_
14	intravenous	intravenous	JJ	_	15	attr	_	_
15	anesthesia	anesthesia	NN	_	10	conj	_	_
16	.	.	.	_	1	p	_	_

1	Emergence	emergence	NN	_	2	com	_	_
2	agitation	agitation	NN	_	7	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	EA	ea	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	can	can	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	a	a	DT	_	11	det	_	_
9	distressing	distressing	JJ	_	11	attr	_	_
10	side	side	JJ	_	11	attr	_	_
11	effect	effect	NN	_	7	obj	_	_
12	of	of	IN	_	14	case	_	_
13	pediatric	pediatric	JJ	_	14	attr	_	_
14	anesthesia	anesthesia	NNS	_	11	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	retrospectively	retrospectively	VBP	_	3	aux	_	_
3	reviewed	review	VBN	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	records	record	NNS	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	7	0	CD	_	10	num	_	_
8	pediatric	pediatric	JJ	_	10	attr	_	_
9	oncology	oncology	NN	_	10	com	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	who	who	WP	_	12	dep	_	_
12	received	receive	VBD	_	10	relcl	_	_
13	low-dose	low-dose	JJ	_	14	attr	_	_
14	drug1	drug0	NN	_	12	obj	_	_
15	in	in	IN	_	16	case	_	_
16	conjunction	conjunction	NN	_	14	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	for	for	IN	_	22	case	_	_
20	total	total	JJ	_	22	attr	_	_
21	intravenous	intravenous	JJ	_	22	attr	_	_
22	anesthesia	anesthesia	NN	_	14	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	TIVA	tiva	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	repeatedly	repeatedly	RB	_	12	adv	_	_
27	for	for	IN	_	29	case	_	_
28	radiation	radiation	NN	_	29	com	_	_
29	therapy	therapy	NN	_	12	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	EA	ea	NN	_	2	com	_	_
2	signs	sign	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	in	in	IN	_	8	case	_	_
6	all	all	DT	_	8	det	_	_
7	7	0	CD	_	8	num	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	association	association	NN	_	4	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	TIVA	tiva	NN	_	10	ppmod	_	_
14	but	but	CC	_	4	cc	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	recur	recur	VB	_	4	conj	_	_
18	in	in	IN	_	19	case	_	_
19	any	any	DT	_	17	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	123	0	CD	_	24	num	_	_
22	subsequent	subsequent	JJ	_	24	attr	_	_
23	anesthetics	anesthetics	NN	_	24	com	_	_
24	sessions	session	NNS	_	19	ppmod	_	_
25	during	during	IN	_	26	case	_	_
26	which	which	WDT	_	30	ppmod	_	_
27	low-dose	low-dose	JJ	_	28	attr	_	_
28	drug2	drug0	NN	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	added	add	VBN	_	24	relcl	_	_
31	to	to	TO	_	32	aux	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	Based	base	VBN	_	3	adv	_	_
2	on	on	IN	_	3	case	_	_
3	this	this	DT	_	7	ppmod	_	_
4	experience	experience	VBP	_	3	acl	_	_
5	,	,	,	_	7	p	_	_
6	we	we	PRP	_	7	dep	_	_
7	suggest	suggest	VBP	_	0	root	_	_
8	that	that	IN	_	16	mark	_	_
9	low-dose	low-dose	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	16	dep	_	_
11	added	add	VBN	_	10	acl	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	associated	associate	VBN	_	7	comp	_	_
17	with	with	IN	_	18	case	_	_
18	prevention	prevention	NN	_	16	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	EA	ea	NN	_	18	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	children	child	NNS	_	18	ppmod	_	_
23	with	with	IN	_	25	case	_	_
24	a	a	DT	_	25	det	_	_
25	history	history	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	EA	ea	NN	_	25	ppmod	_	_
28	with	with	IN	_	30	case	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	TIVA	tiva	NN	_	27	ppmod	_	_
31	.	.	.	_	7	p	_	_

1	-LSB-Efficacy	-lsb-efficacy	NN	_	0	root	_	_
2	of	of	IN	_	7	case	_	_
3	fixed	fixed	JJ	_	7	attr	_	_
4	combination	combination	NN	_	7	attr	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	/	/	:	_	7	p	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	hospitalized	hospitalized	JJ	_	10	attr	_	_
10	patients	patient	NNS	_	1	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	hypertensive	hypertensive	JJ	_	13	attr	_	_
13	disease	disease	NN	_	10	ppmod	_	_
14	]	-rsb-	-RRB-	_	1	p	_	_

1	Efficacy	efficacy	NN	_	11	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	tolerability	tolerability	NN	_	1	conj	_	_
4	of	of	IN	_	9	case	_	_
5	fixed	fixed	JJ	_	9	attr	_	_
6	drug1	drug0	NN	_	9	attr	_	_
7	/	/	:	_	9	p	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	combination	combination	NN	_	1	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	86	0	CD	_	14	num	_	_
14	patients	patient	NNS	_	11	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	hypertensive	hypertensive	JJ	_	17	attr	_	_
17	disease	disease	NN	_	14	ppmod	_	_
18	hospitalized	hospitalize	VBN	_	14	acl	_	_
19	in	in	IN	_	20	case	_	_
20	departments	department	NNS	_	18	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	general	general	JJ	_	24	attr	_	_
23	internal	internal	JJ	_	24	attr	_	_
24	medicine	medicine	NN	_	20	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	cardiology	cardiology	NN	_	24	conj	_	_
27	.	.	.	_	11	p	_	_

1	All	all	DT	_	2	det	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	had	have	VBD	_	4	lv	_	_
4	indications	indication	NNS	_	0	root	_	_
5	for	for	IN	_	7	case	_	_
6	antihypertensive	antihypertensive	JJ	_	7	attr	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	and	and	CC	_	4	cc	_	_
9	were	be	VBD	_	10	aux	_	_
10	randomized	randomize	VBN	_	4	conj	_	_
11	either	either	CC	_	15	cc	_	_
12	to	to	TO	_	15	aux	_	_
13	fixed	fixed	JJ	_	15	attr	_	_
14	combination	combination	NN	_	15	com	_	_
15	drug1	drug0	NN	_	10	ppmod	_	_
16	/	/	:	_	15	p	_	_
17	drug2	drug0	NN	_	15	appo	_	_
18	(	-lrb-	-LRB-	_	17	p	_	_
19	n=43	n=0	CD	_	17	num	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	or	or	CC	_	15	cc	_	_
22	to	to	TO	_	23	aux	_	_
23	therapy	therapy	NN	_	15	conj	_	_
24	which	which	WDT	_	25	dep	_	_
25	corresponded	correspond	VBD	_	23	relcl	_	_
26	to	to	TO	_	29	aux	_	_
27	the	the	DT	_	29	det	_	_
28	hospital	hospital	NN	_	29	com	_	_
29	formulary	formulary	NN	_	25	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	n=43	n=0	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	4	p	_	_

1	Correction	correction	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	therapy	therapy	NN	_	1	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	performed	performed	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	treating	treat	VBG	_	6	ppmod	_	_
9	physician	physician	NN	_	8	obj	_	_
10	at	at	IN	_	12	case	_	_
11	daily	daily	JJ	_	12	attr	_	_
12	rounds	round	NNS	_	8	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Self-control	self-control	NN	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	blood	blood	NN	_	4	com	_	_
4	pressure	pressure	NN	_	1	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	BP	bp	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	was	be	VBD	_	9	aux	_	_
9	performed	performed	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	use	use	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	UA767PC	ua0pc	NN	_	17	com	_	_
17	apparatus	apparatus	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Results	result	NNS	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	BP	bp	NN	_	4	com	_	_
4	self-control	self-control	NN	_	1	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	compared	compare	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	measurements	measurement	NNS	_	6	ppmod	_	_
10	in	in	IN	_	13	mark	_	_
11	order	order	NN	_	13	dep	_	_
12	to	to	TO	_	13	aux	_	_
13	detect	detect	VB	_	6	comp	_	_
14	concealed	conceal	VBN	_	15	attr	_	_
15	inefficacy	inefficacy	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	treatment	treatment	NN	_	15	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Results	result	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Rate	rate	NN	_	17	dep	_	_
2	of	of	IN	_	3	case	_	_
3	achievement	achievement	NN	_	1	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	target	target	NN	_	6	com	_	_
6	BP	bp	NN	_	3	ppmod	_	_
7	with	with	IN	_	10	case	_	_
8	fixed	fixed	JJ	_	10	attr	_	_
9	combination	combination	NN	_	10	com	_	_
10	drug1	drug0	NN	_	3	ppmod	_	_
11	/	/	:	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	93	0	CD	_	12	num	_	_
15	%	%	NN	_	14	meta	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	was	be	VBD	_	0	root	_	_
18	comparable	comparable	JJ	_	17	dep	_	_
19	with	with	IN	_	20	case	_	_
20	that	that	DT	_	18	ppmod	_	_
21	on	on	IN	_	23	case	_	_
22	traditional	traditional	JJ	_	23	attr	_	_
23	therapy	therapy	NN	_	20	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	90	0	CD	_	23	num	_	_
26	%	%	NN	_	25	meta	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	.	.	.	_	17	p	_	_

1	But	but	CC	_	15	cc	_	_
2	the	the	DT	_	3	det	_	_
3	use	use	NN	_	15	dep	_	_
4	of	of	IN	_	7	case	_	_
5	fixed	fixed	JJ	_	7	attr	_	_
6	combination	combination	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	/	/	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	compared	compare	VBN	_	9	acl	_	_
11	with	with	IN	_	13	case	_	_
12	traditional	traditional	JJ	_	13	attr	_	_
13	therapy	therapy	NN	_	10	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	associated	associate	VBN	_	0	root	_	_
16	with	with	IN	_	22	case	_	_
17	lower	low	RBR	_	18	adv	_	_
18	clinical	clinical	JJ	_	22	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	self	self	NN	_	21	advnp	_	_
21	measured	measure	VBD	_	18	conj	_	_
22	BP	bp	NN	_	15	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	quicker	quicker	JJ	_	25	attr	_	_
25	achievement	achievement	NN	_	22	appo	_	_
26	of	of	IN	_	28	case	_	_
27	target	target	NN	_	28	com	_	_
28	BP	bp	NN	_	25	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	5.8+/-2.3	0+/-0	CD	_	28	num	_	_
31	and	and	CC	_	30	cc	_	_
32	9.2+/-1.8	0+/-0	CD	_	33	num	_	_
33	days	day	NNS	_	30	conj	_	_
34	,	,	,	_	30	p	_	_
35	respectively	respectively	RB	_	30	adv	_	_
36	,	,	,	_	30	p	_	_
37	0.05	0	CD	_	30	appo	_	_
38	)	-rrb-	-RRB-	_	30	p	_	_
39	,	,	,	_	22	p	_	_
40	lesser	less	JJR	_	41	attr	_	_
41	number	number	NN	_	22	appo	_	_
42	of	of	IN	_	43	case	_	_
43	drug3	drug0	NN	_	41	ppmod	_	_
44	(	-lrb-	-LRB-	_	48	p	_	_
45	2.5+/-0.6	0+/-0	CD	_	48	num	_	_
46	and	and	CC	_	45	cc	_	_
47	3.0+/-0.9	0+/-0	CD	_	45	conj	_	_
48	days	day	NNS	_	43	prn	_	_
49	,	,	,	_	48	p	_	_
50	respectively	respectively	RB	_	48	adv	_	_
51	)	-rrb-	-RRB-	_	48	p	_	_
52	,	,	,	_	22	p	_	_
53	lower	low	JJR	_	54	attr	_	_
54	rate	rate	NN	_	22	appo	_	_
55	of	of	IN	_	57	case	_	_
56	concealed	conceal	VBN	_	57	attr	_	_
57	inefficacy	inefficacy	NN	_	54	ppmod	_	_
58	of	of	IN	_	59	case	_	_
59	treatment	treatment	NN	_	57	ppmod	_	_
60	(	-lrb-	-LRB-	_	61	p	_	_
61	12	0	CD	_	59	num	_	_
62	and	and	CC	_	61	cc	_	_
63	31	0	CD	_	61	conj	_	_
64	%	%	NN	_	61	meta	_	_
65	,	,	,	_	61	p	_	_
66	respectively	respectively	RB	_	61	adv	_	_
67	,	,	,	_	61	p	_	_
68	0.05	0	CD	_	61	appo	_	_
69	)	-rrb-	-RRB-	_	61	p	_	_
70	.	.	.	_	15	p	_	_

1	Conclusions	conclusion	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	demonstrated	demonstrate	VBN	_	0	root	_	_
4	appropriateness	appropriateness	NN	_	3	obj	_	_
5	of	of	IN	_	7	case	_	_
6	inhospital	inhospital	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	13	case	_	_
9	fixed	fixed	JJ	_	13	attr	_	_
10	drug1	drug0	NN	_	13	attr	_	_
11	/	/	:	_	13	p	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	combination	combination	NN	_	7	ppmod	_	_
14	as	as	IN	_	16	case	_	_
15	an	an	DT	_	16	det	_	_
16	approach	approach	NN	_	3	ppmod	_	_
17	allowing	allow	VBG	_	16	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	achieve	achieve	VB	_	17	comp	_	_
20	target	target	NN	_	21	com	_	_
21	BP	bp	NN	_	19	obj	_	_
22	in	in	IN	_	24	case	_	_
23	shorter	short	JJR	_	24	attr	_	_
24	time	time	NN	_	19	ppmod	_	_
25	,	,	,	_	19	p	_	_
26	with	with	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	use	use	NN	_	19	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	fewer	few	JJR	_	31	attr	_	_
31	drug3	drug0	NNS	_	28	ppmod	_	_
32	,	,	,	_	17	p	_	_
33	and	and	CC	_	17	cc	_	_
34	diminishing	diminish	VBG	_	17	conj	_	_
35	concealed	conceal	VBN	_	36	attr	_	_
36	inefficacy	inefficacy	NN	_	34	obj	_	_
37	of	of	IN	_	38	case	_	_
38	treatment	treatment	NN	_	36	ppmod	_	_
39	.	.	.	_	3	p	_	_

1	Antitumor	antitumor	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	a	a	DT	_	8	det	_	_
7	specific	specific	JJ	_	8	attr	_	_
8	inhibitor	inhibitor	NN	_	4	appo	_	_
9	of	of	IN	_	10	case	_	_
10	HB-EGF	hb-egf	NN	_	8	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	in	in	IN	_	16	case	_	_
13	T-cell	t-cell	NN	_	16	attr	_	_
14	acute	acute	JJ	_	16	attr	_	_
15	lymphoblastic	lymphoblastic	JJ	_	16	attr	_	_
16	leukemia	leukemia	NN	_	2	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	therapeutic	therapeutic	JJ	_	3	attr	_	_
3	outcome	outcome	NN	_	12	dep	_	_
4	for	for	IN	_	8	case	_	_
5	T-cell	t-cell	NN	_	8	attr	_	_
6	acute	acute	JJ	_	8	attr	_	_
7	lymphoblastic	lymphoblastic	JJ	_	8	attr	_	_
8	leukemia	leukemia	NN	_	3	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	T-ALL	t-all	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	remains	remain	VBZ	_	0	root	_	_
13	poor	poor	JJ	_	12	dep	_	_
14	;	;	:	_	12	p	_	_

1	thus	thus	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	novel	novel	JJ	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	targeted	targeted	JJ	_	6	attr	_	_
6	therapies	therapy	NNS	_	9	dep	_	_
7	are	be	VBP	_	9	aux	_	_
8	urgently	urgently	RB	_	9	adv	_	_
9	needed	need	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Recently	recently	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	that	that	IN	_	23	mark	_	_
6	heparin-binding	heparin-binding	JJ	_	11	attr	_	_
7	epidermal	epidermal	JJ	_	11	attr	_	_
8	growth	growth	NN	_	11	attr	_	_
9	factor-like	factor-like	JJ	_	11	attr	_	_
10	growth	growth	NN	_	11	com	_	_
11	factor	factor	NN	_	23	dep	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	HB-EGF	hb-egf	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	11	p	_	_
16	a	a	DT	_	17	det	_	_
17	member	member	NN	_	11	appo	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	EGF	egf	NN	_	21	com	_	_
21	family	family	NN	_	17	ppmod	_	_
22	,	,	,	_	11	p	_	_
23	is	be	VBZ	_	4	comp	_	_
24	a	a	DT	_	26	det	_	_
25	promising	promising	JJ	_	26	attr	_	_
26	target	target	NN	_	23	obj	_	_
27	for	for	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	treatment	treatment	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	various	various	JJ	_	32	attr	_	_
32	types	type	NNS	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	cancer	cancer	NN	_	32	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	present	present	JJ	_	6	attr	_	_
6	study	study	NN	_	2	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	investigate	investigate	VB	_	7	comp	_	_
10	whether	whether	IN	_	12	mark	_	_
11	HB-EGF	hb-egf	NN	_	12	dep	_	_
12	is	be	VBZ	_	9	comp	_	_
13	a	a	DT	_	15	det	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	target	target	NN	_	12	obj	_	_
16	for	for	IN	_	17	case	_	_
17	T-ALL	t-all	NN	_	15	ppmod	_	_
18	,	,	,	_	9	p	_	_
19	and	and	CC	_	9	cc	_	_
20	to	to	TO	_	22	aux	_	_
21	further	far	RB	_	22	adv	_	_
22	elucidate	elucidate	VB	_	9	conj	_	_
23	the	the	DT	_	25	det	_	_
24	antitumor	antitumor	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	22	obj	_	_
26	of	of	IN	_	29	case	_	_
27	a	a	DT	_	29	det	_	_
28	specific	specific	JJ	_	29	attr	_	_
29	inhibitor	inhibitor	NN	_	25	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	HB-EGF	hb-egf	NN	_	29	ppmod	_	_
32	,	,	,	_	29	p	_	_
33	drug1	drug0	NN	_	29	appo	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	drug2	drug0	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	elucidated	elucidate	VBN	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	expression	expression	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	HB-EGF	hb-egf	NN	_	4	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	T-ALL	t-all	NN	_	10	com	_	_
9	cell	cell	NN	_	10	com	_	_
10	lines	line	NNS	_	4	ppmod	_	_
11	,	,	,	_	2	p	_	_
12	and	and	CC	_	2	cc	_	_
13	evaluated	evaluate	VBD	_	2	conj	_	_
14	the	the	DT	_	15	det	_	_
15	effect	effect	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	these	these	DT	_	20	det	_	_
20	cells	cell	NNS	_	15	ppmod	_	_
21	alone	alone	RB	_	15	adv	_	_
22	or	or	CC	_	21	cc	_	_
23	in	in	IN	_	24	case	_	_
24	combination	combination	NN	_	21	conj	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	expression	expression	NN	_	9	dep	_	_
3	of	of	IN	_	7	case	_	_
4	EGFR	egfr	NN	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	EGFR	egfr	NN	_	4	conj	_	_
7	ligands	ligand	NNS	_	2	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	determined	determine	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	flow	flow	NN	_	12	com	_	_
12	cytometry	cytometry	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	RT-PCR	rt-pcr	NN	_	12	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	real-time	real-time	JJ	_	18	attr	_	_
17	quantitative	quantitative	JJ	_	18	attr	_	_
18	PCR	pcr	NN	_	12	conj	_	_
19	.	.	.	_	9	p	_	_

1	Induction	induction	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	apoptosis	apoptosis	NN	_	1	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	assessed	assess	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	TUNEL	tunel	NN	_	8	com	_	_
8	assay	assay	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	HB-EGF	hb-egf	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	strongly	strongly	RB	_	4	adv	_	_
4	expressed	express	VBN	_	0	root	_	_
5	by	by	IN	_	8	case	_	_
6	T-ALL	t-all	NN	_	8	com	_	_
7	cell	cell	NN	_	8	com	_	_
8	lines	line	NNS	_	4	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	the	the	DT	_	12	det	_	_
12	expression	expression	NN	_	19	dep	_	_
13	of	of	IN	_	15	case	_	_
14	both	both	CC	_	15	cc	_	_
15	HB-EGF	hb-egf	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	EGFR	egfr	NN	_	15	conj	_	_
18	was	be	VBD	_	19	aux	_	_
19	enhanced	enhance	VBN	_	4	conj	_	_
20	by	by	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	induced	induce	VBD	_	0	root	_	_
3	apoptosis	apoptosis	NN	_	2	obj	_	_
4	,	,	,	_	2	p	_	_
5	and	and	CC	_	2	cc	_	_
6	furthermore	furthermore	RB	_	14	adv	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	combination	combination	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	plus	plus	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	enhanced	enhance	VBD	_	2	conj	_	_
15	cytotoxicity	cytotoxicity	NN	_	14	obj	_	_
16	in	in	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	T-ALL	t-all	NN	_	20	com	_	_
19	cell	cell	NN	_	20	com	_	_
20	line	line	NN	_	14	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	HB-EGF	hb-egf	NN	_	6	dep	_	_
6	is	be	VBZ	_	3	comp	_	_
7	a	a	DT	_	10	det	_	_
8	promising	promising	JJ	_	10	attr	_	_
9	therapeutic	therapeutic	JJ	_	10	attr	_	_
10	target	target	NN	_	6	obj	_	_
11	for	for	IN	_	12	case	_	_
12	T-ALL	t-all	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Distinct	distinct	JJ	_	3	attr	_	_
2	synergistic	synergistic	JJ	_	3	attr	_	_
3	action	action	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	against	against	IN	_	10	case	_	_
9	Pseudomonas	pseudomonas	FW	_	10	attr	_	_
10	aeruginosa	aeruginosa	FW	_	3	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	The	the	DT	_	4	det	_	_
2	dicarbonyl	dicarbonyl	NN	_	4	com	_	_
3	compound	compound	NN	_	4	com	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	natural	natural	JJ	_	8	attr	_	_
8	constituent	constituent	NN	_	5	obj	_	_
9	of	of	IN	_	11	case	_	_
10	Manuka	manuka	NN	_	11	com	_	_
11	honey	honey	NN	_	8	ppmod	_	_
12	produced	produce	VBN	_	11	acl	_	_
13	from	from	IN	_	15	case	_	_
14	Manuka	manuka	NN	_	15	com	_	_
15	flowers	flower	NNS	_	12	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	New	new	JJ	_	18	attr	_	_
18	Zealand	zealand	NN	_	15	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	possess	possess	VB	_	3	comp	_	_
6	both	both	CC	_	7	cc	_	_
7	anticancer	anticancer	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	antibacterial	antibacterial	JJ	_	7	conj	_	_
10	activity	activity	NN	_	5	obj	_	_
11	.	.	.	_	3	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	observations	observation	NNS	_	3	dep	_	_
3	prompted	prompt	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	investigate	investigate	VB	_	3	comp	_	_
6	the	the	DT	_	7	det	_	_
7	ability	ability	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	as	as	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	potent	potent	JJ	_	13	attr	_	_
13	drug	drug	NN	_	5	ppmod	_	_
14	against	against	IN	_	18	case	_	_
15	multidrug	multidrug	JJ	_	18	attr	_	_
16	resistant	resistant	JJ	_	18	attr	_	_
17	Pseudomonas	pseudomonas	FW	_	18	attr	_	_
18	aeruginosa	aeruginosa	FW	_	13	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	total	total	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	12	0	CD	_	2	ppmod	_	_
5	test	test	VB	_	0	root	_	_
6	P	p	NN	_	5	obj	_	_
7	.	.	.	_	5	p	_	_

1	aeruginosa	aeruginosa	FW	_	2	attr	_	_
2	strains	strain	NNS	_	8	dep	_	_
3	isolated	isolate	VBN	_	2	acl	_	_
4	from	from	IN	_	6	case	_	_
5	various	various	JJ	_	6	attr	_	_
6	hospitals	hospital	NNS	_	3	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	tested	test	VBN	_	0	root	_	_
9	for	for	IN	_	11	case	_	_
10	their	their	PRP$	_	11	poss	_	_
11	resistances	resistance	NNS	_	8	ppmod	_	_
12	against	against	IN	_	14	case	_	_
13	many	many	JJ	_	14	attr	_	_
14	drug1	drug0	NNS	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	most	most	JJS	_	20	dep	_	_
17	of	of	IN	_	18	case	_	_
18	which	which	WDT	_	16	ppmod	_	_
19	are	be	VBP	_	20	aux	_	_
20	applied	apply	VBN	_	14	relcl	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	treatment	treatment	NN	_	20	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	P	p	NN	_	23	ppmod	_	_
26	.	.	.	_	8	p	_	_

1	aeruginosa	aeruginosa	FW	_	2	attr	_	_
2	infections	infection	NNS	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	Results	result	NNS	_	2	dep	_	_
2	revealed	reveal	VBD	_	23	advcl	_	_
3	that	that	IN	_	6	mark	_	_
4	the	the	DT	_	5	det	_	_
5	strains	strain	NNS	_	6	dep	_	_
6	were	be	VBD	_	2	comp	_	_
7	resistant	resistant	JJ	_	6	dep	_	_
8	to	to	TO	_	10	aux	_	_
9	many	many	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	at	at	IN	_	13	case	_	_
12	high	high	JJ	_	13	attr	_	_
13	levels	level	NNS	_	6	ppmod	_	_
14	,	,	,	_	6	p	_	_
15	only	only	RB	_	6	adv	_	_
16	drug1	drug0	NN	_	23	dep	_	_
17	,	,	,	_	16	p	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	16	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	16	conj	_	_
23	showed	show	VBD	_	0	root	_	_
24	resistances	resistance	NNS	_	23	obj	_	_
25	at	at	IN	_	28	case	_	_
26	comparatively	comparatively	RB	_	27	adv	_	_
27	lower	low	JJR	_	28	attr	_	_
28	levels	level	NNS	_	23	ppmod	_	_
29	.	.	.	_	23	p	_	_

1	Following	follow	VBG	_	3	adv	_	_
2	multiple	multiple	JJ	_	3	attr	_	_
3	experimentations	experimentation	NNS	_	6	ppmod	_	_
4	it	it	PRP	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	was	be	VBD	_	6	comp	_	_
10	also	also	RB	_	9	adv	_	_
11	antimicrobic	antimicrobic	JJ	_	9	dep	_	_
12	against	against	IN	_	15	case	_	_
13	all	all	PDT	_	15	det	_	_
14	the	the	DT	_	15	det	_	_
15	strains	strain	NNS	_	11	ppmod	_	_
16	at	at	IN	_	18	case	_	_
17	comparable	comparable	JJ	_	18	attr	_	_
18	levels	level	NNS	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Distinct	distinct	JJ	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	statistically	statistically	RB	_	4	adv	_	_
4	significant	significant	JJ	_	1	conj	_	_
5	synergism	synergism	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	by	by	IN	_	15	case	_	_
13	disc	disc	NN	_	15	com	_	_
14	diffusion	diffusion	NN	_	15	com	_	_
15	tests	test	NNS	_	7	ppmod	_	_
16	when	when	WRB	_	17	adv	_	_
17	compared	compare	VBN	_	7	comp	_	_
18	with	with	IN	_	21	case	_	_
19	their	their	PRP$	_	21	poss	_	_
20	individual	individual	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	17	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	The	the	DT	_	5	det	_	_
2	fractional	fractional	JJ	_	5	attr	_	_
3	inhibitory	inhibitory	JJ	_	5	attr	_	_
4	concentration	concentration	NN	_	5	com	_	_
5	index	index	NN	_	14	dep	_	_
6	of	of	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	combination	combination	NN	_	5	ppmod	_	_
9	evaluated	evaluate	VBN	_	5	acl	_	_
10	by	by	IN	_	12	case	_	_
11	checkerboard	checkerboard	NN	_	12	com	_	_
12	analysis	analysis	NN	_	9	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	was	be	VBD	_	0	root	_	_
15	0.5	0	CD	_	14	obj	_	_
16	,	,	,	_	15	p	_	_
17	which	which	WDT	_	18	dep	_	_
18	confirmed	confirm	VBD	_	15	relcl	_	_
19	synergism	synergism	NN	_	18	obj	_	_
20	between	between	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	pair	pair	NN	_	19	ppmod	_	_
23	.	.	.	_	14	p	_	_

1	Synergism	synergism	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	noted	note	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	combined	combine	VBN	_	4	comp	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	failure	failure	NN	_	10	dep	_	_
3	in	in	IN	_	6	case	_	_
4	an	an	DT	_	6	det	_	_
5	HIV-positive	hiv-positive	JJ	_	6	attr	_	_
6	woman	woman	NN	_	2	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	therapy	therapy	NN	_	6	ppmod	_	_
10	resulting	result	VBG	_	0	root	_	_
11	in	in	IN	_	14	case	_	_
12	two	#crd#	CD	_	14	num	_	_
13	ectopic	ectopic	JJ	_	14	attr	_	_
14	pregnancies	pregnancy	NNS	_	10	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	Since	since	IN	_	3	case	_	_
2	its	its	PRP$	_	3	poss	_	_
3	introduction	introduction	NN	_	8	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	1999	0	CD	_	3	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	remains	remain	VBZ	_	0	root	_	_
9	one	#crd#	CD	_	8	obj	_	_
10	of	of	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	preferred	preferred	JJ	_	14	attr	_	_
13	contraceptive	contraceptive	JJ	_	14	attr	_	_
14	choices	choice	NNS	_	9	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	many	many	JJ	_	17	attr	_	_
17	women	woman	NNS	_	14	ppmod	_	_
18	as	as	IN	_	20	mark	_	_
19	it	it	PRP	_	20	dep	_	_
20	offers	offer	VBZ	_	8	comp	_	_
21	a	a	DT	_	24	det	_	_
22	highly	highly	RB	_	23	adv	_	_
23	effective	effective	JJ	_	24	attr	_	_
24	means	means	NN	_	20	obj	_	_
25	of	of	IN	_	27	case	_	_
26	long-term	long-term	JJ	_	27	attr	_	_
27	contraception	contraception	NN	_	24	ppmod	_	_
28	for	for	IN	_	30	case	_	_
29	three	#crd#	CD	_	30	num	_	_
30	years	year	NNS	_	24	ppmod	_	_
31	that	that	WDT	_	34	dep	_	_
32	does	do	VBZ	_	34	aux	_	_
33	not	not	RB	_	34	neg	_	_
34	rely	rely	VB	_	24	relcl	_	_
35	on	on	IN	_	36	case	_	_
36	adherence	adherence	NN	_	34	ppmod	_	_
37	.	.	.	_	8	p	_	_

1	Like	like	IN	_	3	case	_	_
2	all	all	DT	_	3	det	_	_
3	drug1	drug0	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	certain	certain	JJ	_	8	attr	_	_
6	hepatic	hepatic	JJ	_	8	attr	_	_
7	enzyme-inducing	enzyme-inducing	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	reduce	reduce	VB	_	0	root	_	_
11	its	its	PRP$	_	12	poss	_	_
12	efficacy	efficacy	NN	_	10	obj	_	_
13	.	.	.	_	10	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	present	present	VBP	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	interesting	interesting	JJ	_	5	attr	_	_
5	case	case	NN	_	2	obj	_	_
6	of	of	IN	_	9	case	_	_
7	an	an	DT	_	9	det	_	_
8	HIV-positive	hiv-positive	JJ	_	9	attr	_	_
9	woman	woman	NN	_	5	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	ppmod	_	_
13	having	have	VBG	_	15	lv	_	_
14	tubal	tubal	JJ	_	15	attr	_	_
15	pregnancies	pregnancy	NNS	_	12	acl	_	_
16	on	on	IN	_	19	case	_	_
17	two	#crd#	CD	_	19	num	_	_
18	separate	separate	JJ	_	19	attr	_	_
19	occasions	occasion	NNS	_	15	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	in	in	IN	_	23	case	_	_
23	place	place	NN	_	21	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	CYP	cyp	NN	_	4	com	_	_
4	2D6	0d0	NN	_	1	conj	_	_
5	inhibitors	inhibitor	NNS	_	7	dep	_	_
6	:	:	:	_	7	p	_	_
7	caution	caution	NN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	is	be	VBZ	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	standard	standard	JJ	_	10	attr	_	_
9	hormone	hormone	NN	_	10	com	_	_
10	treatment	treatment	NN	_	6	obj	_	_
11	for	for	IN	_	13	case	_	_
12	breast	breast	NN	_	13	com	_	_
13	cancer	cancer	NN	_	10	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	transformed	transform	VBN	_	0	root	_	_
5	into	into	IN	_	8	case	_	_
6	its	its	PRP$	_	8	poss	_	_
7	active	active	JJ	_	8	attr	_	_
8	metabolites	metabolite	NNS	_	4	ppmod	_	_
9	by	by	IN	_	14	case	_	_
10	the	the	DT	_	14	det	_	_
11	cytochrome	cytochrome	NN	_	12	com	_	_
12	P450	p0	NN	_	14	com	_	_
13	enzyme	enzyme	NN	_	14	com	_	_
14	system	system	NN	_	4	ppmod	_	_
15	,	,	,	_	4	p	_	_
16	especially	especially	RB	_	4	adv	_	_
17	into	into	IN	_	18	case	_	_
18	drug1	drug0	NN	_	4	ppmod	_	_
19	by	by	IN	_	22	case	_	_
20	isoenzyme	isoenzyme	NN	_	22	com	_	_
21	CYP	cyp	NN	_	22	com	_	_
22	2D6	0d0	NN	_	4	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	Co-administration	co-administration	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	8	case	_	_
5	isoenzyme	isoenzyme	JJ	_	8	attr	_	_
6	CYP	cyp	NN	_	8	com	_	_
7	2D6	0d0	NN	_	8	com	_	_
8	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
9	reduces	reduce	VBZ	_	0	root	_	_
10	this	this	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibit	inhibit	VBP	_	0	root	_	_
3	isoenzyme	isoenzyme	NN	_	5	com	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	obj	_	_
6	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	reduce	reduce	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentration	concentration	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	by	by	IN	_	12	case	_	_
11	about	about	RB	_	12	adv	_	_
12	50	0	CD	_	4	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	.	.	.	_	4	p	_	_

1	Two	#crd#	CD	_	3	num	_	_
2	epidemiological	epidemiological	JJ	_	3	attr	_	_
3	studies	study	NNS	_	9	dep	_	_
4	involving	involve	VBG	_	3	acl	_	_
5	about	about	RB	_	6	adv	_	_
6	3700	0	CD	_	7	num	_	_
7	women	woman	NNS	_	4	obj	_	_
8	have	have	VBP	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	a	a	DT	_	11	det	_	_
11	link	link	NN	_	9	obj	_	_
12	between	between	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	use	use	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	14	cc	_	_
18	an	an	DT	_	20	det	_	_
19	increased	increase	VBN	_	20	attr	_	_
20	frequency	frequency	NN	_	14	conj	_	_
21	of	of	IN	_	24	case	_	_
22	breast	breast	NN	_	24	com	_	_
23	cancer	cancer	NN	_	24	com	_	_
24	recurrence	recurrence	NN	_	20	ppmod	_	_
25	.	.	.	_	9	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	studies	study	NNS	_	11	dep	_	_
3	,	,	,	_	2	p	_	_
4	with	with	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	lower	low	JJR	_	7	attr	_	_
7	level	level	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	evidence	evidence	NN	_	7	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	were	be	VBD	_	0	root	_	_
12	less	less	RBR	_	13	adv	_	_
13	convincing	convincing	JJ	_	11	dep	_	_
14	.	.	.	_	11	p	_	_

1	Studies	study	NNS	_	8	dep	_	_
2	of	of	IN	_	7	case	_	_
3	other	other	JJ	_	7	attr	_	_
4	isoenzyme	isoenzyme	JJ	_	7	attr	_	_
5	CYP	cyp	NN	_	7	com	_	_
6	2D6	0d0	NN	_	7	com	_	_
7	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	no	no	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	risk	risk	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	breast	breast	NN	_	17	com	_	_
16	cancer	cancer	NN	_	17	com	_	_
17	recurrence	recurrence	NN	_	13	ppmod	_	_
18	,	,	,	_	8	p	_	_
19	but	but	CC	_	8	cc	_	_
20	they	they	PRP	_	21	dep	_	_
21	lacked	lack	VBD	_	8	conj	_	_
22	statistical	statistical	JJ	_	23	attr	_	_
23	power	power	NN	_	21	obj	_	_
24	.	.	.	_	8	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	better	well	RB	_	2	adv	_	_
4	to	to	TO	_	5	aux	_	_
5	avoid	avoid	VB	_	2	comp	_	_
6	prescribing	prescribing	JJ	_	10	attr	_	_
7	isoenzyme	isoenzyme	JJ	_	10	attr	_	_
8	CYP	cyp	NN	_	10	com	_	_
9	2D6	0d0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	5	obj	_	_
11	to	to	TO	_	12	aux	_	_
12	women	woman	NNS	_	5	ppmod	_	_
13	treated	treat	VBN	_	12	acl	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	breast	breast	NN	_	18	com	_	_
18	cancer	cancer	NN	_	15	ppmod	_	_
19	,	,	,	_	12	p	_	_
20	especially	especially	RB	_	12	adv	_	_
21	drug2	drug0	NNS	_	12	appo	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug3	drug0	NN	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug4	drug0	NN	_	24	conj	_	_
27	.	.	.	_	2	p	_	_

1	Depression	depression	NN	_	5	dep	_	_
2	does	do	VBZ	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	always	always	RB	_	5	adv	_	_
5	require	require	VB	_	0	root	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	5	obj	_	_
8	,	,	,	_	5	p	_	_
9	and	and	CC	_	5	cc	_	_
10	drug2	drug0	NNS	_	11	dep	_	_
11	have	have	VBP	_	5	conj	_	_
12	no	no	DT	_	15	det	_	_
13	proven	proven	JJ	_	15	attr	_	_
14	preventive	preventive	JJ	_	15	attr	_	_
15	impact	impact	NN	_	11	obj	_	_
16	on	on	IN	_	18	case	_	_
17	hot	hot	JJ	_	18	attr	_	_
18	flushes	flush	NNS	_	11	ppmod	_	_
19	linked	link	VBN	_	18	acl	_	_
20	to	to	TO	_	22	aux	_	_
21	the	the	DT	_	22	det	_	_
22	menopause	menopause	NN	_	19	ppmod	_	_
23	.	.	.	_	5	p	_	_

1	If	if	IN	_	9	mark	_	_
2	in	in	IN	_	4	case	_	_
3	certain	certain	JJ	_	4	attr	_	_
4	cases	case	NNS	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	an	an	DT	_	7	det	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	considered	consider	VBN	_	14	advcl	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	may	may	MD	_	14	modal	_	_
14	be	be	VB	_	0	root	_	_
15	advisable	advisable	JJ	_	14	dep	_	_
16	to	to	TO	_	17	aux	_	_
17	replace	replace	VB	_	15	comp	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	with	with	IN	_	20	case	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	Phase	phase	NN	_	3	com	_	_
2	I	i	NN	_	3	com	_	_
3	trial	trial	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	3	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	relapsed	relapsed	JJ	_	13	attr	_	_
12	multiple	multiple	JJ	_	13	attr	_	_
13	myeloma	myeloma	NN	_	9	ppmod	_	_
14	:	:	:	_	3	p	_	_
15	evidence	evidence	NN	_	3	appo	_	_
16	for	for	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	-	-	:	_	3	p	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	interaction	interaction	NN	_	3	appo	_	_
21	via	via	IN	_	22	case	_	_
22	P-glycoprotein	p-glycoprotein	NN	_	20	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	Multiple	multiple	JJ	_	2	attr	_	_
2	myeloma	myeloma	NN	_	6	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	MM	mm	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	is	be	VBZ	_	0	root	_	_
7	an	an	DT	_	10	det	_	_
8	incurable	incurable	JJ	_	10	attr	_	_
9	plasma-cell	plasma-cell	NN	_	10	com	_	_
10	neoplasm	neoplasm	NN	_	6	obj	_	_
11	for	for	IN	_	12	case	_	_
12	which	which	WDT	_	15	ppmod	_	_
13	most	most	JJS	_	14	attr	_	_
14	treatments	treatment	NNS	_	15	dep	_	_
15	involve	involve	VBP	_	10	relcl	_	_
16	a	a	DT	_	18	det	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	agent	agent	NN	_	15	obj	_	_
19	combined	combine	VBN	_	18	acl	_	_
20	with	with	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	preclinical	preclinical	JJ	_	3	attr	_	_
3	combination	combination	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	mTOR	mtor	NN	_	10	com	_	_
9	inhibitor	inhibitor	NN	_	10	com	_	_
10	drug2	drug0	NN	_	3	ppmod	_	_
11	has	have	VBZ	_	12	aux	_	_
12	displayed	display	VBD	_	0	root	_	_
13	synergy	synergy	NN	_	12	obj	_	_
14	in	in	FW	_	15	adv	_	_
15	vitro	vitro	FW	_	12	adv	_	_
16	and	and	CC	_	12	cc	_	_
17	represents	represent	VBZ	_	12	conj	_	_
18	a	a	DT	_	20	det	_	_
19	novel	novel	JJ	_	20	attr	_	_
20	combination	combination	NN	_	17	obj	_	_
21	in	in	IN	_	22	case	_	_
22	MM	mm	NN	_	17	ppmod	_	_
23	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	4	attr	_	_
3	CYP3A	cyp0a	NN	_	4	com	_	_
4	activity	activity	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	lower	low	JJR	_	5	dep	_	_
8	in	in	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	-treated	-treated	JJ	_	9	attr	_	_
11	as	as	IN	_	12	mark	_	_
12	compared	compare	VBN	_	5	comp	_	_
13	with	with	IN	_	18	case	_	_
14	drug2	drug0	NN	_	18	attr	_	_
15	-treated	-treated	JJ	_	18	attr	_	_
16	renal	renal	JJ	_	18	attr	_	_
17	allograft	allograft	NN	_	18	com	_	_
18	recipients	recipient	NNS	_	12	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	identified	identify	VBN	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	as	as	IN	_	11	case	_	_
10	CYP3A	cyp0a	NN	_	11	com	_	_
11	inhibitors	inhibitor	NNS	_	5	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	current	current	JJ	_	4	attr	_	_
4	study	study	NN	_	11	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	renal	renal	JJ	_	8	attr	_	_
7	allograft	allograft	NN	_	8	com	_	_
8	recipients	recipient	NNS	_	4	ppmod	_	_
9	,	,	,	_	11	p	_	_
10	we	we	PRP	_	11	dep	_	_
11	used	use	VBD	_	0	root	_	_
12	intravenously	intravenously	RB	_	15	adv	_	_
13	and	and	CC	_	12	cc	_	_
14	orally	orally	RB	_	12	conj	_	_
15	administered	administer	VBN	_	16	attr	_	_
16	drug1	drug0	NN	_	11	obj	_	_
17	as	as	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	drug	drug	NN	_	20	com	_	_
20	probe	probe	NN	_	11	ppmod	_	_
21	to	to	TO	_	22	aux	_	_
22	assess	assess	VB	_	11	comp	_	_
23	whether	whether	IN	_	36	mark	_	_
24	the	the	DT	_	26	det	_	_
25	study	study	NN	_	26	com	_	_
26	drugs	drug	NNS	_	36	dep	_	_
27	at	at	IN	_	28	case	_	_
28	doses	dose	NNS	_	26	ppmod	_	_
29	that	that	WDT	_	32	dep	_	_
30	are	be	VBP	_	32	aux	_	_
31	generally	generally	RB	_	32	adv	_	_
32	used	use	VBN	_	28	relcl	_	_
33	in	in	IN	_	35	case	_	_
34	clinical	clinical	JJ	_	35	attr	_	_
35	practice	practice	NN	_	32	ppmod	_	_
36	have	have	VBP	_	22	comp	_	_
37	differential	differential	JJ	_	38	attr	_	_
38	effects	effect	NNS	_	36	obj	_	_
39	on	on	IN	_	46	case	_	_
40	in	in	FW	_	41	adv	_	_
41	vivo	vivo	FW	_	46	attr	_	_
42	hepatic	hepatic	JJ	_	46	attr	_	_
43	and	and	CC	_	42	cc	_	_
44	first-pass	first-pass	JJ	_	42	conj	_	_
45	CYP3A	cyp0a	NN	_	46	com	_	_
46	activities	activity	NNS	_	36	ppmod	_	_
47	.	.	.	_	11	p	_	_

1	Systemic	systemic	JJ	_	6	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	apparent	apparent	JJ	_	4	adv	_	_
4	oral	oral	JJ	_	1	conj	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	clearance	clearance	NN	_	7	dep	_	_
7	were	be	VBD	_	0	root	_	_
8	24	0	CD	_	7	obj	_	_
9	%	%	NN	_	8	meta	_	_
10	(	-lrb-	-LRB-	_	20	p	_	_
11	269	0	CD	_	16	num	_	_
12	73	0	CD	_	16	num	_	_
13	vs.	vs.	CC	_	12	cc	_	_
14	354	0	CD	_	15	com	_	_
15	102	0	CD	_	12	conj	_	_
16	ml/min	ml/min	NN	_	20	dep	_	_
17	,	,	,	_	20	p	_	_
18	P	p	NN	_	20	attr	_	_
19	=	=	JJ	_	20	attr	_	_
20	0.022	0	NN	_	8	num	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	and	and	CC	_	8	cc	_	_
23	31	0	CD	_	8	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	(	-lrb-	-LRB-	_	35	p	_	_
26	479	0	CD	_	31	num	_	_
27	190	0	CD	_	31	num	_	_
28	vs.	vs.	CC	_	27	cc	_	_
29	688	0	CD	_	30	com	_	_
30	265	0	CD	_	27	conj	_	_
31	ml/min	ml/min	NN	_	35	dep	_	_
32	,	,	,	_	35	p	_	_
33	P	p	NN	_	35	attr	_	_
34	=	=	JJ	_	35	attr	_	_
35	0.013	0	NN	_	23	num	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	,	,	,	_	23	p	_	_
38	respectively	respectively	RB	_	23	adv	_	_
39	,	,	,	_	23	p	_	_
40	lower	low	JJR	_	8	conj	_	_
41	in	in	IN	_	44	case	_	_
42	drug2	drug0	JJ	_	44	attr	_	_
43	-treated	-treated	JJ	_	44	attr	_	_
44	patients	patient	NNS	_	40	ppmod	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	n	n	NN	_	44	prn	_	_
47	=	=	JJ	_	46	attr	_	_
48	20	0	CD	_	46	num	_	_
49	)	-rrb-	-RRB-	_	46	p	_	_
50	than	than	IN	_	55	case	_	_
51	in	in	IN	_	55	case	_	_
52	matched	matched	JJ	_	55	attr	_	_
53	drug3	drug0	NN	_	55	attr	_	_
54	-treated	-treated	JJ	_	55	attr	_	_
55	patients	patient	NNS	_	40	ppmod	_	_
56	(	-lrb-	-LRB-	_	57	p	_	_
57	n	n	NN	_	55	prn	_	_
58	=	=	JJ	_	57	attr	_	_
59	20	0	CD	_	57	num	_	_
60	)	-rrb-	-RRB-	_	57	p	_	_
61	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	latter	latter	JJ	_	3	dep	_	_
3	displayed	display	VBD	_	0	root	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	clearances	clearance	NNS	_	3	obj	_	_
6	similar	similar	JJ	_	5	attr	_	_
7	to	to	TO	_	8	aux	_	_
8	those	those	DT	_	6	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	two	#crd#	CD	_	12	num	_	_
11	larger	large	JJR	_	12	attr	_	_
12	cohorts	cohort	NNS	_	8	ppmod	_	_
13	of	of	IN	_	17	case	_	_
14	nonmatched	nonmatched	JJ	_	17	attr	_	_
15	drug2	drug0	NN	_	17	attr	_	_
16	-treated	-treated	JJ	_	17	attr	_	_
17	patients	patient	NNS	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	n	n	NN	_	17	prn	_	_
20	=	=	JJ	_	19	attr	_	_
21	58	0	CD	_	19	num	_	_
22	and	and	CC	_	19	cc	_	_
23	n	n	NN	_	19	conj	_	_
24	=	=	JJ	_	23	attr	_	_
25	80	0	CD	_	23	num	_	_
26	)	-rrb-	-RRB-	_	23	p	_	_
27	and	and	CC	_	8	cc	_	_
28	to	to	TO	_	29	aux	_	_
29	those	those	DT	_	8	conj	_	_
30	receiving	receive	VBG	_	29	acl	_	_
31	a	a	DT	_	34	det	_	_
32	drug3	drug0	NN	_	33	advnp	_	_
33	-free	-free	JJ	_	34	attr	_	_
34	regimen	regimen	NN	_	30	obj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	n	n	NN	_	34	prn	_	_
37	=	=	JJ	_	36	attr	_	_
38	6	0	CD	_	36	num	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	dep	_	_
2	implies	imply	VBZ	_	0	root	_	_
3	that	that	IN	_	11	mark	_	_
4	in	in	FW	_	5	adv	_	_
5	vivo	vivo	FW	_	10	attr	_	_
6	hepatic	hepatic	JJ	_	10	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	first-pass	first-pass	JJ	_	6	conj	_	_
9	CYP3A	cyp0a	NN	_	10	com	_	_
10	activities	activity	NNS	_	11	dep	_	_
11	are	be	VBP	_	2	comp	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	lower	low	JJR	_	11	dep	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	than	than	IN	_	20	case	_	_
19	in	in	IN	_	20	case	_	_
20	those	those	DT	_	13	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	drug2	drug0	NN	_	21	obj	_	_
23	,	,	,	_	11	p	_	_
24	indicating	indicate	VBG	_	11	comp	_	_
25	that	that	IN	_	37	mark	_	_
26	,	,	,	_	37	p	_	_
27	at	at	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	doses	dose	NNS	_	37	ppmod	_	_
30	generally	generally	RB	_	31	adv	_	_
31	used	use	VBN	_	29	acl	_	_
32	in	in	IN	_	34	case	_	_
33	clinical	clinical	JJ	_	34	attr	_	_
34	practice	practice	NN	_	31	ppmod	_	_
35	,	,	,	_	37	p	_	_
36	drug3	drug0	NN	_	37	dep	_	_
37	is	be	VBZ	_	24	comp	_	_
38	the	the	DT	_	39	det	_	_
39	stronger	strong	JJR	_	37	obj	_	_
40	of	of	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	two	#crd#	CD	_	39	ppmod	_	_
43	with	with	IN	_	44	case	_	_
44	respect	respect	NN	_	39	ppmod	_	_
45	to	to	TO	_	47	aux	_	_
46	CYP3A	cyp0a	NN	_	47	com	_	_
47	inhibition	inhibition	NN	_	44	ppmod	_	_
48	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	observation	observation	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	lv	_	_
4	important	important	JJ	_	5	attr	_	_
5	implications	implication	NNS	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	context	context	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	drug-drug	drug-drug	JJ	_	11	attr	_	_
11	interactions	interaction	NNS	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	transplant	transplant	NN	_	14	com	_	_
14	recipients	recipient	NNS	_	11	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	-LSB-Influence	-lsb-influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	on	on	IN	_	9	case	_	_
7	MPTP-evoked	mptp-evoked	JJ	_	9	attr	_	_
8	behavior	behavior	NN	_	9	com	_	_
9	violations	violation	NNS	_	1	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	C57BL/6	c0bl/0	NN	_	12	com	_	_
12	mice	mouse	NNS	_	9	ppmod	_	_
13	]	-rsb-	-RRB-	_	1	p	_	_
14	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	[	-lsb-	-LRB-	_	7	p	_	_
7	drug3	drug0	NN	_	5	prn	_	_
8	]	-rsb-	-RRB-	_	7	p	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	10	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	5	prn	_	_
12	,	,	,	_	11	p	_	_
13	p.	p.	FW	_	14	attr	_	_
14	o	o	NN	_	11	appo	_	_
15	.	.	.	_	14	p	_	_
16	)	-rrb-	-RRB-	_	11	p	_	_

1	and/or	and/or	CC	_	3	cc	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	drug2	drug0	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	100	0	CD	_	6	num	_	_
6	mg/kg	mg/kg	NN	_	3	prn	_	_
7	,	,	,	_	6	p	_	_
8	p.	p.	NNP	_	9	com	_	_
9	o.	o.	NNP	_	6	appo	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_
11	,	,	,	_	3	p	_	_
12	as	as	RB	_	13	com	_	_
13	well	well	RB	_	3	cc	_	_
14	as	as	IN	_	13	com	_	_
15	that	that	DT	_	3	conj	_	_
16	of	of	IN	_	18	case	_	_
17	neurotoxin	neurotoxin	NN	_	18	com	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug4	drug0	NN	_	3	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	(	-lrb-	-LRB-	_	26	p	_	_
23	4	0	CD	_	26	num	_	_
24	x	x	CC	_	23	cc	_	_
25	20	0	CD	_	23	conj	_	_
26	mg/kg	mg/kg	NN	_	3	prn	_	_
27	,	,	,	_	26	p	_	_
28	i.	i.	NN	_	29	com	_	_
29	p	p	NN	_	26	appo	_	_
30	.	.	.	_	26	p	_	_
31	)	-rrb-	-RRB-	_	26	p	_	_

1	were	be	VBD	_	2	aux	_	_
2	studied	study	VBN	_	0	root	_	_
3	in	in	IN	_	7	case	_	_
4	elevated	elevated	JJ	_	7	attr	_	_
5	plus	plus	CC	_	4	cc	_	_
6	maze	maze	JJ	_	4	conj	_	_
7	test	test	NN	_	2	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	C57BL/6	c0bl/0	NN	_	10	com	_	_
10	mice	mouse	NNS	_	7	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	On	on	IN	_	3	case	_	_
2	second	#ord#	JJ	_	3	attr	_	_
3	day	day	NN	_	8	ppmod	_	_
4	after	after	IN	_	5	case	_	_
5	injection	injection	NN	_	3	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	decreased	decrease	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	locomot	locomot	NN	_	8	obj	_	_
11	or	or	CC	_	10	cc	_	_
12	activity	activity	NN	_	10	conj	_	_
13	in	in	IN	_	14	case	_	_
14	comparison	comparison	NN	_	10	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	saline	saline	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Acute	acute	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	failed	fail	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	influence	influence	VB	_	7	comp	_	_
10	locomotion	locomotion	NN	_	9	obj	_	_
11	in	in	IN	_	12	case	_	_
12	mice	mouse	NNS	_	10	ppmod	_	_
13	,	,	,	_	7	p	_	_
14	while	while	IN	_	17	mark	_	_
15	their	their	PRP$	_	16	poss	_	_
16	combination	combination	NN	_	17	dep	_	_
17	normalized	normalize	VBN	_	7	comp	_	_
18	motor	motor	NN	_	19	com	_	_
19	activity	activity	NN	_	17	obj	_	_
20	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	4	dep	_	_
3	obtained	obtain	VBN	_	2	acl	_	_
4	confirm	confirm	VBP	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	role	role	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	inflammatory	inflammatory	JJ	_	9	attr	_	_
9	processes	process	NNS	_	6	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	parkinsonism	parkinsonism	NN	_	6	ppmod	_	_
12	and	and	CC	_	4	cc	_	_
13	suggest	suggest	VBP	_	4	conj	_	_
14	expediency	expediency	NN	_	13	obj	_	_
15	of	of	IN	_	17	case	_	_
16	combined	combined	JJ	_	17	attr	_	_
17	pharmacotherapy	pharmacotherapy	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	neurodegenerative	neurodegenerative	JJ	_	20	attr	_	_
20	diseases	disease	NNS	_	17	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Exposure	exposure	NN	_	5	dep	_	_
2	to	to	TO	_	4	aux	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	unaffected	unaffected	JJ	_	5	dep	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	but	but	CC	_	6	cc	_	_
10	greatly	greatly	RB	_	11	adv	_	_
11	increased	increase	VBN	_	6	conj	_	_
12	by	by	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	examined	examine	VBD	_	0	root	_	_
4	drug-drug	drug-drug	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	with	with	IN	_	18	case	_	_
10	the	the	DT	_	18	det	_	_
11	cytochrome	cytochrome	NN	_	12	com	_	_
12	P450	p0	NN	_	18	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	CYP	cyp	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	2B6	0b0	NN	_	18	com	_	_
17	inhibitor	inhibitor	NN	_	18	com	_	_
18	drug2	drug0	NN	_	5	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	the	the	DT	_	23	det	_	_
21	CYP3A	cyp0a	NN	_	23	com	_	_
22	inhibitor	inhibitor	NN	_	23	com	_	_
23	drug3	drug0	NN	_	18	conj	_	_
24	.	.	.	_	3	p	_	_

1	In	in	IN	_	8	case	_	_
2	this	this	DT	_	8	det	_	_
3	randomized	randomized	JJ	_	7	adv	_	_
4	,	,	,	_	7	p	_	_
5	blinded	blinded	JJ	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	crossover	crossover	JJ	_	8	attr	_	_
8	study	study	NN	_	13	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	11	0	CD	_	12	num	_	_
11	healthy	healthy	JJ	_	12	attr	_	_
12	volunteers	volunteer	NNS	_	13	dep	_	_
13	ingested	ingest	VBN	_	0	root	_	_
14	0.2	0	CD	_	15	num	_	_
15	mg/kg	mg/kg	NN	_	16	com	_	_
16	drug1	drug0	NN	_	13	obj	_	_
17	after	after	IN	_	18	case	_	_
18	pretreatments	pretreatment	NNS	_	16	ppmod	_	_
19	with	with	IN	_	21	case	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug2	drug0	NN	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	250	0	CD	_	24	num	_	_
24	mg	mg	NN	_	21	prn	_	_
25	twice	twice	RB	_	26	com	_	_
26	daily	daily	RB	_	24	adv	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	,	,	,	_	21	p	_	_
29	drug3	drug0	NN	_	21	conj	_	_
30	(	-lrb-	-LRB-	_	32	p	_	_
31	200	0	CD	_	32	num	_	_
32	mg	mg	NN	_	29	prn	_	_
33	once	once	RB	_	34	adv	_	_
34	daily	daily	JJ	_	32	attr	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	,	,	,	_	29	p	_	_
37	or	or	CC	_	29	cc	_	_
38	placebo	placebo	NN	_	21	conj	_	_
39	in	in	IN	_	42	case	_	_
40	6-day	0-day	JJ	_	42	attr	_	_
41	treatment	treatment	NN	_	42	com	_	_
42	periods	period	NNS	_	16	ppmod	_	_
43	at	at	IN	_	44	case	_	_
44	intervals	interval	NNS	_	13	ppmod	_	_
45	of	of	IN	_	47	case	_	_
46	4	0	CD	_	47	num	_	_
47	weeks	week	NNS	_	44	ppmod	_	_
48	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	mean	mean	JJ	_	6	attr	_	_
6	area	area	NN	_	3	obj	_	_
7	under	under	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	concentration-time	concentration-time	NN	_	11	com	_	_
11	curve	curve	NN	_	6	ppmod	_	_
12	extrapolated	extrapolate	VBN	_	11	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	infinity	infinity	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	AUC	auc	NN	_	6	prn	_	_
17	(	-lrb-	-LRB-	_	16	p	_	_
18	0-	0-	CD	_	16	num	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	)	-rrb-	-RRB-	_	16	p	_	_
21	of	of	IN	_	23	case	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	6	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	2.4-fold	0-fold	RB	_	3	ppmod	_	_
26	,	,	,	_	3	p	_	_
27	whereas	whereas	IN	_	32	mark	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	treatment	treatment	NN	_	32	dep	_	_
30	did	do	VBD	_	32	aux	_	_
31	not	not	RB	_	32	neg	_	_
32	increase	increase	VB	_	3	comp	_	_
33	the	the	DT	_	34	det	_	_
34	exposure	exposure	NN	_	32	obj	_	_
35	to	to	TO	_	36	aux	_	_
36	drug4	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	ratio	ratio	NN	_	17	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	AUC	auc	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	0-	0-	CD	_	5	num	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	to	to	TO	_	11	aux	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	AUC	auc	NN	_	2	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	0-	0-	CD	_	11	num	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	was	be	VBD	_	17	aux	_	_
16	significantly	significantly	RB	_	17	adv	_	_
17	decreased	decrease	VBN	_	0	root	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	P	p	NN	_	23	com	_	_
23	&amp	&amp	NN	_	17	prn	_	_
24	;	;	:	_	23	p	_	_
25	lt	lt	NN	_	23	appo	_	_
26	;	;	:	_	23	p	_	_
27	0.001	0	CD	_	23	appo	_	_
28	)	-rrb-	-RRB-	_	23	p	_	_
29	drug4	drug0	IN	_	31	case	_	_
30	zole	zole	JJ	_	31	attr	_	_
31	phases	phase	NNS	_	17	ppmod	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	P	p	NN	_	31	prn	_	_
34	=	=	JJ	_	33	attr	_	_
35	0.006	0	CD	_	33	num	_	_
36	)	-rrb-	-RRB-	_	33	p	_	_
37	as	as	IN	_	38	mark	_	_
38	compared	compare	VBN	_	17	comp	_	_
39	to	to	TO	_	40	aux	_	_
40	placebo	placebo	NN	_	38	ppmod	_	_
41	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	drug1	drug0	NN	_	20	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	phases	phase	NNS	_	3	conj	_	_
7	,	,	,	_	20	p	_	_
8	the	the	DT	_	9	det	_	_
9	areas	area	NNS	_	20	dep	_	_
10	under	under	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	effect-time	effect-time	JJ	_	13	attr	_	_
13	curves	curve	NNS	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	self-reported	self-reported	JJ	_	16	attr	_	_
16	drowsiness	drowsiness	NN	_	13	prn	_	_
17	and	and	CC	_	16	cc	_	_
18	performance	performance	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	were	be	VBD	_	0	root	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	higher	high	JJR	_	20	dep	_	_
23	than	than	IN	_	24	case	_	_
24	those	those	DT	_	22	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	placebo	placebo	NN	_	28	com	_	_
28	phase	phase	NN	_	24	ppmod	_	_
29	(	-lrb-	-LRB-	_	33	p	_	_
30	P	p	NN	_	33	attr	_	_
31	&lt	&lt	CD	_	33	num	_	_
32	;	;	:	_	33	p	_	_
33	0.05	0	CD	_	24	num	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	.	.	.	_	20	p	_	_

1	The	the	DT	_	2	det	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	the	the	DT	_	6	det	_	_
6	dosage	dosage	NN	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	reduced	reduce	VBN	_	3	comp	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug2	drug0	NN	_	14	obj	_	_
16	.	.	.	_	3	p	_	_

1	Interaction	interaction	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	different	different	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	1	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	antagonistic	antagonistic	JJ	_	7	dep	_	_
9	in	in	IN	_	10	case	_	_
10	breast	breast	NN	_	8	ppmod	_	_
11	but	but	CC	_	10	cc	_	_
12	not	not	RB	_	16	neg	_	_
13	in	in	IN	_	16	case	_	_
14	other	other	JJ	_	16	attr	_	_
15	cancer	cancer	NN	_	16	com	_	_
16	cells	cell	NNS	_	10	conj	_	_
17	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	1	appo	_	_
5	of	of	IN	_	6	case	_	_
6	cyclooxygenase-2	cyclooxygenase-0	NN	_	4	ppmod	_	_
7	,	,	,	_	1	p	_	_
8	is	be	VBZ	_	10	aux	_	_
9	being	be	VBG	_	10	aux	_	_
10	investigated	investigate	VBN	_	0	root	_	_
11	for	for	IN	_	12	case	_	_
12	enhancement	enhancement	NN	_	10	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	chemotherapy	chemotherapy	NN	_	15	com	_	_
15	efficacy	efficacy	NN	_	12	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	cancer	cancer	NN	_	19	attr	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	trials	trial	NNS	_	12	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	investigates	investigate	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	ability	ability	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	sensitize	sensitize	VB	_	5	acl	_	_
10	cells	cell	NNS	_	9	obj	_	_
11	from	from	IN	_	13	case	_	_
12	different	different	JJ	_	13	attr	_	_
13	origins	origin	NNS	_	10	ppmod	_	_
14	to	to	TO	_	16	aux	_	_
15	several	several	JJ	_	16	attr	_	_
16	drug2	drug0	NNS	_	9	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	16	dep	_	_
3	of	of	IN	_	7	case	_	_
4	the	the	DT	_	5	det	_	_
5	drug	drug	NN	_	7	poss	_	_
6	's	's	POS	_	5	case	_	_
7	mechanism	mechanism	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	action	action	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	sequence	sequence	NN	_	9	conj	_	_
12	of	of	IN	_	13	case	_	_
13	administration	administration	NN	_	9	ppmod	_	_
14	are	be	VBP	_	16	aux	_	_
15	also	also	RB	_	16	adv	_	_
16	investigated	investigate	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	sensitivity	sensitivity	NN	_	42	dep	_	_
3	,	,	,	_	2	p	_	_
4	cell	cell	NN	_	5	com	_	_
5	cycle	cycle	NN	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	apoptosis	apoptosis	NN	_	2	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	DNA	dna	NN	_	10	com	_	_
10	damage	damage	NN	_	2	conj	_	_
11	of	of	IN	_	16	case	_	_
12	five	#crd#	CD	_	16	num	_	_
13	different	different	JJ	_	16	attr	_	_
14	cancer	cancer	NN	_	16	com	_	_
15	cell	cell	NN	_	16	com	_	_
16	lines	line	NNS	_	2	ppmod	_	_
17	(	-lrb-	-LRB-	_	16	p	_	_
18	HeLa	hela	NN	_	16	appo	_	_
19	,	,	,	_	18	p	_	_
20	HCT116	hct0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	HepG2	hepg0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	MCF7	mcf0	NN	_	18	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	U251	u0	NN	_	18	conj	_	_
27	)	-rrb-	-RRB-	_	16	p	_	_
28	to	to	TO	_	29	aux	_	_
29	drug1	drug0	NN	_	2	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	drug2	drug0	NN	_	29	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug3	drug0	NN	_	29	conj	_	_
34	and	and	CC	_	33	cc	_	_
35	drug4	drug0	NN	_	40	attr	_	_
36	drug5	drug0	NN	_	40	attr	_	_
37	following	following	JJ	_	40	attr	_	_
38	different	different	JJ	_	40	attr	_	_
39	incubation	incubation	NN	_	40	com	_	_
40	schedules	schedule	NNS	_	29	conj	_	_
41	were	be	VBD	_	42	aux	_	_
42	analyzed	analyze	VBN	_	0	root	_	_
43	.	.	.	_	42	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	found	find	VBD	_	0	root	_	_
3	antagonism	antagonism	NN	_	2	obj	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	the	the	DT	_	9	det	_	_
8	four	#crd#	CD	_	9	num	_	_
9	drugs	drug	NNS	_	5	conj	_	_
10	in	in	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	breast	breast	NN	_	14	com	_	_
13	cancer	cancer	NN	_	14	com	_	_
14	cells	cell	NNS	_	5	ppmod	_	_
15	MCF7	mcf0	RB	_	16	adv	_	_
16	following	follow	VBG	_	14	acl	_	_
17	all	all	DT	_	19	det	_	_
18	incubation	incubation	NN	_	19	com	_	_
19	schedules	schedule	NNS	_	16	obj	_	_
20	and	and	CC	_	5	cc	_	_
21	between	between	IN	_	22	case	_	_
22	drug2	drug0	NN	_	5	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	28	case	_	_
26	all	all	DT	_	28	det	_	_
27	cell	cell	NN	_	28	com	_	_
28	lines	line	NNS	_	2	ppmod	_	_
29	except	except	IN	_	32	case	_	_
30	for	for	IN	_	32	case	_	_
31	two	#crd#	CD	_	32	num	_	_
32	combinations	combination	NNS	_	2	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	HCT116	hct0	NN	_	35	com	_	_
35	cells	cell	NNS	_	32	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	with	with	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	other	other	JJ	_	6	attr	_	_
5	three	#crd#	CD	_	6	num	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_
7	in	in	IN	_	12	case	_	_
8	the	the	DT	_	12	det	_	_
9	remaining	remain	VBG	_	12	attr	_	_
10	four	#crd#	CD	_	12	num	_	_
11	cell	cell	NN	_	12	com	_	_
12	lines	line	NNS	_	1	ppmod	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	variable	variable	JJ	_	16	attr	_	_
16	interactions	interaction	NNS	_	13	ppmod	_	_
17	.	.	.	_	13	p	_	_

1	Mechanistic	mechanistic	JJ	_	2	attr	_	_
2	investigations	investigation	NNS	_	3	dep	_	_
3	revealed	reveal	VBD	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	exerts	exert	VBZ	_	3	comp	_	_
7	different	different	JJ	_	9	attr	_	_
8	molecular	molecular	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	different	different	JJ	_	12	attr	_	_
12	cells	cell	NNS	_	6	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	lines	line	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	it	it	PRP	_	6	dep	_	_
6	abrogates	abrogate	VBZ	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	drug-induced	drug-induced	JJ	_	10	attr	_	_
9	G2/M	g0/m	NN	_	10	com	_	_
10	arrest	arrest	NN	_	6	obj	_	_
11	enhancing	enhance	VBG	_	10	acl	_	_
12	pre-mature	pre-mature	NN	_	13	com	_	_
13	entry	entry	NN	_	11	obj	_	_
14	into	into	IN	_	15	case	_	_
15	mitosis	mitosis	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	damaged	damaged	JJ	_	18	attr	_	_
18	DNA	dna	NN	_	13	ppmod	_	_
19	thus	thus	RB	_	20	adv	_	_
20	increasing	increase	VBG	_	6	comp	_	_
21	apoptosis	apoptosis	NN	_	20	obj	_	_
22	and	and	CC	_	20	cc	_	_
23	resulting	result	VBG	_	20	conj	_	_
24	in	in	IN	_	25	case	_	_
25	synergism	synergism	NN	_	23	ppmod	_	_
26	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	other	other	JJ	_	3	attr	_	_
3	cells	cell	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	it	it	PRP	_	6	dep	_	_
6	enhances	enhance	VBZ	_	0	root	_	_
7	drug-induced	drug-induced	JJ	_	9	attr	_	_
8	G2/M	g0/m	NN	_	9	com	_	_
9	arrest	arrest	NN	_	6	obj	_	_
10	allowing	allow	VBG	_	9	acl	_	_
11	time	time	NN	_	10	obj	_	_
12	to	to	TO	_	16	aux	_	_
13	repair	repair	NN	_	16	attr	_	_
14	drug-induced	drug-induced	JJ	_	16	attr	_	_
15	DNA	dna	NN	_	16	com	_	_
16	damage	damage	NN	_	11	ppmod	_	_
17	before	before	IN	_	18	case	_	_
18	entry	entry	NN	_	11	ppmod	_	_
19	into	into	IN	_	20	case	_	_
20	mitosis	mitosis	NN	_	18	ppmod	_	_
21	and	and	CC	_	10	cc	_	_
22	decreasing	decrease	VBG	_	10	conj	_	_
23	cell	cell	NN	_	24	com	_	_
24	death	death	NN	_	22	obj	_	_
25	resulting	result	VBG	_	24	acl	_	_
26	in	in	IN	_	27	case	_	_
27	antagonism	antagonism	NN	_	25	ppmod	_	_
28	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	some	some	DT	_	4	det	_	_
3	synergistic	synergistic	JJ	_	4	attr	_	_
4	combinations	combination	NNS	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	celecoxib-induced	celecoxib-induced	JJ	_	7	attr	_	_
7	abrogation	abrogation	NN	_	13	dep	_	_
8	of	of	IN	_	10	case	_	_
9	G2/M	g0/m	NN	_	10	com	_	_
10	arrest	arrest	NN	_	7	ppmod	_	_
11	was	be	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	apoptosis	apoptosis	NN	_	13	ppmod	_	_
16	but	but	CC	_	15	cc	_	_
17	permanent	permanent	JJ	_	18	attr	_	_
18	arrest	arrest	NN	_	15	conj	_	_
19	in	in	IN	_	21	case	_	_
20	G1	g0	NN	_	21	com	_	_
21	phase	phase	NN	_	15	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	8	dep	_	_
3	,	,	,	_	8	p	_	_
4	if	if	IN	_	5	mark	_	_
5	confirmed	confirm	VBN	_	8	advcl	_	_
6	in-vivo	in-vivo	NN	_	5	obj	_	_
7	,	,	,	_	8	p	_	_
8	indicate	indicate	VBP	_	0	root	_	_
9	that	that	IN	_	11	mark	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	is	be	VBZ	_	8	comp	_	_
12	not	not	RB	_	11	neg	_	_
13	a	a	DT	_	15	det	_	_
14	suitable	suitable	JJ	_	15	attr	_	_
15	chemosensitizer	chemosensitizer	NN	_	11	obj	_	_
16	for	for	IN	_	18	case	_	_
17	breast	breast	NN	_	18	com	_	_
18	cancer	cancer	NN	_	15	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	18	conj	_	_
22	for	for	IN	_	24	case	_	_
23	other	other	JJ	_	24	attr	_	_
24	cancers	cancer	NNS	_	21	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	Moreover	moreover	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	combination	combination	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	tailored	tailor	VBN	_	0	root	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	tumor	tumor	NN	_	15	com	_	_
15	type	type	NN	_	11	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug	drug	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	administration	administration	NN	_	20	com	_	_
20	schedule	schedule	NN	_	15	conj	_	_
21	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	interaction	interaction	NN	_	1	conj	_	_
5	and	and	CC	_	1	cc	_	_
6	associated	associate	VBD	_	1	conj	_	_
7	gastrointestinal	gastrointestinal	JJ	_	9	attr	_	_
8	bleeding	bleeding	JJ	_	9	attr	_	_
9	risk	risk	NN	_	6	obj	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	case-control	case-control	JJ	_	13	attr	_	_
13	study	study	NN	_	6	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Bleeding	bleeding	JJ	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	9	det	_	_
4	most	most	RBS	_	5	adv	_	_
5	common	common	JJ	_	9	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	worrisome	worrisome	NN	_	8	advnp	_	_
8	adverse	adverse	JJ	_	5	conj	_	_
9	effect	effect	NN	_	2	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	One	#crd#	CD	_	10	num	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	factors	factor	NNS	_	1	ppmod	_	_
5	that	that	WDT	_	7	dep	_	_
6	might	might	MD	_	7	modal	_	_
7	increase	increase	VB	_	4	relcl	_	_
8	bleeding	bleeding	JJ	_	9	attr	_	_
9	risk	risk	NN	_	7	obj	_	_
10	is	be	VBZ	_	0	root	_	_
11	initiation	initiation	NN	_	10	obj	_	_
12	of	of	IN	_	14	case	_	_
13	interacting	interacting	NN	_	14	com	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	potentiate	potentiate	VB	_	11	relcl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	.	.	.	_	10	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	sought	seek	VBD	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	evaluate	evaluate	VB	_	2	comp	_	_
5	whether	whether	IN	_	10	mark	_	_
6	initiation	initiation	NN	_	10	dep	_	_
7	of	of	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	increases	increase	VBZ	_	4	comp	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	hospitalization	hospitalization	NN	_	12	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	gastrointestinal	gastrointestinal	JJ	_	17	attr	_	_
17	bleeding	bleeding	JJ	_	12	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	users	user	NNS	_	17	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	Medicaid	medicaid	NN	_	3	com	_	_
2	claims	claims	NN	_	3	com	_	_
3	data	datum	NNS	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	1999-2005	0	NN	_	3	num	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	were	be	VBD	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	perform	perform	VB	_	8	comp	_	_
11	an	an	DT	_	14	det	_	_
12	observational	observational	JJ	_	14	attr	_	_
13	case-control	case-control	JJ	_	14	attr	_	_
14	study	study	NN	_	10	obj	_	_
15	nested	nest	VBN	_	14	acl	_	_
16	within	within	IN	_	17	case	_	_
17	person-time	person-time	NN	_	15	ppmod	_	_
18	exposed	expose	VBN	_	17	acl	_	_
19	to	to	TO	_	20	aux	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	those	those	DT	_	24	det	_	_
23	18	0	CD	_	24	num	_	_
24	years	year	NNS	_	18	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	In	in	IN	_	2	case	_	_
2	total	total	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	430,455	0	NN	_	6	num	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	users	user	NNS	_	7	dep	_	_
7	contributed	contribute	VBD	_	0	root	_	_
8	407,370	0	CD	_	9	num	_	_
9	person-years	person-years	NNS	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	use	use	NN	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	incidence	incidence	NN	_	3	com	_	_
3	rate	rate	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	hospitalization	hospitalization	NN	_	3	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	GI	gi	JJ	_	8	attr	_	_
8	bleeding	bleeding	JJ	_	5	ppmod	_	_
9	among	among	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	users	user	NNS	_	5	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	4.48	0	CD	_	15	num	_	_
14	per	per	IN	_	15	case	_	_
15	100	0	CD	_	16	num	_	_
16	person-years	person-years	NNS	_	12	obj	_	_
17	(	-lrb-	-LRB-	_	22	p	_	_
18	95	0	CD	_	20	num	_	_
19	%	%	NN	_	20	meta	_	_
20	CI	ci	CD	_	22	num	_	_
21	,	,	,	_	22	p	_	_
22	4.42-4.55	0	CD	_	12	num	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	12	p	_	_

1	Each	each	DT	_	4	det	_	_
2	gastrointestinal	gastrointestinal	JJ	_	4	attr	_	_
3	bleeding	bleeding	JJ	_	4	attr	_	_
4	cases	case	NNS	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	matched	match	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	50	0	CD	_	9	num	_	_
9	controls	control	NNS	_	6	ppmod	_	_
10	based	base	VBN	_	9	acl	_	_
11	on	on	IN	_	13	case	_	_
12	index	index	NN	_	13	com	_	_
13	date	date	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	state	state	NN	_	13	conj	_	_
16	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	users	user	NNS	_	3	dep	_	_
3	had	have	VBD	_	0	root	_	_
4	an	an	DT	_	7	det	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	odds	odds	NNS	_	7	com	_	_
7	ratio	ratio	NN	_	3	obj	_	_
8	of	of	IN	_	10	case	_	_
9	gastrointestinal	gastrointestinal	JJ	_	10	attr	_	_
10	bleeding	bleeding	JJ	_	7	ppmod	_	_
11	upon	upon	IN	_	12	case	_	_
12	initiation	initiation	NN	_	3	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	21	p	_	_
16	OR	or	CC	_	21	cc	_	_
17	=	=	JJ	_	21	attr	_	_
18	1.73	0	CD	_	17	num	_	_
19	-LSB-95	-lsb-0	CD	_	21	num	_	_
20	%	%	NN	_	19	meta	_	_
21	CI	ci	NN	_	14	prn	_	_
22	,	,	,	_	21	p	_	_
23	1.25-2.38	0	CD	_	21	appo	_	_
24	]	-rsb-	-RRB-	_	23	p	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	,	,	,	_	14	p	_	_
27	drug3	drug0	NN	_	14	appo	_	_
28	(	-lrb-	-LRB-	_	34	p	_	_
29	OR	or	CC	_	34	cc	_	_
30	=	=	JJ	_	34	attr	_	_
31	1.63	0	CD	_	30	num	_	_
32	-LSB-95	-lsb-0	CD	_	34	num	_	_
33	%	%	NN	_	32	meta	_	_
34	CI	ci	NN	_	27	prn	_	_
35	,	,	,	_	34	p	_	_
36	1.11-2.38	0	CD	_	34	appo	_	_
37	]	-rsb-	-RRB-	_	36	p	_	_
38	)	-rrb-	-RRB-	_	34	p	_	_
39	,	,	,	_	14	p	_	_
40	drug4	drug0	NN	_	14	appo	_	_
41	(	-lrb-	-LRB-	_	47	p	_	_
42	OR	or	CC	_	47	cc	_	_
43	=	=	JJ	_	47	attr	_	_
44	1.64	0	CD	_	43	num	_	_
45	-LSB-95	-lsb-0	CD	_	47	num	_	_
46	%	%	NN	_	45	meta	_	_
47	CI	ci	NN	_	40	prn	_	_
48	,	,	,	_	47	p	_	_
49	1.27-2.12	0	CD	_	47	appo	_	_
50	]	-rsb-	-RRB-	_	49	p	_	_
51	)	-rrb-	-RRB-	_	47	p	_	_
52	,	,	,	_	14	p	_	_
53	drug5	drug0	NN	_	14	appo	_	_
54	(	-lrb-	-LRB-	_	62	p	_	_
55	OR	or	CC	_	62	cc	_	_
56	=	=	JJ	_	62	attr	_	_
57	1.47	0	NN	_	62	num	_	_
58	-LSB-95	-lsb-0	CD	_	57	num	_	_
59	%	%	NN	_	57	meta	_	_
60	CI	ci	CD	_	62	num	_	_
61	,	,	,	_	62	p	_	_
62	1.02-2.11	0	CD	_	53	num	_	_
63	]	-rsb-	-RRB-	_	62	p	_	_
64	)	-rrb-	-RRB-	_	62	p	_	_
65	.	.	.	_	3	p	_	_

1	Also	also	RB	_	13	adv	_	_
2	drug1	drug0	NN	_	13	dep	_	_
3	,	,	,	_	2	p	_	_
4	which	which	WDT	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	believed	believe	VBN	_	2	relcl	_	_
8	to	to	TO	_	9	aux	_	_
9	interact	interact	VB	_	7	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NNS	_	9	ppmod	_	_
12	,	,	,	_	2	p	_	_
13	increased	increase	VBD	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	risk	risk	NN	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	GI	gi	JJ	_	18	attr	_	_
18	bleeding	bleeding	JJ	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	25	p	_	_
20	OR	or	CC	_	25	cc	_	_
21	=	=	JJ	_	25	attr	_	_
22	1.75	0	CD	_	23	com	_	_
23	-LSB-95	-lsb-0	CD	_	21	num	_	_
24	%	%	NN	_	23	meta	_	_
25	CI	ci	NN	_	15	prn	_	_
26	,	,	,	_	25	p	_	_
27	1.30-2.35	0	CD	_	25	appo	_	_
28	]	-rsb-	-RRB-	_	27	p	_	_
29	)	-rrb-	-RRB-	_	25	p	_	_
30	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	users	user	NNS	_	18	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	initiated	initiate	VBD	_	2	relcl	_	_
5	drug2	drug0	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug5	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug6	drug0	NN	_	5	conj	_	_
15	had	have	VBD	_	18	lv	_	_
16	an	an	DT	_	18	det	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	risk	risk	NN	_	0	root	_	_
19	of	of	IN	_	20	case	_	_
20	hospitalization	hospitalization	NN	_	18	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	gastrointestinal	gastrointestinal	JJ	_	23	attr	_	_
23	bleeding	bleeding	JJ	_	18	ppmod	_	_
24	.	.	.	_	18	p	_	_

1	However	however	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	the	the	DT	_	5	det	_	_
4	elevated	elevated	JJ	_	5	attr	_	_
5	risk	risk	NN	_	8	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	suggests	suggest	VBZ	_	0	root	_	_
9	that	that	IN	_	16	mark	_	_
10	a	a	DT	_	12	det	_	_
11	drug-drug	drug-drug	JJ	_	12	attr	_	_
12	interaction	interaction	NN	_	16	dep	_	_
13	may	may	MD	_	16	modal	_	_
14	not	not	RB	_	16	neg	_	_
15	have	have	VBP	_	16	aux	_	_
16	been	be	VBN	_	8	comp	_	_
17	responsible	responsible	JJ	_	16	dep	_	_
18	for	for	IN	_	19	case	_	_
19	all	all	DT	_	17	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	observed	observe	VBN	_	24	attr	_	_
23	increased	increase	VBN	_	24	attr	_	_
24	risk	risk	NN	_	19	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	enhances	enhance	VBZ	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	antinociceptive	antinociceptive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	mice	mouse	NNS	_	5	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	7	det	_	_
4	highly	highly	RB	_	5	adv	_	_
5	selective	selective	JJ	_	7	attr	_	_
6	alpha-2-adrenoceptor	alpha-0-adrenoceptor	NN	_	7	com	_	_
7	agonist	agonist	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	was	be	VBD	_	11	aux	_	_
10	recently	recently	RB	_	11	adv	_	_
11	introduced	introduce	VBN	_	0	root	_	_
12	into	into	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	practice	practice	NN	_	11	ppmod	_	_
15	for	for	IN	_	20	case	_	_
16	its	its	PRP$	_	20	poss	_	_
17	sedative	sedative	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	analgesic	analgesic	JJ	_	17	conj	_	_
20	properties	property	NNS	_	14	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	purpose	purpose	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	6	comp	_	_
9	whether	whether	IN	_	14	mark	_	_
10	the	the	DT	_	13	det	_	_
11	psychostimulant	psychostimulant	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	drug1	drug0	NN	_	14	dep	_	_
14	has	have	VBZ	_	8	comp	_	_
15	any	any	DT	_	16	det	_	_
16	effect	effect	NN	_	14	obj	_	_
17	on	on	IN	_	20	case	_	_
18	drug2	drug0	JJ	_	20	attr	_	_
19	-induced	-induced	JJ	_	20	attr	_	_
20	antinociception	antinociception	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	locomotor	locomotor	NN	_	24	com	_	_
23	inhibitor	inhibitor	NN	_	24	com	_	_
24	activity	activity	NN	_	20	conj	_	_
25	in	in	IN	_	26	case	_	_
26	mice	mouse	NNS	_	16	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	acute	acute	JJ	_	29	attr	_	_
29	application	application	NN	_	14	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	both	both	DT	_	3	det	_	_
3	sexes	sex	NNS	_	0	root	_	_
4	of	of	IN	_	7	case	_	_
5	swiss	swiss	NN	_	7	com	_	_
6	albino	albino	NN	_	7	com	_	_
7	mice	mouse	NNS	_	3	ppmod	_	_
8	;	;	:	_	3	p	_	_

1	antinociception	antinociception	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	assessed	assess	VBN	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	hot-plate	hot-plate	JJ	_	6	attr	_	_
6	test	test	NN	_	3	ppmod	_	_
7	and	and	CC	_	3	cc	_	_
8	the	the	DT	_	12	det	_	_
9	locomotor	locomotor	JJ	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	exploratory	exploratory	JJ	_	12	attr	_	_
12	activities	activity	NNS	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	assessed	assess	VBN	_	3	conj	_	_
15	with	with	IN	_	19	case	_	_
16	holed	holed	JJ	_	19	attr	_	_
17	open	open	JJ	_	19	attr	_	_
18	field	field	NN	_	19	com	_	_
19	test	test	NN	_	14	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	animals	animal	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	received	receive	VBN	_	0	root	_	_
5	;	;	:	_	4	p	_	_

1	saline	saline	NN	_	0	root	_	_
2	+	+	CC	_	1	cc	_	_
3	saline	saline	NN	_	1	conj	_	_
4	,	,	,	_	1	p	_	_
5	drug1	drug0	NN	_	1	conj	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	10	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	+	+	CC	_	5	cc	_	_
11	saline	saline	NN	_	1	conj	_	_
12	,	,	,	_	11	p	_	_
13	saline	saline	NN	_	11	conj	_	_
14	+	+	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	11	conj	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	15	0	CD	_	18	num	_	_
18	g/kg	g/kg	NN	_	11	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	11	cc	_	_
21	drug3	drug0	NN	_	11	conj	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	10	0	CD	_	24	num	_	_
24	mg/kg	mg/kg	NN	_	11	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	+	+	CC	_	11	cc	_	_
27	drug4	drug0	NN	_	11	conj	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	15	0	CD	_	30	num	_	_
30	g/kg	g/kg	NN	_	11	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	1	p	_	_
33	intraperitoneally	intraperitoneally	RB	_	1	adv	_	_
34	,	,	,	_	1	p	_	_
35	30	0	CD	_	36	num	_	_
36	min	min	NN	_	1	appo	_	_
37	before	before	IN	_	39	case	_	_
38	hot	hot	JJ	_	39	attr	_	_
39	plate	plate	NN	_	36	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	holed	holed	JJ	_	44	attr	_	_
42	open	open	JJ	_	44	attr	_	_
43	field	field	NN	_	44	com	_	_
44	tests	test	NNS	_	39	conj	_	_
45	.	.	.	_	1	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	hot	hot	JJ	_	5	attr	_	_
4	plate	plate	NN	_	5	com	_	_
5	test	test	NN	_	21	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	mice	mouse	NNS	_	5	ppmod	_	_
8	,	,	,	_	21	p	_	_
9	co-administration	co-administration	NN	_	21	dep	_	_
10	of	of	IN	_	13	case	_	_
11	15	0	CD	_	13	num	_	_
12	g/kg	g/kg	NN	_	13	com	_	_
13	drug1	drug0	NN	_	9	ppmod	_	_
14	with	with	IN	_	17	case	_	_
15	10	0	CD	_	16	num	_	_
16	mg/kg	mg/kg	NN	_	17	com	_	_
17	drug2	drug0	NN	_	9	ppmod	_	_
18	intraperitoneally	intraperitoneally	RB	_	20	com	_	_
19	not	not	RB	_	20	com	_	_
20	only	only	RB	_	21	cc	_	_
21	enhanced	enhance	VBD	_	0	root	_	_
22	,	,	,	_	21	p	_	_
23	but	but	CC	_	21	cc	_	_
24	also	also	RB	_	23	com	_	_
25	prolonged	prolong	VBD	_	21	conj	_	_
26	the	the	DT	_	27	det	_	_
27	duration	duration	NN	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	antinociception	antinociception	NN	_	27	ppmod	_	_
30	induced	induce	VBN	_	29	acl	_	_
31	by	by	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	21	p	_	_

1	At	at	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	same	same	JJ	_	4	attr	_	_
4	time	time	NN	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	the	the	DT	_	9	det	_	_
7	locomotor	locomotor	JJ	_	9	attr	_	_
8	inhibitory	inhibitory	JJ	_	9	attr	_	_
9	effect	effect	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	counteracted	counteract	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	13	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	concluded	conclude	VBD	_	0	root	_	_
3	that	that	IN	_	12	mark	_	_
4	the	the	DT	_	6	det	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	administration	administration	NN	_	12	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	have	have	VB	_	2	comp	_	_
13	beneficial	beneficial	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	12	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	treatment	treatment	NN	_	12	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	pain	pain	NN	_	17	ppmod	_	_
20	without	without	IN	_	21	case	_	_
21	causing	cause	VBG	_	12	ppmod	_	_
22	sedation	sedation	NN	_	21	obj	_	_
23	,	,	,	_	22	p	_	_
24	which	which	WDT	_	25	dep	_	_
25	limits	limit	VBZ	_	22	relcl	_	_
26	the	the	DT	_	27	det	_	_
27	use	use	NN	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	as	as	IN	_	32	case	_	_
31	an	an	DT	_	32	det	_	_
32	drug4	drug0	NN	_	25	ppmod	_	_
33	in	in	IN	_	34	case	_	_
34	humans	human	NNS	_	32	ppmod	_	_
35	.	.	.	_	2	p	_	_

1	Interaction	interaction	NN	_	2	com	_	_
2	study	study	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	with	with	IN	_	9	case	_	_
8	co-administered	co-administered	VBN	_	9	attr	_	_
9	drugs	drug	NNS	_	2	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	are	be	VBP	_	6	aux	_	_
5	drug3	drug0	RB	_	6	adv	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	treating	treat	VBG	_	6	ppmod	_	_
9	urinary	urinary	JJ	_	13	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	respiratory	respiratory	JJ	_	9	conj	_	_
12	tract	tract	NN	_	13	com	_	_
13	infections	infection	NNS	_	8	obj	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	have	have	VB	_	6	lv	_	_
6	interactions	interaction	NNS	_	3	comp	_	_
7	with	with	IN	_	8	case	_	_
8	drugs	drug	NNS	_	6	ppmod	_	_
9	that	that	WDT	_	10	dep	_	_
10	are	be	VBP	_	8	relcl	_	_
11	active	active	JJ	_	10	dep	_	_
12	in	in	IN	_	15	case	_	_
13	gastro	gastro	NN	_	15	attr	_	_
14	intestinal	intestinal	JJ	_	15	attr	_	_
15	tract	tract	NN	_	10	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Being	be	VBG	_	2	adv	_	_
2	drug1	drug0	NN	_	11	ppmod	_	_
3	and	and	CC	_	2	cc	_	_
4	lomefloxacin	lomefloxacin	NN	_	5	com	_	_
5	drug2	drug0	NN	_	2	conj	_	_
6	the	the	DT	_	8	det	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	study	study	NN	_	11	dep	_	_
9	of	of	IN	_	8	case	_	_
10	was	be	VBD	_	11	aux	_	_
11	carried	carry	VBN	_	0	root	_	_
12	out	out	RP	_	11	prt	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	14	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	14	conj	_	_
21	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	studied	study	VBN	_	0	root	_	_
5	at	at	IN	_	11	case	_	_
6	neutral	neutral	JJ	_	11	attr	_	_
7	,	,	,	_	6	p	_	_
8	acidic	acidic	JJ	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	basic	basic	JJ	_	6	conj	_	_
11	conditions	condition	NNS	_	4	ppmod	_	_
12	both	both	CC	_	11	cc	_	_
13	at	at	IN	_	15	case	_	_
14	room	room	JJ	_	15	attr	_	_
15	temperature	temperature	NN	_	11	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	37	0	CD	_	18	num	_	_
18	C	c	NN	_	15	conj	_	_
19	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	16	dep	_	_
3	of	of	IN	_	5	case	_	_
4	dissolution	dissolution	NN	_	5	com	_	_
5	medium	medium	NN	_	2	ppmod	_	_
6	simulating	simulate	VBG	_	5	acl	_	_
7	various	various	JJ	_	9	attr	_	_
8	body	body	NN	_	9	com	_	_
9	environments	environment	NNS	_	6	obj	_	_
10	with	with	IN	_	11	case	_	_
11	response	response	NN	_	6	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	pH	ph	NN	_	11	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	examined	examine	VBN	_	0	root	_	_
17	in	in	IN	_	20	mark	_	_
18	order	order	NN	_	20	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	elucidate	elucidate	VB	_	16	comp	_	_
21	the	the	DT	_	22	det	_	_
22	interactions	interaction	NNS	_	20	obj	_	_
23	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	response	response	NN	_	18	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	after	after	IN	_	8	case	_	_
8	interaction	interaction	NN	_	2	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	co-administered	co-administered	NN	_	11	com	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	at	at	IN	_	14	case	_	_
13	different	different	JJ	_	14	attr	_	_
14	conditions	condition	NNS	_	8	ppmod	_	_
15	and	and	CC	_	8	cc	_	_
16	temperature	temperature	NN	_	8	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	noted	note	VBN	_	0	root	_	_
19	using	use	VBG	_	18	comp	_	_
20	a	a	DT	_	23	det	_	_
21	Shimadzu	shimadzu	NN	_	23	com	_	_
22	HPLC	hplc	NN	_	23	com	_	_
23	system	system	NN	_	19	obj	_	_
24	with	with	IN	_	26	case	_	_
25	PDA	pda	NN	_	26	com	_	_
26	detector	detector	NN	_	23	ppmod	_	_
27	.	.	.	_	18	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	seen	see	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	interaction	interaction	NN	_	9	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	drug1	drug0	NNS	_	5	ppmod	_	_
9	was	be	VBD	_	3	comp	_	_
10	more	more	RBR	_	9	adv	_	_
11	at	at	IN	_	13	case	_	_
12	37	0	CD	_	13	num	_	_
13	C	c	NN	_	9	ppmod	_	_
14	than	than	IN	_	17	case	_	_
15	at	at	IN	_	17	case	_	_
16	room	room	JJ	_	17	attr	_	_
17	temperature	temperature	NN	_	9	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	reacts	react	VBZ	_	0	root	_	_
5	faster	fast	JJR	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	12	case	_	_
11	acidic	acidic	JJ	_	12	attr	_	_
12	media	medium	NNS	_	7	ppmod	_	_
13	whereas	whereas	IN	_	14	com	_	_
14	with	with	IN	_	12	cc	_	_
15	drug5	drug0	NN	_	12	conj	_	_
16	in	in	IN	_	18	case	_	_
17	basic	basic	JJ	_	18	attr	_	_
18	media	medium	NNS	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	18	conj	_	_
21	in	in	IN	_	23	case	_	_
22	neutral	neutral	JJ	_	23	attr	_	_
23	media	medium	NNS	_	15	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	ensures	ensure	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	interaction	interaction	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	selected	select	VBN	_	10	attr	_	_
10	class	class	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drugs	drug	NNS	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	achieve	achieve	VB	_	16	advcl	_	_
5	the	the	DT	_	11	det	_	_
6	effective	effective	JJ	_	7	adv	_	_
7	therapeutic	therapeutic	JJ	_	11	attr	_	_
8	effect	effect	NN	_	11	attr	_	_
9	appropriate	appropriate	JJ	_	11	attr	_	_
10	time	time	NN	_	11	com	_	_
11	intervals	interval	NNS	_	4	obj	_	_
12	between	between	IN	_	13	case	_	_
13	administrations	administration	NNS	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	is	be	VBZ	_	0	root	_	_
17	essential	essential	JJ	_	16	dep	_	_
18	.	.	.	_	16	p	_	_

